Sentence,class,file
"Hypercoagulable disorders, like factor V Leiden  mutation, presence of anticardiolipin antibody, antithrombin Journal of Stroke  201 5;17(3):362- 365 http://dx.doi.org/10.5853/jos.2015.17.3.362",Non-OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.362Vol.,OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
3 / September 2015 http://j-stroke.org  363 A  B  C D  E  F Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
"Malignant CVT in Polycythemia http://dx.doi.org/10.5853/jos.2015.17.3.362 364 http://j-stroke.orgtorial herniation; either at onset or after worsening despite anti - coagulation.10 In a series by Théaudin et al.10 regarding the per - formance of decompressive surgery in malignant CVT , none of  the 12 patients with malignant CVT had polycythemia as a risk  factor.",Non-OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.362Vol.,OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
"3 / September 2015 http://j-stroke.org  365ers JA, Stam J, Wermer MJ.",Non-OADS,/arxiv_data1/oa_pdf/73/11/jos-17-3-362.PMC4635717.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 366 http://j-stroke.orgDabigatran Effect on Left Ventricular Thrombus in  a Patient with Acute Ischemic Stroke Kyuyoon Chung, Y oung Min Paek, Hye Jung Lee, Keun-Sik Hong Department of Neurology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, KoreaLetter to the Editor Dear Sir: Anticoagulation in acute ischemic stroke (AIS) is not gener - ally recommended because of the risk of intracranial bleeding.",Non-OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
"We might have three options for this case: warfarin alone, Journal of Stroke  201 5;17(3):366- 368 http://dx.doi.org/10.5853/jos.2015.17.3.366",Non-OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.366Vol.,OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
"3 / September 2015 http://j-stroke.org  367bridging heparin and warfarin, and non-vitamin K oral anticoagu - lants.",Non-OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
"Dabigatran Effect on LV Thrombus http://dx.doi.org/10.5853/jos.2015.17.3.366 368 http://j-stroke.orgCorrespondence: Keun-Sik Hong Department of Neurology, Ilsan Paik Hospital, Inje University, 170 Juhwa-ro,  Ilsanseo-gu, Goyang 10380, Korea  Tel: +82-31-910-7680, Fax: +82-31-910-7368 E-mail: nrhks@paik.ac.kr Received: July 24, 2015 Revised: August 7, 2015 Accepted: August 10, 2015 The authors have no financial conflicts of interest.fore, further research is needed to better understand the re - sponse of LV or left atrial appendage thrombus to dabigatran or  other non-vitamin K oral anticoagulants.",Non-OADS,/arxiv_data1/oa_pdf/be/21/jos-17-3-366.PMC4635718.pdf
"312 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"Keywords Cryptogenic stroke; P wave dispersion; Echocardiography; Paroxysmal atrial fi - brillation; StrainOriginal Article Introduction Cryptogenic stroke (CS) refers to a cerebral ischemia of un - known origin.1 While atrial fibrillation (AF) is the most com - mon associated cardiac arrhythmia making up to 12% of strokes  among the general population,2 asymptomatic paroxysmal AF (PAF) is often suspected as the underlying cause of CS.3 The  progressive nature of AF is well established and known to lead  to electro-anatomical remodeling and atrial fibrosis.4 Atrial fi - brosis develops from complex interactions among several cellu - lar and neurohumoral mediators, with the resultant fibrotic tis - sue causing a low a voltage response and other electrophysio -Journal of Stroke  201 5;17(3):312- 319 http://dx.doi.org/10.5853/jos.2015.17.3.312",Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.312Vol.,OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
3 / September 2015 http://j-stroke.org  313logical changes in the left atrium (LA) that act as a substrate for  the occurrence of AF.,Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"Left Atrial Remodeling and Cryptogenic Stroke http://dx.doi.org/10.5853/jos.2015.17.3.312 314 http://j-stroke.orgLA structural remodeling analysis using conventional  and speckle tracking echocardiography Electrocardiogram-guided echocardiographic measurements  were carried out using a commercially available ultrasound de - vice (ie33, Philips Medical System, Bothell, Washington, USA).",OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.312Vol.,OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"3 / September 2015 http://j-stroke.org  315CS and control group, respectively ( P= 0.001).",OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"Left Atrial Remodeling and Cryptogenic Stroke http://dx.doi.org/10.5853/jos.2015.17.3.312 316 http://j-stroke.orgstructural, functional, and electrical impairments in conjunc - tion with other risk factors i.e.",Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.312Vol.,OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
3 / September 2015 http://j-stroke.org  317and an improvement in LA strain correlated with a reversion of  LA remodeling in patients who underwent catheter ablation for  AF.,Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"Left Atrial Remodeling and Cryptogenic Stroke http://dx.doi.org/10.5853/jos.2015.17.3.312 318 http://j-stroke.orgleft shunt, as exclusion of PFO was only conﬁrmed by TEE us - ing contrast bubbles.",Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.312Vol.,OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
3 / September 2015 http://j-stroke.org  31935-41.,Non-OADS,/arxiv_data1/oa_pdf/39/ad/jos-17-3-312.PMC4635719.pdf
"238 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Keywords Vessel wall imaging; Intracranial artery; Cervical carotid artery; High-resolution  magnetic resonanceReviewJournal of Stroke  201 5;17(3):238- 255 http://dx.doi.org/10.5853/jos.2015.17.3.238 Introduction Ischemic stroke caused by cerebrovascular disease is a major  cause of mortality and morbidity worldwide, and the noninva - sive in vivo  assessment of plaques and arterial walls is a funda - mental aspect in guiding therapy.1-3 Luminal evaluation is the tra - ditional method for evaluating and understanding vascular pa - thology.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  239are representative black-blood techniques.4 Double inversion re - covery is usually used with two-dimensional (2D) spin-echo or  turbo/fast spin-echo sequences because of the single-slice se - quential acquisition, which leads to the disadvantages of limited  spatial resolution, a long scan time, and partial volume effects de - spite the effective suppression of blood signal.7,8 Motion-sensi - tized driven equilibrium prepulses have recently been used in 3D  HR-MRI by applying gradients along each axis.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 240 http://j-stroke.orgto be consistent with those of cervical carotid artery plaques.35  The lipid core appears as an isointense area on T1-weighted im - ages and as a hypo- to isointense area on T2-weighted images;  the fibrous component appears as an isointense area on T1- and  T2-weighted images; and calcification appears as an area of dark  signal intensity on T1- and T2-weighted images.35 Plaque enhancement is the most common and reliable find - ing, which depends on T1-weighted imaging with gadolinium- based contrast enhancement.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  241toms are present in 52% of patients with intracranial artery dis - section, followed by subarachnoid hemorrhage in 28% of pa - tients.49 Intracranial artery dissection is estimated to be responsi - ble for approximately 3%-5% of subarachnoid hemorrhage cas - es.12 Intracranial artery dissection tends to be more common in  Asian populations.50 In European populations, intracranial artery  dissection is believed to comprise < 10% of all spontaneous cer - vicocephalic artery dissections in adults,51 but this percentage is  > 90% in Asian populations.49 This difference may also be asso - ciated with the higher incidence of intracranial atherosclerosis  that is observed in Asian populations.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 242 http://j-stroke.orgtebral artery with the highest incidence (68.7%).49 Wang et al.,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  243tively diagnosed in intracranial artery dissections, and intramural  hematoma and aneurysmal dilatation can be helpful criteria.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 244 http://j-stroke.orgVasculitis Central nervous system (CNS) vasculitis encompasses a  broad spectrum of cerebrovascular diseases that demonstrate  various inflammatory and destructive characteristics.,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  245to the following features: less, diffuse, uniform, and continuous  wall thickening and enhancement; a shorter interval to restore  (3 months vs. 7-17 months); and a higher rate of resolution  (88.9% vs. 33.3%), in comparison with vasculitis.77,84 Although  the pathophysiology remains unclear, alterations in cerebral vas - cular tone are associated with various exogenous and endogenous  factors that are believed to cause RCVS.83 The shortening and  overlapping of smooth muscle cells result in increased wall thick - ness and luminal stenosis according to an experimental vaso - spasm study, which may explain the wall thickening observed on  HR-MR.85 The absence of arterial inflammation in RCVS may  be consistent with weak enhancement on HR-MR81,82 (T able 1).",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 246 http://j-stroke.orgjective characterization of plaque echogenicity by using B-mode  US; however, this remains an ongoing subject of research.59  US with color Doppler can also assess IMT , and an increase  in the IMT of the common carotid artery could be used to pre - dict cardiovascular events.103,108 The arterial wall may demon - strate two parallel echogenic lines that are separated by a rela - tively hypoechoic intermediate area on longitudinal B-mode  US, and the distance between these lines is the IMT (Figure 9).",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  247reliably accurate for diagnosing severe stenosis ( > 70%) (85%  sensitivity and 93% specificity).,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 248 http://j-stroke.orgAccording to previous studies, the signal intensities of the lipid  cores vary on T2-weighted imaging.120,121 These variations in sig - nal intensity seem to result from (i) the different entities of the  lipid cores (liquid vs. solid) and (ii) differences in the echo times  used on T2-weighted imaging.122 Two-thirds of the lipids in the  lipid core are in the solid or semiliquid phase, which demonstrate  very poor signals; moreover, it is difficult to directly image the li - pidic components.123 Some of the lipids in the plaque tend to  liquify at body temperature, which may demonstrate higher sig - nal intensities on T2-weighted imaging.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  249but isointense on TOF MRI.,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 250 http://j-stroke.orga useful and reliable method; however, the applications of nucle - ar medicine are still confined to clinical research.",Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  25126.,OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 252 http://j-stroke.org167-172.,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  253and temporal patterns of reversible cerebral vasoconstriction  syndrome and central nervous system vasculitis.,Non-OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"Role of Vessel Wall Imaging and Radiological Features http://dx.doi.org/10.5853/jos.2015.17.3.238 254 http://j-stroke.orgBoden-Albala B, et al.",OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.238 http://j-stroke.org  2552008;27:1341-1346.,OADS,/arxiv_data1/oa_pdf/fe/dd/jos-17-3-238.PMC4635720.pdf
"256 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Keywords Connectome; Connectivity; Network; Stroke; Resting-state functional MRI;  Diffusion tensor imagingReviewJournal of Stroke  201 5;17(3):256- 267 http://dx.doi.org/10.5853/jos.2015.17.3.256 Introduction The need for a connectome-based approach The term “Connectome” was proposed by Olaf Sporns to de - note “the complete set of all neural connections of the human  brain” .1,2 Thereafter, this term has been widely used, and the hu - man connectome project was initiated to investigate thorough  and detailed connectivity maps of the human brain (http:// www.humanconnectomeproject.org).",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  257mined.,OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Stroke Connectome and Cognitive Sequela of Stroke http://dx.doi.org/10.5853/jos.2015.17.3.256 258 http://j-stroke.orgcorrespond to the white matter tracts, and landmasses to the  each cortical region.",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  259tural connectivities have been suggested as useful in differenti - ating various neurodegenerative disorders.10 Basic parameters for connectivity and connectome The basic elements of neural networks and connectome are  nodes and edges.,OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Stroke Connectome and Cognitive Sequela of Stroke http://dx.doi.org/10.5853/jos.2015.17.3.256 260 http://j-stroke.orgthe connections are randomly wired, and the wiring probabili - ties of one specific node to multiple remote nodes are relatively  higher than those for adjacent nodes.",OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  261method by which to characterize and visualize whole-brain con - nectivities.,OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Stroke Connectome and Cognitive Sequela of Stroke http://dx.doi.org/10.5853/jos.2015.17.3.256 262 http://j-stroke.orghomologous regions, via transcallosal connections.",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  263cortex, which were the regions impaired in patients with post- stroke dementia.43 In patients with right hemispheric stroke,48 poor cognitive re - covery was shown to be associated with increased resting-state  functional activity in the contralateral hemisphere, including  the default mode, frontotemporal, and basal ganglia networks,  while the good cognitive recovery group did not show any sig - nificant differences from healthy controls.",OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Stroke Connectome and Cognitive Sequela of Stroke http://dx.doi.org/10.5853/jos.2015.17.3.256 264 http://j-stroke.orgtients with hemianopia were enhanced in the ipsilesional tempo - ropolar and orbitofrontal areas and the contralesional associative  visual cortex, compared to healthy controls.",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  265territorial infarction, multiple lacunes, and severe cerebral atro - phy might distort the results of standardized analysis protocols.",Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
Stroke Connectome and Cognitive Sequela of Stroke http://dx.doi.org/10.5853/jos.2015.17.3.256 266 http://j-stroke.orgischemic depolarization is the major cause of rapid reversible  damage to dendrites and spines.,Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.3.256 http://j-stroke.org  267covery after stroke: A 3T fMRI pilot study.,Non-OADS,/arxiv_data1/oa_pdf/d3/4f/jos-17-3-256.PMC4635721.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  327Intravenous Tissue Plasminogen Activator Improves  the Outcome in Very Elderly Korean Patients with  Acute Ischemic Stroke Jay Chol Choi,a,* Ji Sung Lee,b,* T ai Hwan Park,c Sang-Soon Park,c Y ong-Jin Cho,d Jong-Moo Park,e  Kyusik Kang,e Kyung Bok Lee,f Soo-Joo Lee,g Y oungchai Ko,g Jae Guk Kim,g Jun Lee,h Ki-Hyun Cho,i  Joon-T ae Kim,i Kyung-Ho Yu,j Byung-Chul Lee,j Mi-Sun Oh,j Jae-Kwan Cha,k Dae-Hyun Kim,k  Hyun-Wook Nah,k Dong-Eog Kim,l Wi-Sun Ryu,l Beom Joon Kim,m Hee-Joon Bae,m Wook-Joo Kim,n  Dong-Ick Shin,o Min-Ju Y eo,o Sung Il Sohn,p Jeong-Ho Hong,p Juneyoung Lee,q Keun-Sik Hongd aDepartment of Neurology, Jeju National University, Jeju, Korea bClinical Research Center, Asan Medical Center, Seoul, Korea cDepartment of Neurology, Seoul Medical Center, Seoul, Korea dDepartment of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea eDepartment of Neurology, Eulji General Hospital, Eulji University, Seoul, Korea fDepartment of Neurology, Soonchunhyang University College of Medicine, Seoul, Korea gDepartment of Neurology, Eulji University Hospital, Daejeon, Korea hDepartment of Neurology, Y eungnam University Hospital, Daegu, Korea iDepartment of Neurology, Chonnam National University Hospital, Gwangju, Korea jDepartment of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea kDepartment of Neurology, Dong-A University College of Medicine, Busan, Korea lDepartment of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea mDepartment of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea nDepartment of Neurology, Ulsan University Hospital, Ulsan, Korea oDepartment of Neurology, Chungbuk National University Hospital, Cheongju, Korea pDepartment of Neurology, Keimyung University Dongsan Medical Center, Daegu, Korea qDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea Correspondence:  Keun-Sik Hong  Department of Neurology, Ilsan Paik  Hospital, Inje University, 170 Juhwa-ro,   Ilsanseo-gu, Goyang 10380, Korea  Tel: +82-31-910-7680 Fax: +82-31-910-7368 E-mail: nrhks@paik.ac.kr Received: February 17, 2015 Revised: April 20, 2015 Accepted: April 29, 2015 *Jay Chol Choi and Ji Sung Lee  contributed equally to the manuscript as  the first author.",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"TPA treatment was associated  with an increased risk of symptomatic intracranial hemorrhage (multivariable analysis, 5.45  [2.80-10.59], P<0.001; PS-matched analysis, 4.52 [2.24-9.13], P<0.001), but did not increase the Original ArticleJournal of Stroke  201 5;17(3):327- 335 http://dx.doi.org/10.5853/jos.2015.17.3.327",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"TPA in Very Elderly Korean Patients with Stroke http://dx.doi.org/10.5853/jos.2015.17.3.327 328 http://j-stroke.orgIntroduction Stroke population as well as global population is aging.1 In de - veloped countries, the proportion of elderly patients among stroke  population increased,2 and more than 30% of stroke patients were  aged ≥ 80 years and 7.2% to 14.2% were aged ≥ 85 years.3-6 How - ever, very elderly patients were excluded from or substantially  under-represented in earlier intravenous tissue-plasminogen acti - vator (TPA) trials.7-11 In the third International Stroke T rial (IST- 3) where 53% of 3,035 patients enrolled were aged > 80 years,  the benefit of TPA was greater in patients aged > 80 years than in  those ≤ 80 years, but the result did not reach statistical signifi - cance.12 In an updated pooled analysis of randomized clinical tri - als (RCT s),13 intravenous TPA significantly increased the excel - lent outcome defined by modified Rankin Scale (mRS) score 0-1  in patients aged > 80 years as well as those ≤ 80 years.",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
Methods Database and subjects The Clinical Research Center for Stroke-5 (CRCS-5) registry  is a prospective registry of patients with acute ischemic stroke ad - mitted to 15 academic centers in Korea (http://www.stroke-crc.,OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.327Vol.,OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"3 / September 2015 http://j-stroke.org  329nine, and hemoglobin); (3) vascular risk factors (hypertension,  diabetes mellitus, hyperlipidemia, smoking, atrial fibrillation,  and prior history of stroke and coronary artery disease); (4)  medications prior to the index stroke (antiplatelet agents, statins  and oral anticoagulants); (5) characteristics of the index stroke  including initial stroke severity measured by the National Insti - tutes of Health Stroke Scale (NIHSS) score, symptomatic steno - sis or occlusion of intracranial or extracranial artery (SYSO); (6)  thrombolytic treatment (use of TPA, dosage of TPA, and onset  to treatment time); (7) outcomes after the index stroke (mRS  scores at discharge and at 3 months after the stroke and SICH).",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"TPA in Very Elderly Korean Patients with Stroke http://dx.doi.org/10.5853/jos.2015.17.3.327 330 http://j-stroke.orgBecause the baseline characteristics of the two groups were  expected to differ significantly, particularly for stroke severity, we  conducted propensity score (PS)-matched analysis in addition  to multivariable analysis.",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.327Vol.,OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"3 / September 2015 http://j-stroke.org  331Results Of 3,720 patients with acute ischemic stroke ≥ 80 years old  enrolled in the CRCS-5 registry between April 2008 and Nov  2013, we excluded 1,386 patients in the following order: (1) 196  patients without relevant acute ischemic stroke on neuroimag - ing; (2) 108 patients who admitted to the participating hospitals  beyond 7 days from symptom onset; (3) 918 patients with a  pre-stroke mRS score > 1; (4) 131 patients treated with intraar - terial or combined intravenous and intraarterial thrombolysis;  (5) 29 patients who were treated with TPA at outside hospitals;  (6) 3 patients in whom discharge mRS scores were unavailable;  and (7) 1 patient who were treated with intravenous TPA due to  pulmonary embolism (Figure 1).",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
TPA in Very Elderly Korean Patients with Stroke http://dx.doi.org/10.5853/jos.2015.17.3.327 332 http://j-stroke.orgcharge (T able 2).,Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.327Vol.,OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"3 / September 2015 http://j-stroke.org  333Discussion In this study of very elderly Korean patients with acute isch - emic stroke, there was a significant outcome improvement with  intravenous TPA treatment in routine clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
TPA in Very Elderly Korean Patients with Stroke http://dx.doi.org/10.5853/jos.2015.17.3.327 334 http://j-stroke.organd risk of the treatment.,Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.327Vol.,OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
3 / September 2015 http://j-stroke.org  335national stroke trial [IST-3]): a randomised controlled trial.,Non-OADS,/arxiv_data1/oa_pdf/cf/7e/jos-17-3-327.PMC4635722.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  229Patent Foramen Ovale and Stroke–Current Status Oh Y oung Bang,a Mi Ji Lee,a Sookyung Ryoo,a Suk Jae Kim,a Ji Won Kimb aDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea bDepartment of Neurology, National Medical Center, Seoul, Korea Correspondence:  Oh Young Bang Department of Neurology, Samsung  Medical Center, Sungkyunkwan  University, 81 Irwon-ro, Gangnam-gu,  Seoul 06351, Korea Tel: +82-2-3410-3599 Fax: +82-2-3410-0052 E-mail: ohyoung.bang@samsung.com Received: June 12, 2015 Revised: June 30, 2015 Accepted: July 8, 2015 This study was supported by the Korean  Healthcare Technology R &D Project,  Ministry of Health & Welfare (A110208).",Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
"Several fac - tors possibly associated with increased risk of stroke recurrence  in patients with PFO include a right-to-left shunt (RLS) detect - able in resting conditions,8 amount of RLS under Valsalva,9 and  a combination of PFO with either atrial septal aneurysm (ASA)  or increased interatrial septal mobility.6 However, such findings  were not confirmed in other studies.7,10 Despite these controver - sial results, interest in PFO has emerged recently because of a re - newed focus on ESUS, especially in younger patients, technical  advances in the diagnosis of PFO, and the emergence of endo - vascular device closure as a treatment option.8,11 Journal of Stroke  201 5;17(3):229- 237 http://dx.doi.org/10.5853/jos.2015.17.3.229",Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
Patent Foramen Ovale and Stroke http://dx.doi.org/10.5853/jos.2015.17.3.229 230 http://j-stroke.orgDiagnosis of patent foramen ovale Various tools can be used to detect PFO and RLS (Figure 2).,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
http://www.heart.org/HEARTORG/Conditions/More/ CardiovascularConditionsofChildhood/Patent-Foramen-Ovale-PFO_ UCM_469590_Article.jsp.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.229Vol.,OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
3 / September 2015 http://j-stroke.org  231monitoring is based on the intracranial detection of intravenous - ly injected microemboli.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
Patent Foramen Ovale and Stroke http://dx.doi.org/10.5853/jos.2015.17.3.229 232 http://j-stroke.orginfarcts associated with cardiac disease are underrecognized.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.229Vol.,OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
3 / September 2015 http://j-stroke.org  233 Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
Patent Foramen Ovale and Stroke http://dx.doi.org/10.5853/jos.2015.17.3.229 234 http://j-stroke.orgTable 2.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.229Vol.,OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
3 / September 2015 http://j-stroke.org  235be helpful but also could be harmful (arrhythmogenic).,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
Patent Foramen Ovale and Stroke http://dx.doi.org/10.5853/jos.2015.17.3.229 236 http://j-stroke.org25.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.229Vol.,OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
3 / September 2015 http://j-stroke.org  2371488-1493.,Non-OADS,/arxiv_data1/oa_pdf/d7/64/jos-17-3-229.PMC4635723.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 354 http://j-stroke.orgThe Effects of Transcranial Direct-Current  Stimulation on Cognition in Stroke Patients Gi Jeong Yun,a Min Ho Chun,a Bo Ryun Kimb aDepartment of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea bDepartment of Rehabilitation Medicine, Jeju National University Hospital, Jeju, Korea Correspondence:  Min Ho Chun Department of Rehabilitation Medicine,  Asan Medical Center, University of Ulsan  College of Medicine, 88 Olympic-ro  43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3800 Fax: +82-2-3010-6964 E-mail: mhchun@amc.seoul.kr Received: December 18, 2014 Revised: March 12, 2015 Accepted: April 22, 2015 The authors have no financial conflicts of  interest.Background and Purpose To investigate whether transcranial direct-current stimulation  (tDCS) can improve cognition in stroke patients.",Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
Research has suggest - ed that rehabilitation programs designed to maximize neuroplas -Journal of Stroke  201 5;17(3):354- 358 http://dx.doi.org/10.5853/jos.2015.17.3.354,Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.354Vol.,OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
"3 / September 2015 http://j-stroke.org  355ticity are effective for improving memory functions in these pa - tients.5 Recently, transcranial direct-current stimulation (tDCS) and  repetitive transcranial magnetic stimulation (rTMS), noninva - sive methods for stimulating the cerebral cortex, have been in - tensively studied as a treatment for brain injury.",Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
"Transcranial Direct-Current Stimulation in Stroke http://dx.doi.org/10.5853/jos.2015.17.3.354 356 http://j-stroke.orgPre- and post-treatment comparison  The results from post-treatment CNT suggested that the left- FTAS group showed significant improvement in the backward  digit span test, the verbal learning test-delayed recall, a visual  span test, and the K-MMSE.",Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
http://dx.doi.org/10.5853/jos.2015.17.3.354Vol.,OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
3 / September 2015 http://j-stroke.org  357covery of poststroke patients.,Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
"Transcranial Direct-Current Stimulation in Stroke http://dx.doi.org/10.5853/jos.2015.17.3.354 358 http://j-stroke.orgone A, Fregni F. Repeated sessions of noninvasive brain DC  stimulation is associated with motor function improvement in  stroke patients.",Non-OADS,/arxiv_data1/oa_pdf/b4/5b/jos-17-3-354.PMC4635724.pdf
"Thus, © B Standaert, A Alwan, D Strens, M Raes, and MJ Postma *Correspondence to: B Standaert; Email: baudouin.a.standaert@gsk.comSubmitted: 12/10/2014; Revised: 02/23/2015; Accepted: 03/08/2015 http://dx.doi.org/10.1080/21645515.2015.1029212 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Pediatrics 2009;123(3):e393-e400; PMID:19254975; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
J Infect Dis 2007; 195 Suppl 1:S26-S35; PMID:17387649; http://dx.doi.org/10.1086/516717 3.,OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Scand J Infect Dis 2010; 42(2):142-7; PMID: 19916900; http://dx.doi.org/10.3109/00365540903380495 4.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Arch Public Health 2010;86(1):83-4; http://dx.doi.org/10.1186/0778-7367- 68-2-83 5.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Am J Psychiatry 2008; 165(11):1482-6; PMID:18676590; http://dx.doi.org/10.1176/appi.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Acad Emerg Med 2003; 10(2):127-33; http://dx.doi.org/10.1111/j.1553-2712.2003.tb00029.x 10.,OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
BMC Fam Pract 2010; 11:22; PMID:20230601; http://dx.doi.org/ 10.1186/1471-2296-11-22 12.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
J Qual Clin Pract 1999; 19(4):211-4; http://dx.doi.org/10.1046/j.1440- 1762.1999.00334.x 14.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Ann Intern Med 1995; 122 (6):415-21; http://dx.doi.org/10.7326/0003-4819- 122-6-199503150-00003 15.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Int J Qual Health Care2003; 15(2):147-54; http://dx.doi.org/10.1093/ intqhc/mzg019 16.,OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
"Hum Vaccin 2011; 7 (7):734-48; PMID:21734466; http://dx.doi.org/ 10.4161/hv.7.7.15511 17. do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira WK, Cortez-Escalante JJ, Lopman B, Flan- n e r yB ,d eO l i v e i r aL H ,C a r m oE H ,e ta l .D e c l i n e in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis.",Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
PLoS Med 2011 Apr; 8(4): e1001024; PMID:21526228; http://dx.doi.org/ 10.1371/journal.pmed.1001024 18.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Lancet Infect Dis 2014; 14 (5):416-25; PMID:24758998; http://dx.doi.org/ 10.1016/S1473-3099(14)70035-0 19.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Lancet Infect Dis 2006; 6(12):805-12; PMID:17123900; http://dx.doi.org/10.1016/S1473-3099(06)70657-0 20.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Pediatr Infect Dis J 2011; 30(7):120-5; http://dx.doi.org/10.1097/INF.0b013e318214b811 23.,OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Pediatrics 2011; 127(2):e264-e270; http://dx.doi.org/10.1542/peds.2010-1830 25.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
BMC Infect Dis 2012; 12:62; http://dx.doi.org/10.1186/ 1471-2334-12-62 26.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Lancet 2000; 356(9225):185-9; http://dx.doi.org/10.1016/S0140-6736(00)02478-8 28.,OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
Am J Psychiatry 2008; 165 (11): 1482-6; http://dx.doi.org/10.1176/appi.ajp.2008.0712192930.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
PLoS One 2015; 10(2): e0116198; PMID:25679391; http://dx.doi.org/ 10.1371/journal.pone.0116198 32.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
PLoS One 2013; 8(1): e53864; PMID:23349754; http://dx.doi.org/10.1371/ journal.pone.0053864 34.,Non-OADS,/arxiv_data1/oa_pdf/86/74/khvi-11-09-1029212.PMC4635727.pdf
"The following problems with nucleoside and nucleotide analogs require attention: 1) a © Jinfeng Liu, Yuling Feng, Jing Wang, Xuelan Li, Chunmei Lei, Dongfang Jin, Weihong Feng, Yuan Yang, Yingli He, Yuanyuan Li, Dan Du, Xuebin Zhang, Li Ji n, Taotao Yan, Tianyan Chen, and Yingren Zhao*Correspondence to: Tianyan Chen; Email: chentianyan@126.com; Yingren Zhao; Email: zhaoyingren@sohu.comSubmitted: 10/19/2014; Revised: 12/29/2014; Accepted: 01/08/2015 http://dx.doi.org/10.1080/21645515.2015.1010890 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Vaccine 2009;27:6550-7; PMID:19729084; http://dx.doi.org/ 10.1016/j.vaccine.2009.08.048 2.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Arch Pediatr 2000; 7:879-82; PMID:10985190; http://dx.doi.org/10.1016/S0929-693X(00)80199-2 3.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Acta Paediatr Jpn 1989; 31:663- 8; PMID:2533788; http://dx.doi.org/10.1111/j.1442-200X.1989.tb01376.x 5.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
J Med Virol 1986; 18:327-34; PMID:2940333; http://dx.doi.org/10.1002/ jmv.1890180405 7.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
J Med Virol 2011; 83:791-5; PMID:21360547; http://dx.doi.org/ 10.1002/jmv.22043 8.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Obstet Gynecol 2010; 116:147-59; PMID:20567182; http://dx.doi.org/10.1097/AOG.0b013e3181e45951 10.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
J Hepatol 2012; 57:515-21; PMID:22617152; http://dx.doi.org/10.1016/j.jhep.2012.04.021 11.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
PloS one 2014; 9:e106221; PMID:25170938; http://dx.doi.org/10.1371/journal.pone.0106221 12.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Int J Gynaecol Obstet 2007; 96:167-70; PMID:17296201; http://dx.doi.org/10.1016/j.ijgo.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
J Viral Hepat 2006; 13:597-604; PMID:16907846; http://dx.doi.org/ 10.1111/j.1365-2893.2006.00738.x 17.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
BMC Infects Dis 2013; 13:524; PMID:24195671; http://dx.doi.org/10.1186/1471- 2334-13-524 20.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Scand J Infect Dis 2003; 35:814-9; PMID:14723355; http://dx.doi.org/10.1080/ 00365540310016547 21.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Pediatr Infect Dis J 2001; 20:63-75; PMID:11176570; http://dx.doi.org/ 10.1097/00006454-200101000-00013 22.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Lancet 2000; 355:561-5; PMID:10683019; http://dx.doi.org/10.1016/S0140- 6736(99)07239-6 23.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Vaccine 2005; 23:4158-66; PMID:15964484; http://dx.doi.org/10.1016/j.vaccine.2005.03.01724.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Microbes Infect 2013; 15:409-15;PMID:23500187; http://dx.doi.org/10.1016/j.micinf.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Retrovirology 2012; 9:101; PMID:23217137; http://dx.doi.org/10.1186/1742- 4690-9-101 27.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Am J Pathol 2006; 168:1210-26; PMID:16565496; http://dx.doi.org/ 10.2353/ajpath.2006.050482 28.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
World J Gastroenterol 2012; 18:4677-83; PMID:23002336; http://dx.doi.org/10.3748/wjg.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Hum Pathol 2004;35:536-45; PMID:15138926; http://dx.doi.org/ 10.1016/j.humpath.2004.01.015 37.,OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
J Hepatol 2011; 55:1215-21; PMID:21703206; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
Vaccine 2012;30:5335-40; PMID:22749833; http://dx.doi.org/ 10.1016/j.vaccine.2012.06.036 2076 Volume 11 Issue 8 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/bd/88/khvi-11-08-1010890.PMC4635728.pdf
"It describes the average num- ber of successful transmissions generated by one infectious indi- vidual in a fully susceptible population.13-16 R0is unique to every type of infection and to the population density of a region.13,15The higher the R 0, the more likely the spread of the pathogen to susceptible subjects.12,13,15For example,© Carla D Scarbrough Lefebvre, Augustin Terlinden, and Baudouin Standaert *Correspondence to: Carla D Scarbrough Lefebvre; Email: carla.d.le febvre@gmail.com Submitted: 12/18/2014; Revised: 04/28/2015; Accepted: 05/12/2015http://dx.doi.org/10.1080/21645515.2015.1052196 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Med Decis Making 2003; 23: 76-82; PMID:12583457; http://dx.doi.org/10.1177/0272989X02239651 3.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pharmacoeconomics 2008; 26: 191-215; PMID:18282015; http://dx.doi.org/10.2165/ 00019053-200826030-00004 4.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vaccin Immunother 2013; 9: 834-40; PMID:23357859; http://dx.doi.org/ 10.4161/hv.236375.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Journal of Economic Analysis and Policy 2007; 7; http://dx.doi.org/10.2202/1935-1682.1487 6.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vaccin Immunother 2012; 8: 184-8; PMID:22426372;http://dx.doi.org/10.4161/hv.18444 7.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
"Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials.Lancet Infect Dis 2011; 11: 482-7; PMID:21616458; http://dx.doi.org/10.1016/S1473-3099(10)70318-2 8.",Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pharmacoeconomics 2011; 29: 371-86;PMID:21504239; http://dx.doi.org/10.2165/ 11539960-000000000-00000 10.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines2003; 2: 649-60; PMID:14711326; http://dx.doi.org/ 10.1586/14760584.2.5.649 11.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Clin Virol 2006; 35: 121-9; PMID:16289903; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Stat Med 1999; 18: 3263-82; PMID:10602150; http://dx.doi.org/10.1002/(SICI) www.tandfonline.com 2153 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Infect Dis 2011; 52: 911-6; PMID:21427399; http://dx.doi.org/10.1093/cid/cir007 15.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Value Health 2012; 15: 828-34; PMID:22999132; http://dx.doi.org/10.1016/j.jval.2012.06.011 16.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2005; 191 Suppl 1: S97-106; PMID:15627236; http://dx.doi.org/10.1086/425271 17.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Med Decis Making 2009; 29: 557-69; PMID:19605882;http://dx.doi.org/10.1177/0272989X09334419 21.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Infect Dis 2013; 13: 25; PMID:23339290; http://dx.doi.org/10.1186/ 1471-2334-13-25 22.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Pharmacoecon Outcomes Res 2002; 2: 443-55;PMID:19807468; http://dx.doi.org/10.1586/ 14737167.2.5.443 23.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines2009; 8: 851-61; PMID:19538112; http://dx.doi.org/ 10.1586/erv.09.48 24.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Am J Epidemiol 1997; 146: 789-803; PMID:9384199; http://dx.doi.org/ 10.1093/oxfordjournals.aje.a009196 27.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2004; 22: 4342-50;PMID:15474727; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J 1998; 17: S132-6; PMID:9781746; http://dx.doi.org/10.1097/ 00006454-199809001-00008 29.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J 1998; 17: 196-9; PMID:9535245; http://dx.doi.org/10.1097/00006454-199803000-00005 30.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Reduction in pediatric rotavirus-related hospitaliza- tions after universal rotavirus vaccination in Belgium.Pediatr Infect Dis J 2011; 30: e120-5; PMID:21436757; http://dx.doi.org/10.1097/ INF.0b013e318214b811 32.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Micro- biol Infect 2011; 18: 918-23; PMID:22070637;http://dx.doi.org/10.1111/j.1469- 0691.2011.03700.x 33.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2010; 28: 4073-8;PMID:20398617; http://dx.doi.org/10.1016/j.vaccine.2010.03.075 34.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
N Engl J Med 2003; 348: 1737-46; PMID:12724479; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
N Engl J Med 2009; 360: 244-56; PMID:19144940; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Lancet Infect Dis 2011; 11: 760-8; PMID:21621466; http://dx.doi.org/10.1016/S1473- 3099(11)70090-1 38.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2011; 29: 2791-6; PMID:21320539; http://dx.doi.org/10.1016/j.vaccine.2011.01.104 40.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J2012; 31: 501-8; PMID:22327872; http://dx.doi.org/ 10.1097/INF.0b013e31824de9f6 41.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2008; 26: 1737-41; PMID:18325642; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Infect Dis 2011; 53: 245-53; PMID:21705316; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Infect Dis 2013; 13: 112; PMID:23452879; http://dx.doi.org/10.1186/1471- 2334-13-112 45.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Br J Hosp Med (Lond) 2013; 74: 212-6; PMID:23571392; http://dx.doi.org/10.12968/hmed.2013.74.4.212 46.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2007; 119: e22- 9; PMID:17200247; http://dx.doi.org/10.1542/ peds.2006-1572 48.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2006; 24: 6980-9; PMID:16860909; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Infect Dis 2013; 13: 303; PMID:23815523; http://dx.doi.org/10.1186/1471- 2334-13-303 50.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
JInfect Dis 2008; 197 Suppl 2: S71-5; PMID:18419413; http://dx.doi.org/10.1086/522156 51.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Jama 2005; 294:202-10; PMID:16014594; http://dx.doi.org/ 10.1001/jama.294.2.202 52.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vaccin 2011; 7: 881-2; PMID:21785283; http://dx.doi.org/ 10.4161/hv.7.8.16273 53.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines 2008; 7: 1493-506;PMID:19053206; http://dx.doi.org/10.1586/ 14760584.7.10.1493 54.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PMID:21742835; http://dx.doi.org/10.1093/infdis/ jir285 55.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Self-boost- ing vaccines and their implications for herd immunity.Proc Natl Acad Sci U S A 2012; 109: 20154-9; PMID:23169630; http://dx.doi.org/10.1073/ pnas.1209683109 56.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PLoS One 2009; 4: e6284; PMID:19606227; http://dx.doi.org/10.1371/journal.pone.0006284 57.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2014;209 Suppl 1: S32-5; PMID:24626870; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Lancet Infect Dis 2006; 6: 112-7; PMID:16439331; http://dx.doi.org/10.1016/S1473-3099(06)70384-X 59.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Proc Biol Sci 2010; 277: 3239-45; PMID:20534609; http://dx.doi.org/10.1098/rspb.2010.0994 60.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Infect Dis 1999; 28: 1230-7; PMID:10451158; http://dx.doi.org/ 10.1086/514776 61.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
"Reassessing the cost-effec- tiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.Med Decis Making 2006; 26: 38-47; PMID:16495199; http://dx.doi.org/10.1177/ 0272989X05284109 62. de Vries R, Kretzschmar M, Schellekens JF, Ver- steegh FG, Westra TA, Roord JJ, Postma MJ.Cost-effectiveness of adolescent pertussis vaccina- tion for the Netherlands: using an individual-based dynamic model.",Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PLoS One 2010; 5: e13392;PMID:20976213; http://dx.doi.org/10.1371/ journal.pone.0013392 63.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2001; 19: 470-4; http://dx.doi.org/10.1016/S0264-410X (00)00193-6 64.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2012; 130: e600-6;PMID:22908102; http://dx.doi.org/10.1542/ peds.2012-0132 65.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Annu Rev Med 1992; 43: 451-63; PMID:1580601;http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines 2013; 12: 555-65; PMID:23659302; http://dx.doi.org/10.1586/ erv.13.36 67.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Epidemiology 2011; 22: 505-15; PMID:21540743; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J R Soc Interface 2008; 5: 1505-8; PMID:18713723; http://dx.doi.org/ 10.1098/rsif.2008.0271 70.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2009; 200: 1602-5; PMID:19827945;http://dx.doi.org/10.1086/644783 71.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2010; 125: 747- 55; PMID:20308208; http://dx.doi.org/10.1542/ peds.2009-1653 72.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2009; 27: 6186-95;PMID:19815120; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Pharmacoecon Out- comes Res 2012; 12: 357-71; PMID:22812559; http://dx.doi.org/10.1586/erp.12.11 74.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines 2013; 12: 585-7; PMID:23750788; http://dx.doi.org/10.1586/ erv.13.43 75.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Am J Gastroenterol 2012; 107: 691-7; PMID:22290404; http://dx.doi.org/10.1038/ ajg.2012.7 76.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pharmacoeconomics 2011; 29: 199-211; PMID:21250759; http://dx.doi.org/10.2165/ 11584930-000000000-00000 77.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Jama 2007; 298: 1772-8;PMID:17940232; http://dx.doi.org/10.1001/ jama.298.15.1772 78.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
N Engl J Med 2006;354: 1455-63; PMID:16598044; http://dx.doi.org/ 10.1056/NEJMoa051642 81.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Curr Infect Dis Rep 2013; 15: 184-90; PMID:23381547;http://dx.doi.org/10.1007/s11908-013-0326-482.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Expert Rev Vaccines 2011; 10: 187-99; PMID:21332268;http://dx.doi.org/10.1586/erv.10.163 83.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Lancet 2011; 378: 1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8 84.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 32: 527-34; PMID:24342249; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Ther 2008; 30: 341-57; PMID:18343273; http://dx.doi.org/10.1016/j.clinthera.2008.02.003 87.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PLoS One 2013; 8: e60732; PMID:23613740; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 1996; 174 Suppl 3: S314-9; PMID:8896538; http://dx.doi.org/10.1093/infdis/174.Supplement_3.S314 89.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2008; 197 Suppl 2:S94-S100; PMID:18419417; http://dx.doi.org/ 10.1086/522155 90.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hepatology 2000; 31: 469-73;PMID:10655272; http://dx.doi.org/10.1002/ hep.510310229 91.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2007; 120: 189-99; PMID:17606579; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
"Srinivasa Rao AS, Chen MH, Pham BZ, Tricco AC, Gilca V, Duval B, Krahn MD, Bauch CT. Cohort effects in dynamic models and their impact on vacci- nation programmes: an example from hepatitis A.BMC Infect Dis 2006; 6: 174; PMID:17147828; http://dx.doi.org/10.1186/1471-2334-6-174 94.",Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Jama 2001; 285: 1729-35;PMID:11277827; http://dx.doi.org/10.1001/ jama.285.13.1729 95.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Jama 2005; 294: 797-802; PMID:16106004; http://dx.doi.org/10.1001/jama.294.7.797 www.tandfonline.com 2155 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vaccin Immunother 2014; 10: 3594-600; PMID:25483695;http://dx.doi.org/10.4161/hv.34426 97.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vac-cin Immunother 2015; 11: 214-9; PMID:25483538; http://dx.doi.org/10.4161/hv.36153 98.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2008; 122: e744-51; PMID:18762511; http://dx.doi.org/10.1542/ peds.2008-0567 99.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2008; 197 Suppl 2:S224-7; PMID:18419401; http://dx.doi.org/ 10.1086/522162 100.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J 2010; 29: 199- 204; PMID:19949362; http://dx.doi.org/10.1097/INF.0b013e3181bbf2a0 102.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Public Health 2005; 5: 68; PMID:15960856; http://dx.doi.org/10.1186/1471-2458-5-68 103.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Med Decis Making 2006; 26: 434-46; PMID:16997923; http://dx.doi.org/10.1177/0272989X06290485 104.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2014; 32: 277-83; PMID:24275483; http://dx.doi.org/10.1016/j.vaccine.2013.11.008 105.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Epidemiol Infect 2007; 135: 908-13; PMID:17291380; http://dx.doi.org/10.1017/S0950268807007893 106.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2011; 29: 8580-4; PMID:21939721; http://dx.doi.org/10.1016/j.vaccine.2011.09.024 108.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J 2009; 28: 954-9; PMID:19536039; http://dx.doi.org/10.1097/ INF.0b013e3181a90b16 109.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Ann Intern Med2013; 159: 739-45; PMID:24297190; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2005; 191: 2002-7; PMID:15897984; http://dx.doi.org/ 10.1086/430325 111.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Infect Dis 2011; 52: 332-40; PMID:21217180; http://dx.doi.org/10.1093/cid/ ciq077 112.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Epidemiol Infect 2005; 133: 245-53;PMID:15816149; http://dx.doi.org/10.1017/ S095026880400281X 113.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2010; 28: 2532-8; PMID:20117265; http://dx.doi.org/10.1016/j.vaccine.2010.01.036 114.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Epidemiol Infect 2011; 139: 658-65; PMID:20727248; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Emerg Infect Dis 2013;19: 61-8; PMID:23259937; http://dx.doi.org/ 10.3201/eid1901.120741 117.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2013; 208: 1859-68; PMID:23922376; http://dx.doi.org/10.1093/infdis/ jit405 118.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Epidemiol Infect 2012; 140: 1131-40; PMID:21906410; http://dx.doi.org/10.1017/ S0950268811001786 119.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2003; 21: 4243-9; PMID:14505905; http://dx.doi.org/10.1016/S0264-410X(03)00459-6 120.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Int J Toxicol 2005; 24: 205-13; PMID:16126614; http://dx.doi.org/ 10.1080/10915810591000659 121.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Infect Control Hosp Epidemiol 2008; 29: 1157-63; PMID:18999945; http://dx.doi.org/ 10.1086/591975 123.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PLoS One 2013; 8: e77709;PMID:24204928; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatr Infect Dis J 2005; 24: S75-82; PMID:15876932; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Vaccine Immunol 2010; 17: 1055-65; PMID:20463105; http://dx.doi.org/10.1128/ CVI.00131-10 127.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2012; 129: 968-70; PMID:22529282; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Eur J Epidemiol 2000; 16: 601-6; PMID:11078115; http://dx.doi.org/ 10.1023/A:1007626510002 129.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Int J Epidemiol 2000; 29: 753-6; PMID:10922355; http://dx.doi.org/10.1093/ije/29.4.753 130.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2012; 30: 552-64; PMID:22133508; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Infect Dis 2013; 13: 54; PMID:23363553; http://dx.doi.org/10.1186/1471-2334-13-54 132.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Public Health 2011; 11:462; PMID:21663620; http://dx.doi.org/10.1186/ 1471-2458-11-462 133.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
PLoS One 2013; 8: e53864;PMID:23349754; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vac- cine 2009; 27: 4025-30; PMID:19389452; http://dx.doi.org/10.1016/j.vaccine.2009.04.030 135.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Hum Vac- cin Immunother 2013; 9: 1272-88; PMID:23571226; http://dx.doi.org/10.4161/ hv.24253 136.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
J Infect Dis 2011; 204: 980-6; PMID:21878425;http://dx.doi.org/10.1093/infdis/jir492 137.,OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
BMC Cancer 2013; 13: 10; PMID:23298365; http://dx.doi.org/10.1186/1471-2407-13-10 138.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2013; 31: 3863-71; PMID:23830974; http://dx.doi.org/ 10.1016/j.vaccine.2013.06.064 140.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2010; 28: 5473-84; PMID:20573580; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Model for assessing human papillomavirus vaccination strategies.Emerg Infect Dis 2007; 13: 28-41; PMID:17370513; http://dx.doi.org/10.3201/eid1301.060438 142.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Pediatrics 2012; 130: e249-56; PMID:22778297; http://dx.doi.org/10.1542/ peds.2011-3587 143.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Vaccine 2007; 25: 1719-26;PMID:17229493; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Clin Infect Dis 2001; 33: 1004-10; PMID:11528572; http://dx.doi.org/10.1086/322639 145.,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
Am J Prev Med 2007; 32: 186-193; PMID:17296470; http://dx.doi.org/ 10.1016/j.amepre.2006.10.016 www.tandfonline.com 2157 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/5a/97/khvi-11-09-1052196.PMC4635729.pdf
"The serotypes reportedover this period in order of frequency included serotypes 3 © Masanari Shiramoto, Ryuzo Hanada, Christine Juergens, Yasuko Shoji, Mizuki Yoshida, Barry Ballan, David Cooper, William C Gruber, Daniel A Scott, and Beate Schmoele-Thoma*Correspondence to: Masanari Shiramoto; Email: masanari-shiramoto@lta-med.comSubmitted: 10/27/2014; Revised: 02/27/2015; Accepted: 03/13/2015 http://dx.doi.org/10.1080/21645515.2015.1030550 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
J Infect Chemother 2004; 10:359–63;PMID:15614462; http://dx.doi.org/10.1007/ s10156-004-0351-1 4.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Intern Med 2013; 52:317–24; PMID:23370738; http://dx.doi.org/ 10.2169/internalmedicine.52.8830 2204 Volume 11 Issue 9 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: http://www.mhlw.go.jp/english/database/db-hw/popu late/dl/02.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Epide-miol Infect 2010; 138:61–68; PMID:19538821; http://dx.doi.org/10.1017/S0950268809990239 8.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
BMC Health Serv Res 2012; 12:313; PMID:22970727; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
J Infect Dis 2012; 205:1408–16; PMID:22457293; http://dx.doi.org/10.1093/infdis/ jis212 10.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
"N Engl J Med 2001; 345:1042–53; PMID:11586958; http://dx.doi.org/ 10.1056/NEJMra011223 11. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU.",OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2011;29:7207–11; PMID:21689707; http://dx.doi.org/ 10.1016/j.vaccine.2011.06.056 12.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2014; 25:2364–74; PMID:24606865; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2013; 31:3577–84; PMID:23688526; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Hum Vaccin Immunother2014; 10(5):1343–53 PMID:24576885; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Avail-able at: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidan ces/Vaccines/ucm074794.htm.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Biometrics 1999; 55:1202–9; PMID:11315068; http://dx.doi.org/10.1111/j.0006-341X.1999.01202.x 19.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Hum Vaccin Immunother 2014; 10 (7):1850–8; PMID:25424792; http://dx.doi.org/ 10.4161/hv.28633 20.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
N Engl J Med 2015; 372:1114–1125; PMID:25785969; http://dx.doi.org/ 10.1056/NEJMoa1408544 22.,OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2012; 30:6802–8; PMID:23000122; http://dx.doi.org/ 10.1016/j.vaccine.2012.09.019 25.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2003;22:96–103; PMID:14604576; http://dx.doi.org/ 10.1016/S0264-410X(03)00521-8 26.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2012; 30:4435–44; PMID:22542818; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2013; 31:3594–602; PMID:23688525; http://dx.doi.org/10.1016/j.vaccine.2013.04.084 28.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
J Infect Dis 2010;201:659–61; PMID:20113178; http://dx.doi.org/ 10.1086/651376 30.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Hum Vaccin 2011; 7:919– 28; PMID:21860256; http://dx.doi.org/10.4161/ hv.7.9.15996 31.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vaccine 2014; 32:1181–6; PMID:24120483; http://dx.doi.org/10.1016/j.vaccine.2013.09.060 33.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: http://www.cdc.gov/abcs/reports-ﬁndings/surv-reports.,OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb_C/1234859711901.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: http://www.ecdc.europa.eu/en/ Pages/home.aspx.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Available at: https://www.amc.nl/web/ Research/Overview/Departments/Medical-Microbiol ogy/Medical-Microbiology/Current-research/Reference- Laboratory-for-Bacterial-Meningitis.htm?print Dtrue.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
JAMA 1993; 270:1826–31; PMID:8411526; http://dx.doi.org/10.1001/ jama.1993.03510150060030 38.,OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Emerg Infect Dis 2013; 19:1074–83; PMID:23763847; http://dx.doi.org/10.3201/eid1907.121830 40.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Clin Vaccine Immunol 2006; 13:165–9;PMID:16467321; http://dx.doi.org/10.1128/ CVI.13.2.165-169.2006 41.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
2015; 33:327–32; PMID:25448102; http://dx.doi.org/ 10.1016/j.vaccine.2014.11.023 44.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Nat Rev Immunol2009; 9:185–94; PMID:19240757; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
World J Vaccine 2013; 3:123–9; http://dx.doi.org/ 10.4236/wjv.2013.3401746.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
Vac-cine 1997; 15:1133–7; PMID:9269058; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ee/fc/khvi-11-09-1030550.PMC4635730.pdf
The Cochrane Collaboration;2011. http://www.cochrane-handbook.org.,OADS,/arxiv_data1/oa_pdf/cf/f7/medi-94-e668.PMC4635732.pdf
"Vaccines targeting the C. difﬁcile toxins include toxoids19-23 and toxin fragments.24-29Formaldehyde-inactivated native C. © Yuan-kai Wang, Ya-xian Yan, Hyeun Bum Kim, Xianghong Ju, Song Zhao, Keshan Zhang, Saul Tzipori, and Xingmin Sun *Correspondence to: Xingmin Sun; Email: Xingmin.Sun@tufts.eduSubmitted: 10/31/2014; Revised: 04/29/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/21645515.2015.1052352 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
28(11): p. 1219-27; http://dx.doi.org/10.1086/522676 3.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
30(1): p. 57-66; http://dx.doi.org/10.1086/592981 4.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
377(9759): p. 63-73;PMID:21084111; http://dx.doi.org/10.1016/S0140- 6736(10)61266-4 5.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
16(5): p. 222-9; http://dx.doi.org/10.1016/j.tim.2008.01.011 6.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
28(2): p. 140-5; http://dx.doi.org/10.1086/5117988.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
2010; 31(5): p. 431-55; PMID:20307191; http://dx.doi.org/10.1086/651706 9.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
81(956): p. 367-9; http://dx.doi.org/10.1136/ pgmj.2004.028480 11.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
28(32): p. 5245-53; http://dx.doi.org/10.1016/j.vaccine.2010.05.062 13.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
342(6): p. 390-7; http://dx.doi.org/10.1056/ NEJM200002103420604 14.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
357(9251): p. 189-93; http://dx.doi.org/10.1016/S0140-6736(00)03592-3 15.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
11(1): p. 5-10; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
"20(8): p. 528-34; http://dx.doi.org/ 10.1007/s100960100550 18. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ.",OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
42(3): p. 1035-41;http://dx.doi.org/10.1128/JCM.42.3.1035-1041.2004 19.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
71(3): p. 1608-10; http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003 20.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
205(1): p. 128-33; PMID:22124129; http://dx.doi.org/10.1093/infdis/jir688 22.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
128(3): p. 764-70; http://dx.doi.org/ 10.1053/j.gastro.2004.11.004 23.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
225(2): p. 325-9; http://dx.doi.org/10.1016/S0378-1097(03) 00560-3 25.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
79(6): p. 2295-302; PMID:21482682; http://dx.doi.org/10.1128/IAI.00130-11 26.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
30(8): p. 1492-501;PMID:22200503; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
30(13): p. 2245- 9; PMID:22306375; http://dx.doi.org/10.1016/j.vaccine.2012.01.065 31.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
69(2): p. 988-95; http://dx.doi.org/10.1128/IAI.69.2.988- 995.2001 32.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
30(28): p. 4249-58;PMID:22537987; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
81(6): p. 2190-6; PMID:23545305; http://dx.doi.org/ 10.1128/IAI.01074-12 34.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
27(27): p. 3598-604; http://dx.doi.org/10.1016/j.vaccine.2009.03.058 35.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
9(1): p.63-73; PMID:23143772; http://dx.doi.org/10.4161/ hv.22434 36.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
81(8):p. 2851-60; PMID:23716610; http://dx.doi.org/ 10.1128/IAI.01341-12 37.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
80(8): p. 2678- 88; PMID:22615245; http://dx.doi.org/10.1128/ IAI.00215-12 38.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
6(8): p. e1001061; PMID:20808849; http://dx.doi.org/10.1371/journal.ppat.1001061 39.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
10(9): p. R102; http://dx.doi.org/ 10.1186/gb-2009-10-9-r102 40.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
57 (Pt 6): p. 725-31; http://dx.doi.org/10.1099/ jmm.0.47736-0 41.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
159(Pt 7): p. 1254-66; http://dx.doi.org/ 10.1099/mic.0.066712-0 43.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
74(10): p. 6006-10; http://dx.doi.org/10.1128/IAI.00545-06 44.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
273(31): p. 19566-72; http://dx.doi.org/10.1074/ jbc.273.31.19566 45.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
32(6): p. 700-5; PMID:24342251; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
192(19): p. 4983-90; http://dx.doi.org/10.1128/ JB.00610-10 www.tandfonline.com 2221 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
8: p. 192; http://dx.doi.org/10.1186/1471-2180-8-192 50.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
79(7): p. 2856-64; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1d/6d/khvi-11-09-1052352.PMC4635733.pdf
"11The development of neutralizing antibodies to H7N9 is also delayedin H7N9-infected humans, when compared to the typicalimmune response to other IAV infections, and IgG avidity to © Rui Liu, Leonard Moise, Ryan Tassone, Andres H Gutierrez, Frances E Terry, Kotou Sangare, Matthew T Ardito, William D Martin, and Anne S De Groot *Correspondence to: Anne S De Groot; Email: dr.annie.degroot@gmail.comSubmitted: 12/19/2014; Revised: 04/28/2015; Accepted: 05/13/2015 http://dx.doi.org/10.1080/21645515.2015.1052197 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
"Results Genome analysis and epitope predictionIn previously published work, we analyzed 4 human H7N9 inﬂuenza sequences (A/Hangzhou/1/2013, A/Anhui/1/2013, A/Shanghai/1/2013, and A/Shanghai/2/2013) from GISAID (http://platform.gisaid.org/) for HLA class II-restricted epitopes, and constructed immunogenic consensus sequences (ICS) toenable broad HLA and strain coverage.",OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Lancet Infect Dis 2012; 12:687-95; PMID:22738893; http://dx.doi.org/10.1016/S1473- 3099(12)70121-4 3.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
N Engl J Med 2009;361:1945-52; PMID:19745214; http://dx.doi.org/ 10.1056/NEJMoa0906453 5.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Vaccine 2011; 29:3299-309; PMID:21349362; http://dx.doi.org/10.1016/j.vaccine.2011.02.019 6.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
http://www.nih.gov/news/health/sep2013/niaid-18.htm 8.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Media Release Novartise 2013; http://www.novartis.com/n ewsroom/media-releases/ en/2013/1743124.shtml 9.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
N Engl J Med 2013; 369:2564-6; PMID:24224560; http://dx.doi.org/10.1056/NEJMc1313186 10.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
JAMA 2014; 14:1409-19; http://dx.doi.org/ 10.1001/jama.2014.12854 12.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Emerg Infect Dis 2013; 20:192-200; http://dx.doi.org/10.3201/eid2002.131094 13.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
PLoS One 2012; 7: e49704; PMID:23239968; http://dx.doi.org/10.1371/journal.pone.0049704 15.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
PLoS One 2012; 7: e46952; PMID:23077537; http://dx.doi.org/10.1371/ journal.pone.0046952 17.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Infect Dis 2013; 207:297-305; PMID:23148285; http://dx.doi.org/10.1093/infdis/ jis684 18.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Hum Vaccin Immunother 2013; 9:950-6; PMID:23807079; http://dx.doi.org/10.4161/hv.24939 19.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
BMC Bioinformatics 2014; 15:S1; PMID:25104221; http://dx.doi.org/ 10.1186/1471-2105-15-S4-S1 20.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Bioin- formatics 2009; 25:i39-i44; PMID:19478014; http://dx.doi.org/10.1093/bioinformatics/btp221 www.tandfonline.com 2251 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Virol 2008; 82:3438-51; PMID:18216107; http://dx.doi.org/ 10.1128/JVI.01700-07 22.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Hum Vaccin Immunother 2013; 9:1577-86; PMID:23584251; http://dx.doi.org/10.4161/ hv.24615 23.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Vaccin Immunother 2014; 10:256-62; http://dx.doi.org/ 10.4161/hv.28135 26.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Genome Res 2003; 13:2498-504; PMID:14597658; http://dx.doi.org/10.1101/gr.1239303 27.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Hum Vaccin Immunother 2013; 9:1598-1607; PMID:23846304; http://dx.doi.org/10.4161/hv.25598 28.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Clin Immunol 2009; 131:189-201;PMID:19269256; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
N Engl J Med 2009; 361:2405-13; PMID:19745216; http://dx.doi.org/ 10.1056/NEJMoa0907413 30.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Infect Dis 2010; 202:1011-20; PMID:20715930; http://dx.doi.org/10.1086/ 656188 31.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Hum Vaccin Immunother 2012; 8:1243-1249; PMID:22894960; http://dx.doi.org/10.4161/hv.2111732.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Expert Rev Clin Pharmacol 2013; 6:651-62; PMID:24164613; http://dx.doi.org/10.1586/17512433.2013.835698 34.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Clin Immunol 2013; 149:534- 55; PMID:24263283; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
2014; (http://www.who.int/inﬂuenza/human_animal_interface/latest_update_h7n9/en/) 36.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Int J Infect Dis 2014; 29C:254-8; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Curr Med Chem 2005; 12:2849-65;PMID:16305475; http://dx.doi.org/10.2174/ 092986705774454733 40.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Clin Invest 2005; 115: 3602-12; PMID:16308574; http://dx.doi.org/10.1172/JCI25078 41.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Immunity 2013; 38:373-83; PMID:23395677; http://dx.doi.org/10.1016/j.immuni.2012.10.021 43.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
PLoS Comput Biol 2012;8:e1002412; PMID:22396638; http://dx.doi.org/ 10.1371/journal.pcbi.1002412 44.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Virol 2011; 85:1310-21; PMID:21084470; http://dx.doi.org/ 10.1128/JVI.01966-10 45.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Clin Immunol 2010; 137:5-14; PMID:20708973; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Vaccine 2009; 27:6512-21; PMID:19729082; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Nucleic Acids Res 2012; 40:D71-5; PMID:22102590; http://dx.doi.org/10.1093/nar/gkr981 49.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Int Immunol 2013; 25:447-57;PMID:23524391; http://dx.doi.org/10.1093/intimm/ dxt005 50.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Neuroimmunol 2005; 169:31-8; PMID:16150497; http://dx.doi.org/10.1016/j.jneuroim.2005.07.014 51.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
J Immunol 2008; 180:1758-68; PMID:18209073; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Arthritis Rheum 2012; 64:2158-68; PMID:22231228; http://dx.doi.org/ 10.1002/art.34372 53.,Non-OADS,/arxiv_data1/oa_pdf/88/77/khvi-11-09-1052197.PMC4635734.pdf
Available at http://www.ohri.ca/programs/clinical_epi-demiology/oxford.asp.,Non-OADS,/arxiv_data1/oa_pdf/f6/a6/medi-94-e1440.PMC4635742.pdf
Available at http://www.cochrane-handbook.org.,OADS,/arxiv_data1/oa_pdf/f6/a6/medi-94-e1440.PMC4635742.pdf
http://www.ncbi.nlm.nih.gov/pubmed/?term ¼Zincþtransporter þgenes þ andþurological þcancers%3A þintegrated þanalysis þsuggests þaþ roleþforþZIP11 þinþbladder þcancer.,Non-OADS,/arxiv_data1/oa_pdf/e1/c8/medi-94-e1494.PMC4635744.pdf
"2010 Cancer Registry Report, 2014. http://www.hpa.gov.tw/BHPNet/Portal/File/StatisticsFile/201305061037065219/99%E5%B9%B4%E7%99%8C%E7%97%87%E7%99%BB%E8%A8%98%E5%A0%B1%E5%91%8A.pdf.",Non-OADS,/arxiv_data1/oa_pdf/e1/c8/medi-94-e1494.PMC4635744.pdf
"The National Health Research Institute (NHRI) is in charge of the entire insurance claims database, namely the NHIRD, which consists of healthcare data from>97% of the entire Taiwan population ( http://www.nhi.gov.tw/ ).",OADS,/arxiv_data1/oa_pdf/25/3c/medi-94-e1520.PMC4635746.pdf
"In addition, all clinicalcomorbidities, complications, and outcomes were selected according to the International Classification of Diseases, Ninth Revision (ICD-9) (Supplemental Table 1, http://links.lww.com/MD/A413).",Non-OADS,/arxiv_data1/oa_pdf/06/8b/medi-94-e1524.PMC4635747.pdf
"3 and Supplemental Table 2, http://links.lww.com/MD/A413).",Non-OADS,/arxiv_data1/oa_pdf/06/8b/medi-94-e1524.PMC4635747.pdf
"Therewere no significant differences in any arrhythmia events between the 2 groups (Supplemental Table 2, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/06/8b/medi-94-e1524.PMC4635747.pdf
"Details of the search strategy are provided in Table S1, http://links.lww.com/MD/A415.",OADS,/arxiv_data1/oa_pdf/81/96/medi-94-e1539.PMC4635750.pdf
"18 Supplementary Figure S1, http://links.lww.com/MD/A415shows the risk of bias of the included trials.",Non-OADS,/arxiv_data1/oa_pdf/81/96/medi-94-e1539.PMC4635750.pdf
"Sensitivity Analysis and Publication Bias The results of sensitivity analyses using random-effects models were highly consistent with the main findings from fixed-effects models, and are displayed in the SupplementaryFigures S2–S4, http://links.lww.com/MD/A415.",Non-OADS,/arxiv_data1/oa_pdf/81/96/medi-94-e1539.PMC4635750.pdf
2015. http://stroke.ahajournals.org/content/early/2015/05/05/STROKEA-HA.115.009160.long.,Non-OADS,/arxiv_data1/oa_pdf/81/96/medi-94-e1539.PMC4635750.pdf
"After the billing process, the Taiwan National Health ResearchInstitute (NHRI) compiles data from NHI claims and then provides the National Health Insurance Research Database (NHIRD) for research (http://nhird.nhri.org.tw/).",OADS,/arxiv_data1/oa_pdf/f8/09/medi-94-e1566.PMC4635757.pdf
"The NHIRD comprises comprehensive information on clinical visits for each insuredperson, such as the demographic characteristics, inpatient andoutpatient dates, diagnostic codes in accordance with the Inter- national Classification of Disease, Revision 9, Clinical Modi- fication (ICD-9-CM), and patient prescriptions (http://nhird.nhri.org.tw/en/index.html).",Non-OADS,/arxiv_data1/oa_pdf/8b/cb/medi-94-e1585.PMC4635760.pdf
"Then the aorticmaximum diameter obtained (see Figure S1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/2f/a4/medi-94-e1591.PMC4635762.pdf
"The aortic maximum diameter decrease ratio at each follow-up point was calculated using the following formula: DDR i¼ðDpre/C0DiÞ=Dpre where D preand D istand for the aortic maximum diameter before TEVAR and at i months follow-up, respectively, and DDR istands for the aortic maximum diameter decrease ratio at i months follow-up.21 The areas of true lumen, contrast-enhanced (perfused) false lumen, and noncontrast-enhanced (thrombosed) false lumen were manually determined on the CT slices (see FigureS2, http://links.lww.com/MD/A423, Supplemental Content,which demonstrates the measurement of interested areas in pre- and post-TEVAR CT slices; see Figure S3, http:// links.lww.com/MD/A423, Supplemental Content, whichdemonstrates measurement processes of the whole and throm- bosed false lumen areas in high and low BPV groups at different follow-up points).",Non-OADS,/arxiv_data1/oa_pdf/2f/a4/medi-94-e1591.PMC4635762.pdf
"In bivariate analysis, 17 variables (age in years and 16 dichotomized variables) significantly predicted the compositeendpoint (see Supplement, http://links.lww.com/MD/A432).Using multivariable logistic regression, we identified 6 out of these 17 parameters, that were predictive for the composite endpoint of recurrent bleeding, need for intervention such asangiography or emergency surgery and death within 30 days afterthe index hemorrhage: CRP >5 mg/dL (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.06 –4.15), white blood cell count>11,300 per mL, (OR 2.46, 95% CI 1.66–3.66), ALT>35 U/L for women or >50 U/L for men (OR 1.85, 95% CI 1.04–3.29), thrombocytes /C2150,000 and <150,000 per mL (OR 1.84, 95% CI 1.2–2.82; and OR 2.82, 95% CI 1.36–5.85, respectively), creatinine >0.9 mg/dL for women or >1.1 mg/dL for men (OR 2.15, 95% CI 1.28–3.62), and hemoglobin <10 g/TABLE 1.",Non-OADS,/arxiv_data1/oa_pdf/a5/f1/medi-94-e1614.PMC4635768.pdf
"METHODS Data Source The Taiwanese government established a universal, single- payer health insurance program in 1995, providing insurancecoverage for more than 99% of the country’s population (http://www.nhi.gov.tw/).",Non-OADS,/arxiv_data1/oa_pdf/25/e6/medi-94-e1621.PMC4635771.pdf
"There were 1485 patients in the UTI cohort and 5940 patients in the non-UTI cohort (Supplementary Table 1, http://links.lww.com/MD/A427).",Non-OADS,/arxiv_data1/oa_pdf/70/ca/medi-94-e1625.PMC4635772.pdf
"When we used propensity score matching, the UTI cohort still had a higher risk of allergic rhinitis than that of the non-UTI cohort (adjusted HR ¼1.39, 95% CI ¼1.27–1.53; Supple- mentary Table 2, http://links.lww.com/MD/A427).",Non-OADS,/arxiv_data1/oa_pdf/70/ca/medi-94-e1625.PMC4635772.pdf
"Wikipedia, the free encyclopedia, http://en.wikipedia.",Non-OADS,/arxiv_data1/oa_pdf/79/e8/medi-94-e1637.PMC4635777.pdf
"http://www.fao.org/docrep/x5042e/x5042e0a.htm.Accessed February 21, 2015.",Non-OADS,/arxiv_data1/oa_pdf/79/e8/medi-94-e1637.PMC4635777.pdf
http://www.inchem.org/documents/icsc/icsc/eics0694.htm.,Non-OADS,/arxiv_data1/oa_pdf/79/e8/medi-94-e1637.PMC4635777.pdf
"Recently, a similar meta-analysis by Liu et al 44has been published online (http://www.ncbi.nlm.nih.gov/pubmed/ 26023935) during our manuscript under review.",Non-OADS,/arxiv_data1/oa_pdf/77/a4/medi-94-e1640.PMC4635778.pdf
"Questionnaires (available at http://www.unav.es/ departamento/preventiva/sun) have been validated andtested.9,10The self-administered questionnaire covers 136 indi- vidual semiquantitative food items.",Non-OADS,/arxiv_data1/oa_pdf/d2/c2/medi-94-e0924.PMC4635786.pdf
1998; http://www.gpo.gov/fdsys/pkg/FR-1998-02-11/html/98-3422.htm.Accessed 5/7/13.,OADS,/arxiv_data1/oa_pdf/16/f0/medi-94-e1315.PMC4635790.pdf
"links.lww.com/MD/A384 and Figure 1, http://links.lww.com/ MD/A384).",Non-OADS,/arxiv_data1/oa_pdf/87/31/medi-94-e1336.PMC4635792.pdf
http://www.nhi.gov.tw/ Resource/webdata/21717_1_20120808UniversalHealthCoverage.pdf.,Non-OADS,/arxiv_data1/oa_pdf/87/31/medi-94-e1336.PMC4635792.pdf
"The comparison cohort (n ¼6269) comprised patients without a history of DM who were randomly selected from theRCIPD and matched with the patients with DM in a 1:1 ratioaccording to age (each 5-year span), sex, and index year (supplementary Figure 1, http://links.lww.com/MD/A411).",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"We were able toidentify 3996 patients in DM and non-DM cohorts after pro- pensity score matching (see supplementary Tables 1 and 2, http://links.lww.com/MD/A411).",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"Multiple logistic regression model analysis revealed that, compared with the patients with-out DM, the patients with DM did not exhibit excessive risks of30-day postgastrectomy mortality or morbidities (including 30- and 90-day postoperative mortality), as shown in supplementary Table 1, http://links.lww.com/MD/A411.To further verify our observation, we used the second method, propensity matching method, to select the DM and non- DM cohorts (n ¼3996, respectively) from our database.",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"As expected, there existed no differences in baseline characteristicsand comorbidities between DM and non-DM cohorts after propensity matching (supplementary Table 2, http://links.lww.- com/MD/A411).",OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"SupplementaryTables 4 and 5, http://links.lww.com/MD/A411 illustrate thejoint effects of total gastrectomy and DM on the OR of 30- and 90-day mortality.",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"Not surprisingly, we found that total gas- trectomy was associated in marginal increase in the 30-daymortality rate (adjusted OR 1.39, 95% CI 0.93–2.09; supple- mentary Table 4, http://links.lww.com/MD/A411) and signifi- cantly elevated risk of 90-day mortality (adjusted OR 1.30, 95%CI 1.06–1.60; supplementary Table 5, http://links.lww.com/MD/A411) in nondiabetic cohorts.",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"Moreover, total gastrectomy is associated with increased 90-day mortality in nondiabetic cohort (supple- mentary Table 5, http://links.lww.com/MD/A411).",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"As shown in supplementary Tables 4 and 5,http://links.lww.com/MD/A411, patients undergoing total gas-trectomy exhibited higher surgical mortality risks than those who did not have total gastrectomy.",Non-OADS,/arxiv_data1/oa_pdf/ab/4b/medi-94-e1467.PMC4635800.pdf
"Partici-pants (n ¼106) in the second stage were recruited from the Lushan County of Pingdingshan City, Luolong district of Luoyang City, and Gushi County of Xinyang city to corroboratethe calibrated model attained among the first stage population(Supplementary Table 1, http://links.lww.com/MD/A401).",Non-OADS,/arxiv_data1/oa_pdf/87/ce/medi-94-e1475.PMC4635802.pdf
"In multivariate analysis of OS(see supplementary Table S1, http://links.lww.com/MD/ A404), N classification and FH tumor type were independent prognostic factors for overall survival ( P¼0.011 and 0.034).",Non-OADS,/arxiv_data1/oa_pdf/fa/9d/medi-94-e1505.PMC4635808.pdf
"In multivariate analysis of DMFS (see supplementary Table S2, http://links.lww.com/MD/A404), high preEBV-DNA level was associated with a high risk of distant metastasis (HR 2.524, 95%CI 1.242–5.127, P¼0.010).",Non-OADS,/arxiv_data1/oa_pdf/fa/9d/medi-94-e1505.PMC4635808.pdf
"Image Postprocessing and Analysis All DCE-MRI analyses were conducted using open-source software packages, including the Rpackage (http://dcemri.sour- ceforge.net/) and a medical image nonrigid registration package(http://cmictig.cs.ucl.ac.uk/wiki/index.php/NiftyReg).",OADS,/arxiv_data1/oa_pdf/3d/96/medi-94-e1529.PMC4635813.pdf
"Many articles have proposed using image registration methods 13to handle body motion within time domain.11,14Here, the workstation provided an automatic nonlinear registration framework15to help remove any error of misalignment between consecutive MRI scans, thus making our results more accurate (for more visual results, please refer to Supplemental Digital Content, http://links.lww.com/MD/A431).",Non-OADS,/arxiv_data1/oa_pdf/3d/96/medi-94-e1529.PMC4635813.pdf
"All S. aureus reagent files used in our in silico typing were downloaded on August 27, 2014 (http://saureus.mlst.net).These data included allele-specific FASTA nucleotide sequences across the 7 representative S. aureus genes ( arcC, aroE, glpF , gmk, pta, tpiA, yqiL ).",OADS,/arxiv_data1/oa_pdf/d1/8e/medi-94-e1534.PMC4635816.pdf
Available from: http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html.,OADS,/arxiv_data1/oa_pdf/d1/8e/medi-94-e1534.PMC4635816.pdf
"MRI Data Processing Functional data were analyzed using DPARSFA (http:// rfmri.org/DPARSF),27REST (http://www.restfmri.net)28and SPM8 (www.fil.ion.ucl.ac.uk/spm).",OADS,/arxiv_data1/oa_pdf/93/e8/medi-94-e1550.PMC4635820.pdf
"Diffusion-tensor images data were preprocessed and ana- lyzed using the Pipeline for Analyzing Brain Diffusion Imagestoolkit (PANDA; http://www.nitrc.org/projects/panda), 30 which synthesizes procedures in FSL (http://fsl.fmrib.ox.",OADS,/arxiv_data1/oa_pdf/93/e8/medi-94-e1550.PMC4635820.pdf
"http://www.ncbi.nlm,nih.gov/bookshelf/br.fcgi?book=eurekah&part=A28844.",Non-OADS,/arxiv_data1/oa_pdf/ab/c9/medi-94-e1571.PMC4635822.pdf
"5: 605-610, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.605 ▣ORIGINAL ARTICLE  •Received 13 April 2015, revised 1 September 2015, accepted 3 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/41/ea/kjp-53-5-605.PMC4635823.pdf
"*Corresponding author (saraa96@yahoo.com) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Seropositivity of Toxoplasmosis in Pregnant Women by  ELISA at Minia University Hospital, Egypt  Amany M. Kamal1, Azza K. Ahmed1,*, Manal Z. M. Abdellatif1, Mohamed Tawfik2, Ebtesam E. Hassan3  1Department of Parasitology, Faculty of Medicine, Minia University, Minia 61519, Egypt; 2Department of Obstetrics and Gynecology, Faculty of  Medicine, Minia University, Minia 61519, Egypt; 3Department of Public Health and Preventive Medicine, Faculty of Medicine, Minia University,   Minia 61519, Egypt Abstract:  Toxoplasmosis is considered as an important risk factor for bad obstetric history (BOH) and one of the major  causes of congenitally acquired infections.",Non-OADS,/arxiv_data1/oa_pdf/41/ea/kjp-53-5-605.PMC4635823.pdf
"5: 653-659, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.653 ▣BRIEF COMMUNICATION  •Received 1 June 2015, revised 10 August 2015, accepted 14 August 2015.",Non-OADS,/arxiv_data1/oa_pdf/e4/45/kjp-53-5-653.PMC4635824.pdf
"© 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Detection of Tick-Borne Pathogens in the Korean Water  Deer ( Hydropotes inermis argyropus ) from Jeonbuk  Province, Korea Giyong Seong1,†, Yu-Jung Han1,†, Sung-Suck Oh2, Joon-Seok Chae2, Do-Hyeon Yu3, Jinho Park4, Bae-Keun Park5,  Jae-Gyu Yoo6, Kyoung-Seong Choi1,* 1College of Ecology and Environmental Science, Kyungpook National University, Sangju 37224, Korea; 2Laboratory of Veterinary Internal Medicine,  BK21 PLUS Program for Creative Veterinary Science Research, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul  National University, Seoul 08826, Korea; 3College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea; 4College of  Veterinary Medicine, Chonbuk National University, Iksan 54596, Korea; 5College of Veterinary Medicine, Chungnam National University, Daejoen  34134, Korea; 6Laboratory of Veterinary Clinics, National Institute of Animal Science Rural Development Administration, Jeonju 54875, Korea Abstract:  The objective of this study was to investigate the prevalence of tick-borne pathogens in the Korean water deer  (Hydropotes inermis argyropus ).",Non-OADS,/arxiv_data1/oa_pdf/e4/45/kjp-53-5-653.PMC4635824.pdf
"5: 611-618, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.611 ▣ORIGINAL ARTICLE •Received 3 March 2015, revised 7 July 2015, accepted 29 July 2015.",Non-OADS,/arxiv_data1/oa_pdf/f2/c4/kjp-53-5-611.PMC4635825.pdf
"*Corresponding author (sungshik@jnu.ac.kr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Identification and Prevalence of Globocephalus samoensis   (Nematoda: Ancylostomatidae) among Wild Boars ( Sus  scrofa coreanus ) from Southwestern Regions of Korea  Kyu-Sung Ahn1, Ah-Jin Ahn1, Tae-Hoon Kim1, Guk-Hyun Suh2, Kyoung-Woong Joo3, Sung-Shik Shin1,* 1Department of Parasitology and Department of Theriogenology, College of Veterinary Medicine, Chonnam National University, Gwangju 61186,  Korea; 2Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea; 3Department of  Clinical Pathology, Gwangju Health University, Gwangju 62287, Korea Abstract:  This study describes the first record of Globocephalus samoensis  (Nematoda: Ancylostomatidae) recovered in  wild boars from southwestern regions of Korea.",Non-OADS,/arxiv_data1/oa_pdf/f2/c4/kjp-53-5-611.PMC4635825.pdf
"5: 545-551, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.545 ▣ORIGINAL ARTICLE  •Received 23 July 2015, revised 30 September 2015, accepted 30 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/ad/5d/kjp-53-5-545.PMC4635826.pdf
"*Corresponding author (tsyong212@yuhs.ac) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Schistosoma mansoni -Related Hepatosplenic Morbidity in  Adult Population on Kome Island, Sengerema District,  Tanzania Godfrey M. Kaatano1, Duk-Young Min2, Julius E. Siza1, Tai-Soon Yong3,*, Jong-Yil Chai4, Yunsuk Ko5,   Su-Young Chang5, John M. Changalucha1 , Keeseon S. Eom6, Han-Jong Rim7  1National Institute for Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/ad/5d/kjp-53-5-545.PMC4635826.pdf
"5: 535-543, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.535 ▣ORIGINAL ARTICLE  •Received 23 July 2015, revised 30 September 2015, accepted 30 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/2c/66/kjp-53-5-535.PMC4635827.pdf
"*Corresponding author (tsyong212@yuhs.ac) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Integrated Schistosomiasis and Soil-Transmitted  Helminthiasis Control over Five Years on Kome Island,  Tanzania Godfrey M. Kaatano1, Julius E. Siza1, Joseph R. Mwanga1, Duk-Yong Min2, Tai-Soon Yong3,*, Jong-Yil Chai4,  Yunsuk Ko5, Su Young Chang5, Cyril M. Kullaya5, Han-Jong Rim6, John M. Changalucha1, Keeseon S. Eom7 1National Institute for Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/2c/66/kjp-53-5-535.PMC4635827.pdf
"5: 553-559, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.553 ▣ ORIGINAL ARTICLE  •Received 23 July 2015, revised 30 September 2015, accepted 30 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/ff/cb/kjp-53-5-553.PMC4635828.pdf
"*Corresponding author (keeseon.eom@gmail.com) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Improved Socio-Economic Status of a Community  Population Following Schistosomiasis and Intestinal Worm  Control Interventions on Kome Island, North-Western  Tanzania Joseph R. Mwanga1, Godfrey M. Kaatano1, Julius E. Siza1, Su Young Chang2, Yunsuk Ko2, Cyril M. Kullaya2,   Jackson Nsabo2, Keeseon S. Eom3,*, Tai-Soon Yong4, Jong-Yil Chai5, Duk-Young Min6, Han-Jong Rim7,   John M. Changalucha1 1National Institute for Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/ff/cb/kjp-53-5-553.PMC4635828.pdf
"5: 619-625, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.619 ▣ORIGINAL ARTICLE  •Received 16 June 2015, revised 23 July 2015, accepted 27 July 2015.",Non-OADS,/arxiv_data1/oa_pdf/84/67/kjp-53-5-619.PMC4635829.pdf
"*Corresponding author (wmsohn@gnu.ac.kr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Larval Gnathostoma spinigerum  Detected in Asian Swamp  Eels, Monopterus albus,  Purchased from a Local Market in  Yangon, Myanmar Jong-Yil Chai1, Woon-Mok Sohn2,*, Byoung-Kuk Na2, Jong-Bok Park3, Hoo-Gn Jeoung3, Eui-Hyug Hoang3,   Thi Thi Htoon4, Htay Htay Tin4   1Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul 03080, Korea; 2Department of Parasitology  and Tropical Medicine, and Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 52727, Korea; 3Korea Association  of Health Promotion, Seoul 07649, Korea; 4National Health Laboratory, Yangon 11191, Myanmar  Abstract:  The present study was performed to determine the infection status of swamp eels with Gnathostoma  sp.",Non-OADS,/arxiv_data1/oa_pdf/84/67/kjp-53-5-619.PMC4635829.pdf
"5: 515-524, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.515 ▣ ORIGINAL ARTICLE •Received 23 July 2015, revised 30 September 2015, accepted 4 October 2015.",Non-OADS,/arxiv_data1/oa_pdf/f2/03/kjp-53-5-515.PMC4635830.pdf
"*Corresponding author (cjy@snu.ac.kr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Prevalence of Schistosomes and Soil-Transmitted  Helminths among Schoolchildren in Lake Victoria Basin,  Tanzania  Julius E. Siza1, Godfrey M. Kaatano1, Jong-Yil Chai2,*, Keeseon S. Eom3, Han-Jong Rim4, Tai-Soon Yong5,   Duk-Young Min6, Su Young Chang7, Yunsuk Ko7, John M. Changalucha1 1National Institute of Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/f2/03/kjp-53-5-515.PMC4635830.pdf
[http://apps.who.int/tdr/svc/diseases/schistoso - miasis] Accessed on 16 December 2014.,Non-OADS,/arxiv_data1/oa_pdf/f2/03/kjp-53-5-515.PMC4635830.pdf
"5: 561-569, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.561 ▣ORIGINAL ARTICLE  •Received 23 July 2015, revised 30 September 2015, accepted 30 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/7f/41/kjp-53-5-561.PMC4635831.pdf
"*Corresponding author (keeseon.eom@gmail.com) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Improved Perceptions and Practices Related to  Schistosomiasis and Intestinal Worm Infections Following  PHAST Intervention on Kome Island, North-Western  Tanzania  Joseph R. Mwanga1, Godfrey M. Kaatano1, Julius E. Siza1, Su Young Chang2, Yunsuk Ko2, Cyril M. Kullaya2,   Jackson Nsabo2, Keeseon S. Eom3,*, Tai-Soon Yong4, Jong-Yil Chai5, Duk-Young Min6, Han-Jong Rim7,   John M. Changalucha1 1National Institute for Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/7f/41/kjp-53-5-561.PMC4635831.pdf
"5: 583-595, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.583 ▣MINI-REVIEW •Received 8 May 2015, revised 10 August 2015, accepted 10 August 2015.",Non-OADS,/arxiv_data1/oa_pdf/2e/04/kjp-53-5-583.PMC4635832.pdf
"*Corresponding author (lmarchat@gmail.com) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.DEAD/DExH-Box RNA Helicases in Selected Human  Parasites Laurence A. Marchat1,*, Silvia I. Arzola-Rodríguez2, Olga Hernandez-de la Cruz2, Itzel Lopez-Rosas1,   Cesar Lopez-Camarillo2 1Institutional Program of Molecular Biomedicine, Biotechnology Program, National School of Medicine and Homeopathy of the National Polytechnic  Institute, Mexico City, CP 07320, Mexico; 2Genomics Sciences Program, Autonomous University of Mexico City, Mexico City, CP 03100, Mexico Abstract:  DEAD/DExH-box RNA helicases catalyze the folding and remodeling of RNA molecules in prokaryotic and eu - karyotic cells, as well as in many viruses.",Non-OADS,/arxiv_data1/oa_pdf/2e/04/kjp-53-5-583.PMC4635832.pdf
"5: 525-533, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.525 ▣ORIGINAL ARTICLE  •Received 23 July 2015, revised 30 September 2015, accepted 4 October 2015.",Non-OADS,/arxiv_data1/oa_pdf/28/ca/kjp-53-5-525.PMC4635833.pdf
"*Corresponding author (cjy@snu.ac.kr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Prevalence of Schistosomes and Soil-Transmitted  Helminths and Morbidity Associated with Schistosomiasis  among Adult Population in Lake Victoria Basin, Tanzania  Julius E. Siza1, Godfrey M. Kaatano1, Jong-Yil Chai2,*, Keeseon S. Eom3, Han-Jong Rim4, Tai-Soon Yong5,   Duk-Young Min6, Su Young Chang7, Yunsuk Ko7, John M. Changalucha1 1National Institute of Medical Research, P .O.",Non-OADS,/arxiv_data1/oa_pdf/28/ca/kjp-53-5-525.PMC4635833.pdf
"5: 641-645, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.641 ▣BRIEF COMMUNICATION  •Received 18 August 2015, revised 25 September 2015, accepted 25 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/15/ff/kjp-53-5-641.PMC4635834.pdf
"© 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Monitoring of Fasciola  Species Contamination in Water  Dropwort by COX1  Mitochondrial and ITS-2 rDNA  Sequencing Analysis In-Wook Choi1,†, Hwang-Yong Kim2,†, Juan-Hua Quan3, Jae-Gee Ryu2, Rubing Sun1, Young-Ha Lee1,* 1Department of Infection Biology, Chungnam National University School of Medicine, Daejeon 35015, Korea; 2Microbial Safety Team, National  Institute of Agricultural Science, Rural Development Administration, Wanju 55365, Korea; 3Department of Gastroenterology, The Affiliated Hospital of  Guangdong Medical College, Zhanjiang 524-001, Guangdong, China Abstract:  Fascioliasis, a food-borne trematode zoonosis, is a disease primarily in cattle and sheep and occasionally in  humans.",Non-OADS,/arxiv_data1/oa_pdf/15/ff/kjp-53-5-641.PMC4635834.pdf
"5: 647-651, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.647 ▣BRIEF COMMUNICATION  •Received 22 April 2015, revised 31 July 2015, accepted 19 August 2015.",Non-OADS,/arxiv_data1/oa_pdf/38/73/kjp-53-5-647.PMC4635835.pdf
"*Corresponding author (mkose@aku.edu.tr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Infections of Larval Stages of Dicrocoelium dendriticum   and Brachylaima  sp.",Non-OADS,/arxiv_data1/oa_pdf/38/73/kjp-53-5-647.PMC4635835.pdf
"5: 571-574, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.571 ▣BRIEF COMMUNICATION •Received 30 September 2015, revised 4 October 2015, accepted 4 October 2015.",Non-OADS,/arxiv_data1/oa_pdf/90/65/kjp-53-5-571.PMC4635836.pdf
"*Corresponding author (cjy@snu.ac.kr) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.High Malaria Prevalence among Schoolchildren on Kome  Island, Tanzania Min-Jae Kim1, Bong-Kwang Jung1, Jong-Yil Chai1,*, Keeseon S. Eom2, Tai-Soon Yong3, Duk-Young Min4,   Julius E. Siza5, Godfrey M. Kaatano5, Josephat Kuboza5, Peter Mnyeshi5, John M. Changalucha5, Yunsuk Ko6,   Su Young Chang6, Han-Jong Rim7 1Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul 03080, Korea; 2Department of Parasitology  and Medical Research Institute, Chungbuk National University School of Medicine, Cheongju 28644, Korea; 3Department of Environmental Medical  Biology and Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul 03722, Korea; 4Department of Microbiology and  Immunology, Eulji University College of Medicine, Daejeon 34824, Korea; 5National Institute of Medical Research, Mwanza, Tanzania; 6Good  Neighbors International, Tanzania Western Chapter, Mwanza, Tanzania; 7Department of Parasitology, College of Medicine, Korea University,   Seoul 02841, Korea Abstract:  In order to determine the status of malaria among schoolchildren on Kome Island (Lake Victoria), near Mwanza,  Tanzania, a total of 244 schoolchildren in 10 primary schools were subjected to a blood survey using the fingerprick  method.",Non-OADS,/arxiv_data1/oa_pdf/90/65/kjp-53-5-571.PMC4635836.pdf
"5: 597-603, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.597 ▣ORIGINAL ARTICLE  •Received 31 May 2015, revised 5 August 2015, accepted 14 August 2015.",Non-OADS,/arxiv_data1/oa_pdf/99/d1/kjp-53-5-597.PMC4635837.pdf
"© 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Activation of MAPK Is Required for ROS Generation and  Exocytosis in HMC-1 Cells Induced by Trichomonas  vaginalis -Derived Secretory Products Giimaa Narantsogt1,2,†, Arim Min1,†, Young Hee Nam1, Young Ah Lee1, Kyeong Ah Kim1, Gurbadam Agvaandaram2,  Temuulen Dorjsuren2, Jamel El-Benna3, Myeong Heon Shin1,* 1Department of Environmental Medical Biology, Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul 03722, Korea;  2Department of Basic Science, School of Pharmacy and Biomedicine, Mongolian National  University of Medical Sciences, Ulaanbaatar, Mongolia;  3DR-CNRS Centre de Recherche Biomedical, INSERM U773, Universite Paris & Denis Diderot, Paris, France Abstract:  Trichomonas vaginalis  is a flagellated protozoan parasite that causes vaginitis and cervicitis in women and as - ymptomatic urethritis and prostatitis in men.",Non-OADS,/arxiv_data1/oa_pdf/99/d1/kjp-53-5-597.PMC4635837.pdf
"5: 627-639, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.627 ▣ORIGINAL ARTICLE  •Received 9 April 2015, revised 26 July 2015, accepted 3 September 2015.",Non-OADS,/arxiv_data1/oa_pdf/fb/f3/kjp-53-5-627.PMC4635838.pdf
"*Corresponding author (kino624@hama-med.ac.jp) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Metagonimus yokogawai  (Trematoda: Heterophyidae):  From Discovery to Designation of a Neotype Takeshi Shimazu1, Hideto Kino2,* 110486-2 Hotaka-Ariake, Azumino, Nagano 399-8301, Japan; 2Department of Infectious Diseases, Hamamatsu University School of Medicine,  Hamamatsu, Shizuoka 431-3192, Japan  Abstract:  Metagonimus yokogawai  (Katsurada, 1912) Katsurada, 1912 (Trematoda: Heterophyidae) is parasitic in the  small intestine of mammals including man and birds in Far Eastern Russia, Korea, Japan, China, and Taiwan.",Non-OADS,/arxiv_data1/oa_pdf/fb/f3/kjp-53-5-627.PMC4635838.pdf
"5: 575-581, October 2015   http://dx.doi.org/ 10.3347/kjp.2015.53.5.575 ▣MINI-REVIEW •Received 25 March 2015, revised 2 June 2015, accepted 4 August 2015.",Non-OADS,/arxiv_data1/oa_pdf/65/78/kjp-53-5-575.PMC4635839.pdf
"*Corresponding author (roland20@wp.pl) © 2015, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Plasmodium knowlesi  as a Threat to Global Public Health Roland Wesolowski *, Alina Wozniak, Celestyna Mila-Kierzenkowska, Karolina Szewczyk-Golec The Chair of Medical Biology, Ludwik Rydygier Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland Abstract:  Malaria is a tropical disease caused by protozoans of the Plasmodium  genus.",Non-OADS,/arxiv_data1/oa_pdf/65/78/kjp-53-5-575.PMC4635839.pdf
"© Jos /C19e Garcia-Sicilia, Javier Arístegui, F /C19elix Ome ~naca, Alfonso Carmona, Juan C Tejedor, Jos /C19e M Merino, Pilar García-Corbeira, Karl Walravens, Vinod Bambure, Philippe Moris, Adrian Caplanusi, Paul Gillard, and Ilse Dieussaert*Correspondence to: Jos /C19e Garcia-Sicilia; Email: jgarcia-sicilia@telefonica.net Submitted: 03/18/2015; Revised: 05/29/2015; Accepted: 06/14/2015 http://dx.doi.org/10.1080/21645515.2015.1063754 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
"A sum-mary of the studies protocols can be accessed at http://www.gsk-clinicalstudyregister.com/ (GSK study ID 113462 and 113528).Study participants Participants included in Study A and Study B were healthy children 6–35 months and 3–17 years of age at the time of vacci-nation, respectively.",Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
JAMA 2009; 302:1880-7; PMID:19822626; http://dx.doi.org/10.1001/jama.2009.1536 2.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Science 2009; 324:1557-61; PMID:19433588; http://dx.doi.org/10.1126/science.1176062 3.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
N Engl J Med 2009; 360:2605-15; PMID:19423869; http://dx.doi.org/ 10.1056/NEJMoa0903810 4.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
N Engl J Med 2010; 362:1708-19; PMID:20445182; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Lancet 2009; 374:2072-9;PMID:19913290; http://dx.doi.org/10.1016/S0140- 6736(09)61638-X 6.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
JAMA 2009; 302:1872-9; PMID:19822627; http://dx.doi.org/10.1001/jama.2009.1496 7.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
"Pandemic (H1N1) 2009 - update 94.Accessed April 27, 2015 at: http://www.who.int/csr/ don/2010_04_01/en/ 8.",Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
"Accessed April 24, 2015 at: http://www.who.int/inﬂuenza/human_animal_inter face/virology_laboratories_and_vaccines/inﬂuenza_virus_infections_humans_feb14.pdf?ua=1) 10.",Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Curr Opin Pediatr 2010; 22:83-7; PMID:20068413; http://dx.doi.org/10.1097/ MOP.0b013e328335031711.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
AmJ Epidemiol 2009; 170:679-86; PMID:19679750; http://dx.doi.org/10.1093/aje/kwp237 12.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
JAMA 2010; 303:943-50; PMID:20215608; http://dx.doi.org/10.1001/ jama.2010.250 13.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Arch Dis Child 2008;93:433-8; PMID:18192315; http://dx.doi.org/ 10.1136/adc.2006.101477 14.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
JAMA 2010; 303:73-4; PMID:20026596; http://dx.doi.org/ 10.1001/jama.2009.1929 15.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Vaccine 2010; 28:1740-5; PMID: 20034605; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830 17.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065 20.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Vaccine 2011; 29:4353- 61; PMID:21504774; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650 22.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Inﬂuenza Other Respir Viruses 2013; 7:55-65;PMID:22405557; http://dx.doi.org/10.1111/j.1750- 2659.2012.00349.x24.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Clin Vaccine Immunol 2011; 18:835-43; PMID:21450978; http://dx.doi.org/ 10.1128/CVI.00480-10 25.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875- 010-9490-6 26.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
J Infect Dis 2011; 203:1054-62; PMID:21450995; http://dx.doi.org/10.1093/infdis/ jiq174 27.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
BMC Infect Dis 2014; 14:425; PMID:25078387; http://dx.doi.org/10.1186/1471- 2334-14-425 28.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Emerg Infect Dis 2008; 14:121-8; PMID:18258091;http://dx.doi.org/10.3201/eid1401.061283 29.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
J Infect Dis 2011; 203:158-67; PMID:21288814; http://dx.doi.org/10.1093/infdis/jiq039 30.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Lancet Infect Dis 2014; 14:227-38; PMID:24360892; http://dx.doi.org/10.1016/S1473-3099(13)70238-X 33.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
PLoS One 2011; 6:e20433; PMID:21633708; http://dx.doi.org/10.1371/journal.pone.0020433 34.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Ann Neurol 2011; 70:410-7; PMID:21866560; http://dx.doi.org/10.1002/ ana.22587 35.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Lancet 2007; 369:499-511; PMID:17292770; http://dx.doi.org/10.1016/S0140-6736(07)60237-2 37.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Curr Opin Neurobiol 2011; 21:897-903; PMID:21963829; http://dx.doi.org/ 10.1016/j.conb.2011.09.003 38.,OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Vaccine 2011; 29:2120-6; PMID:21238573; http://dx.doi.org/10.1016/j.vaccine.2010.12.125 40.,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
Immunoﬂuores- cence analysis of T-cell responses in health and disease.J Clin Immunol 2000; 20:391-9; PMID:11202228; http://dx.doi.org/10.1023/A:1026403724413 www.tandfonline.com 2369 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/ad/95/khvi-11-10-1063754.PMC4635840.pdf
"Carbonic anhydrase IX (CA9, best known as CAIX) is a hypoxia–induced, © Shawn C Chafe and Shoukat Dedhar *Correspondence to: Shoukat Dedhar; Email: sdedhar@bccrc.caSubmitted: 04/30/2015; Accepted: 05/02/2015 http://dx.doi.org/10.1080/2162402X.2015.1048955 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
Nat Med 2013; 19:1423-37; PMID:24202395; http://dx.doi.org/ 10.1038/nm.3394 2.,OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175 3.,Non-OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi.org/10.1084/jem.20131916 5.,Non-OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
BMC Cancer 2011; 11: 504; PMID:22128892; http://dx.doi.org/10.1186/ 1471-2407-11-504 6.,Non-OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
"Chafe SC, Lou Y, Sceneay J, Vallejo M, Hamilton MJ, McDonald PC, Bennewith KL, Moller A, Dedhar S.Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production.Cancer Res 2015; 75:996-1008; PMID:25623234; http://dx.doi.org/10.1158/0008-5472.CAN-14-3000 8.",Non-OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/70/ad/koni-04-12-1048955.PMC4635843.pdf
"7-13We believeKeywords: immunization, immunization information systems, mobile applications,mobile technology, vaccine hesitancy © Kumanan Wilson, Katherine M Atkinson, and Jacqueline Westeinde *Correspondence to: Kumanan Wilson; Email:kwilson@ohri.ca Submitted: 05/11/2015 Accepted: 05/27/2015 http://dx.doi.org/10.1080/21645515.2015.1057362 This is an Open Access article distributed under theterms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
"Ingraham N. Apple has sold 700 million iPhones, 25 million Apple TVs http://www.theverge.com/2015/ 3/9/8164357/apple-watch-event-700-million-iphones- sold.",Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
The Verge: Vox Media 2015 4. https://www.apple.com/researchkit/ 5. https://developer.apple.com/healthkit/ 6. https://www.apple.com/ca/ios/whats-new/health/ 7.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
JAMA 2012; 307(16):1702-08; http://dx.doi.org/10.1001/jama.2012.502 9.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Am J Public Health 2012; 102(2):e15-e21; PMID:22390457; http://dx.doi.org/10.2105/AJPH.2011.300331 10.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Jama 2012; 307(16):1702-8; PMID:22535855; http://dx.doi.org/10.1001/jama.,OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Hum Vaccines Immunother 2013; 9 (8):1802-11; PMID:23807361; http://dx.doi.org/ 10.4161/hv.25031 12.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Prev Med 2013; 57 (2):75-80; PMID:23624252; http://dx.doi.org/ 10.1016/j.ypmed.2013.04.007 2398 Volume 11 Issue 10 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Vaccine 2015; 33(14):1629-32; PMID:25704801; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Canadian National Vaccine Safety Network; iTunes; Accessed December 2014; URL:https://itunes.apple.com/ca/app/canadian-national-vaccine/id938262382?,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Availiable from: http://www.phac- aspc.gc.ca/publicat/ccdr-rmtc/04vol30/dr3005a-eng.php 21.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
"Health Map http://healthmap.org/en/ Accessed January 20, 2014 25.",Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
Lancet Infect Dis 2013; 13(7):606-13; PMID:23676442; http://dx.doi.org/10.1016/ S1473-3099(13)70108-7 26.,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
J Service Res 2000; 2(4):307-20;http://dx.doi.org/10.1177/109467050024001 27.,OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
http://www.ihtsdo.org/snomed-ct. Accesssed May 4 2015 www.tandfonline.com 2399 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/00/50/khvi-11-10-1057362.PMC4635844.pdf
"Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.Nicotine & Tobacco Research , 2015, 1456–1464 doi:10.1093/ntr/ntv024 Original investigation Advance Access publication April 26, 2015 1456 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/99/9d/ntv024.PMC4635856.pdf
http://journals.lww.com/ lww-medicalcare/pages/default.aspx .,Non-OADS,/arxiv_data1/oa_pdf/99/9d/ntv024.PMC4635856.pdf
"3These rec- ommendations can be category A recommendations, where the © Litjen Tan *Correspondence to: Litjen J Tan; Email: lj.tan@immunize.org Submitted: 07/15/2014; Revised: 10/13/2014; Accepted: 10/26/2014http://dx.doi.org/10.4161/21645515.2014.982998 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"As part ofthis effort, ACOG has launched a comprehensive website to pro-mote efforts to vaccinate the pregnant patient: http://www.immunizationforwomen.org/.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
The American College of Physicians (ACP) The American College of Physicians (ACP) has launched an initiative to improve adult immunization by tying it to qualityimprovement through its Quality Connect programs (http://immunization.acponline.org/).,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Vaccine 2010; 28 Suppl 1:A68-A75; PMID:20413002; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"Centers for Dis- ease Control and Prevention [serial online] 2014; http://www.cdc.gov/vaccines/hcp/acip-recs/index.html Accessed June 12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Vaccine 2011; 29:7049-57; PMID:21782873; http://dx.doi.org/10.1016/j.vaccine.2011.07.030 10.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Am J Infect Control 2011; 39:488- 94; PMID:21288599; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"National Adult and Inﬂuenza Immunization Summit [serial online] 2014;http://www.izsummitpartners.org/ Accessed June 1, 2014 14.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Vaccine 2013; 31:279-84; PMID:23174197; http://dx.doi.org/10.1016/j.vaccine.2012.11.033 15.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Am J Med 2008; 121:S28-35;PMID:18589065; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Vaccine 2012; 30:3778-89; PMID:22172504; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Am J Public Health 2013;103:1419-27; PMID:23763402; http://dx.doi.org/ 10.2105/AJPH.2012.301189 20.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Am J Public Health 2013; 103:164-9; PMID:22698055; http://dx.doi.org/10.2105/AJPH.2011.300600 22.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"Guide to Community Preven- tive Services [serial online] 14 A.D.;http://www.thecommunityguide.org/vaccines/index.html Accessed June 30, 2014 29.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"General Accounting Ofﬁce [serial online] 2011;http://www.gao.gov/products/GAO-12-61 Accessed June 30, 201430.",Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Int J Public Health 2013; 58:865-74;PMID:23354183; http://dx.doi.org/10.1007/s00038- 012-0438-x 31.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Vaccine 2012; 30:5222-8; PMID:22721901; http://dx.doi.org/ 10.1016/j.vaccine.2012.06.012 32.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
Ann Fam Med 2013; 11:429-36; PMID:24019274; http://dx.doi.org/10.1370/afm.1542 33.,Non-OADS,/arxiv_data1/oa_pdf/58/51/khvi-11-09-982998.PMC4635860.pdf
"4,5Clonal expansion (i.e., high clonality), or the large © Wei Zhu, Claire Germain, Zheng Liu, Yinong Sebastian, Priyanka Devi, Samantha Knockaert, Philip Brohawn, Kim Lehmann, Diane Damotte, Pierre Valid ire, Yihong Yao, Viia Valge-Archer, Scott A Hammond, Marie-Caroline Dieu-Nosjean, and Brandon W Higgs*Correspondence to: Wei Zhu; Email: zhuw@medimmune.comSubmitted: 02/13/2015; Revised: 04/08/2015; Accepted: 04/16/2015 http://dx.doi.org/10.1080/2162402X.2015.1051922 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
http://www.R-project.org).,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Bioinformatics 2014; 30:3181-8.; PMID:25095879; http://dx.doi.org/ 10.1093/bioinformatics/btu523 3.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immunol Rev 1988; 105:5-26;PMID:3058579; http://dx.doi.org/10.1111/j.1600- 065X.1988.tb00763.x 5.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Science 1996;271:1086-91; PMID:8599084; http://dx.doi.org/ 10.1126/science.271.5252.1086 6.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immunol Res 1999; 20:101-8; PMID:10580635; http://dx.doi.org/10.1007/BF02786466 7.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Trends Immunol 2009; 30:301-5; PMID:19541537; http://dx.doi.org/10.1016/j.it.2009.04.007 8.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2007; 178:6912-22; PMID:17513740; http://dx.doi.org/10.4049/ jimmunol.178.11.6912 9.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immunol Rev 1997; 160:63-77; PMID:9476666; http://dx.doi.org/ 10.1111/j.1600-065X.1997.tb01028.x 10.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Exp Med 2008; 205:711-23; PMID:18332179; http://dx.doi.org/10.1084/jem.20071140 11.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immunol Rev 2005; 205:72-93;PMID:15882346; http://dx.doi.org/10.1111/j.0105- 2896.2005.00275.x 12.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284 14.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Trends Immunol 2014; 35:571-80; PMID:25443495; http://dx.doi.org/10.1016/j.it.2014.09.006 15.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Am J Respir CritCare Med 2014; 189:832-44; PMID:24484236; http://dx.doi.org/10.1164/rccm.201309-1611OC16.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Cancer Res 2011; 71:6391-9; PMID:21900403; http://dx.doi.org/10.1158/0008- 5472.CAN-11-0952 17.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Genome Res 2009; 19:1817-24; PMID:19541912; http://dx.doi.org/10.1101/gr.092924.109 18.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Genome Res 2011; 21:790-7; PMID:21349924; http://dx.doi.org/10.1101/gr.115428.110 19.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Blood 2009; 114:4099-107; PMID:19706884; http://dx.doi.org/ 10.1182/blood-2009-04-217604 20.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Cell 2005; 122:333-6; PMID:16096054; http://dx.doi.org/10.1016/j.cell.2005.07.015 22.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immu-nity 2000; 13:37-45; PMID:10933393; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Pathol 2013; 231:433-40; PMID:24027095; http://dx.doi.org/10.1002/path.4260 24.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Analysis of T Cell receptor Vbdiversity in peripheral CD4 Cand CD8 CT lym- phocytes obtained from patients with chronic severe Hepatitis B. Hepat Mon 2014; 14:e15900; PMID:24693310; http://dx.doi.org/10.5812/ hepatmon.15900 25.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Curr Opin Immu- nol 2013; 25:646-52; PMID:24140071; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245 27.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Cancer Res 2011; 71:5601-5; PMID:21846822;http://dx.doi.org/10.1158/0008-5472.CAN-11-1316 28.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Nat Med 2004;10:942-9; PMID:15322536; http://dx.doi.org/ 10.1038/nm1093 30.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Cancer Immunol Immunother 2013; 62:1453-61; PMID:23771160; http://dx.doi.org/10.1007/s00262-013-1446-2 31.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immunol Rev 2014; 257:72-82; PMID:24329790; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol Methods 2013; 391(1-2):14-21;PMID:23428915; http://dx.doi.org/10.1016/j.jim.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immu- nol 2014; 192:2689-98; PMID:24510963; http://dx.doi.org/10.4049/jimmunol.1302064 36.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Annu Rev Immunol 2000; 18:529-60;PMID:10837068; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immun Age-ing 2007; 4:4; PMID:17683521; http://dx.doi.org/ doi:10.1186/1742-4933-4-4 38.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Mech Ageing Dev 2009; 130:105- 21; PMID:18372004; http://dx.doi.org/10.1016/j.mad.2008.02.004 39.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Immun Ageing 2007; 4:4; PMID:17683521; http://dx.doi.org/10.1186/1742-4933-4-4 41.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
2007; 25:267-96; PMID:17134371; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Nat Med 1999; 5:677-85;PMID:10371507; http://dx.doi.org/10.1038/9525 45.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Cancer Res 2005; 65:2026-34; PMID:15753403; http://dx.doi.org/10.1158/0008- 5472.CAN-04-3337 46.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Blood 2006; 107:2871-78; PMID:16339406; http://dx.doi.org/10.1182/blood-2005-07-3014 47.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
CancerCell 2005; 7:239-49; PMID:15766662; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Exp Med 2003; 198:569-80; PMID:12925674; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
"K h o n gH T ,R e s t i f oN P .N a t u r a ls e l e c t i o no ft u m o rv a r - iants in the generation of “tumor escape” phenotypes.Nat Immunol 2002; 3:999-1005; PMID:12407407; http://dx.doi.org/10.1038/ni1102-999 51.",Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Science 1992; 258:1795-98; PMID:1465616; http://dx.doi.org/10.1126/science.146561652.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2015; 194:3475-86; PMID:25725111; http://dx.doi.org/10.4049/jimmunol.1402711 53.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
"Immunol Rev 2013; 255:165-81; PMID:23947354; http://dx.doi.org/10.1111/imr.12087 5 5 .T u r n e rD L ,B i c k h a mK L ,T h o m eJ J ,K i mC Y , D’Ovidio F, Wherry EJ, Farber DL.",Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Mucosal Immunol 2014; 7:501-10; PMID:24064670; http://dx.doi.org/ 10.1038/mi.2013.67 56.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2011; 187:5510-4; PMID:22058417; http://dx.doi.org/10.4049/ jimmunol.1102243 57.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Nature 2009; 462:510-3; PMID:19898495; http://dx.doi.org/10.1038/nature 08511 58.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2014; 192:2965-9; PMID:24591367; http://dx.doi.org/10.4049/jimmunol.1400019 59.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
PLoS One 2011; 6: e16245; PMID:21298112; http://dx.doi.org/10.1371/ journal.pone.0016245 60.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2005; 174:7446-52;PMID:15905594; http://dx.doi.org/10.4049/ jimmunol.174.11.7446 61.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Pgp-1hi T lympho- cytes accumulate with age in mice and respond poorlyto concanavalin A. Eur J Immunol 1989; 19:977-82; PMID:2666144; http://dx.doi.org/10.1002/eji.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2009; 182:784-92; PMID:19124721; http://dx.doi.org/10.4049/ jimmunol.182.2.784 63.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2012; 189:2356-64; PMID:22855706; http://dx.doi.org/10.4049/ jimmunol.1200382 64.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Immunol 2006; 177:5393-404; PMID:17015725; http://dx.doi.org/10.4049/jimmunol.177.8.5393 65.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
Proc Natl Acad Sci U S A 2007;104:20878-83; PMID:18093919; http://dx.doi.org/ 10.1073/pnas.0709205105 66.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
J Clin Oncol 2015; 33: 1191-6; PMID:25713437; http://dx.doi.org/ 10.1200/JCO.2014.56.6018 68.,Non-OADS,/arxiv_data1/oa_pdf/ba/38/koni-04-12-1051922.PMC4635865.pdf
"*Correspondence to: Barbara K Felber; Email: Barbara.felber@nih.gov Submitted: 11/26/2014; Revised: 01/05/2015; Accepted: 01/18/2015 http://dx.doi.org/10.1080/21645515.2015.1016671 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Curr Opin Immunol 2011; 23:421-9; PMID:21530212; http://dx.doi.org/10.1016/j.coi.2011.03.008 2.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Front Immunol 2013;4:354; PMID:24204366; http://dx.doi.org/10.3389/ ﬁmmu.2013.00354 3.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Vaccine 2008; 26:3112-20; PMID:18430495; http://dx.doi.org/10.1016/j.vaccine.2008.02.036 5.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Virol 2011; 85:9578-87; PMID:21734035; http://dx.doi.org/10.1128/JVI.05060-11 6.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Hum Vaccin Immunother 2012; 8:1620-9; PMID:22894956; http://dx.doi.org/10.4161/hv.21407 7.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Med Primatol 2005; 34:262-70; PMID:16128921; http://dx.doi.org/10.1111/j.1600- 0684.2005.00124.x 8.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Vaccine 2004; 22:1744-50; PMID:15068858;http://dx.doi.org/10.1016/j.vaccine.2004.01.036 9.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Vaccine 2007;25:4967-82; PMID:17335943; http://dx.doi.org/ 10.1016/j.vaccine.2006.11.070 10.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
AIDS Res Hum Retroviruses 2005; 21:629-43; PMID:16060834; http://dx.doi.org/ 10.1089/aid.2005.21.629 11.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Infect Dis 2013; 208:818-29; PMID:23840043; http://dx.doi.org/10.1093/infdis/jit236 13.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Med Primatol 2007; 36:276-84; PMID:17669216; http://dx.doi.org/10.1111/j.1600-0684.2007.00245.x 14.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Vaccine 2006; 24:4677- 87; PMID:16288822; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Curr Opin Virol 2012; 1:233-40; PMID:22440782; http://dx.doi.org/ 10.1016/j.coviro.2011.08.003 16.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLoS One 2014; 9:e91550; PMID:24626482; http://dx.doi.org/10.1371/journal.pone.0091550 18.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Vaccine 2013; 31:3747-55 ; PMID:23624057; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Proc Natl Acad Sci U S A 2013; 110:2975-80; PMID:23359688; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Immunol 2011; 187:3391-401; PMID:21844392; http://dx.doi.org/ 10.4049/jimmunol.1101421 21.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PloS One 2010; 5; e9015; PMID:20126394; http://dx.doi.org/10.1371/ journal.pone.0009015 22.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
N Engl J Med 2013; 369:2083-92; PMID:24099601; http://dx.doi.org/10.1056/NEJMoa1310566 23.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Nat Med 2007; 13:46-53; PMID:17173051; http://dx.doi.org/10.1038/nm1520 24.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Virol 2004; 78:3233-43; PMID:15016844; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Dis Markers 2009; 27:105-20; PMID:19893207; http://dx.doi.org/10.1155/2009/ 360362 26.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Virol 2006; 80:3122-5; PMID:16501126; http://dx.doi.org/ 10.1128/JVI.80.6.3122-3125.2006 27.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLoS One 2008; 3:e1424; PMID:18183304; http://dx.doi.org/10.1371/journal.pone.0001424 28.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Transl Med 2011; 9:208; PMID:22152067; http://dx.doi.org/ 10.1186/1479-5876-9-208 29.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLoS One 2012; 7:e29717; PMID:22238642; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Virol 2009; 83:3993-7; PMID:19091871; http://dx.doi.org/10.1128/JVI.01108-08 31.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
J Virol 2007; 81:3667-72; PMID:17251285; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Curr HIV Res 2007; 5:199-209; PMID:17346134; http://dx.doi.org/10.2174/1570162 07780077057 33.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLoS One 2012; 7:e34723; PMID:22509350; http://dx.doi.org/10.1371/journal.pone.0034723 34.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLos One 2013; 8:e60245; PMID:23555935; http://dx.doi.org/10.1371/journal.pone.0060245 35.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
PLoS One 2014; 9:e86254; PMID:24465991; http://dx.doi.org/ 10.1371/journal.pone.0086254 36.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Retrovirology 2013; 10:117; PMID:24156704; http://dx.doi.org/10.1186/ 1742-4690-10-117 38.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Clin Immunol 2014; 153:308-22; PMID:24907411; http://dx.doi.org/10.1016/j.clim.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Clin Immunol 2014; 55:91-107; PMID:25229164; http://dx.doi.org/10.1016/j.clim.2014.09.005 40.,Non-OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
Proc Natl Acad Sci U S A 2009; 06:15831-6; PMID:19717425; http://dx.doi.org/10.1073/ pnas.0902628106 42.,OADS,/arxiv_data1/oa_pdf/90/77/khvi-11-08-1016671.PMC4635869.pdf
"Baseline demographic and lesion character-istics were similar between the two groups (Appendix 1and 2, Supplemental digital content 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/95/ca/mca-26-699.PMC4635872.pdf
"43The B pentamers engage © Kenneth Bagley, Rong Xu, Ayuko Ota-Setlik, Michael Egan, Jennifer Schwartz, and Timothy Fouts *Correspondence to: Kenneth Bagley; Email: bagley@profectusbiosciences.comSubmitted: 11/07/2015; Revised: 03/06/2015; Accepted: 03/20/2015 http://dx.doi.org/10.1080/21645515.2015.1026498 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Res 2008; 42:219-32; PMID:19066740;http://dx.doi.org/10.1007/s12026-008-8076-3 2.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2002; 20:3399-408;PMID:12213410; http://dx.doi.org/10.1016/S0264- 410X(02)00269-4 3.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev 2011; 239:62-84;PMID:21198665; http://dx.doi.org/10.1111/j.1600- 065X.2010.00980.x 5.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2008; 26:2100-10;PMID:18378365; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Proc Natl Acad Sci U S A 1993; 90:11478-82; PMID:8265577; http://dx.doi.org/ 10.1073/pnas.90.24.11478 7.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nat Biotechnol 1998; 16:867-70; PMID:9743122; http://dx.doi.org/ 10.1038/nbt0998-867 8.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Expert Opin Drug Deliv 2005; 2:255-68; PMID:16296752; http://dx.doi.org/ 10.1517/17425247.2.2.255 10.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Virol 2007; 81:5257-69; PMID:17329330; http://dx.doi.org/10.1128/JVI.00055-07 12.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Gene Ther 1999; 6:508-14; PMID:10476210; http://dx.doi.org/ 10.1038/sj.gt.3300847 13.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2004; 22:2489-93; PMID:15193413; http://dx.doi.org/10.1016/j.vaccine.2003.11.073 14.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2004; 22:1820-5; PMID:15068866; http://dx.doi.org/10.1016/j.vaccine.2003.09.053 15.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Biotechnol 2000; 83:147-52; PMID:11000470; http://dx.doi.org/10.1016/S0168- 1656(00)00308-416.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immu- nol 2000; 164:4635-40; PMID:10779767; http://dx.doi.org/10.4049/jimmunol.164.9.4635 17.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2002;20:3148-54; PMID:12163266; http://dx.doi.org/ 10.1016/S0264-410X(02)00250-5 19.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Virol 2002; 76:4536-46; PMID:11932419; http://dx.doi.org/10.1128/JVI.76.9.4536-4546.2002 20.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vet Immunol Immunopathol 1999; 72:189- 202; PMID:10614509; http://dx.doi.org/10.1016/S0165-2427(99)00132-4 21.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2006; 24:5016-26; PMID:16621198; http://dx.doi.org/ 10.1016/j.vaccine.2006.03.046 22.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Yonsei Med J 1999; 40:355-62; PMID:10487139; http://dx.doi.org/10.3349/ymj.1999.40.4.355 24.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Eur J Immu-nol 1998; 28:1089-103; PMID:9541605; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Interferon Cytokine Res 2000; 20:311-9;PMID:10762079; http://dx.doi.org/10.1089/ 10799900050023906 26.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Clin Immunol 1999;92:90-6; PMID:10413656; http://dx.doi.org/ 10.1006/clim.1999.4730 29.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2005; 175:633-9; PMID:16002657; http://dx.doi.org/10.4049/jimmunol.175.2.633 31.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nat Biotechnol 2005; 23:1059-62;PMID:16151391; http://dx.doi.org/10.1038/ nbt0905-1059 32.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Expert Rev Vac- cines 2008; 7:175-91; PMID:18324888; http://dx.doi.org/10.1586/14760584.7.2.175 33.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2007; 25:4967-82; PMID:17335943; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
AIDS Res Hum Retro- viruses 2005; 21:629-43; PMID:16060834; http://dx.doi.org/10.1089/aid.2005.21.629 36.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
AIDS Res Hum Retroviruses 2005; 7:629-643; PMID:16060834; http://dx.doi.org/10.1089/ aid.2005.21.629 37.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2006; 24:4510-23; PMID:16140439; http://dx.doi.org/10.1016/j.vaccine.2005.08.024 38.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2006;24:4677-87; PMID:16288822; http://dx.doi.org/ 10.1016/j.vaccine.2005.10.035 39.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Res Immunol 1997; 148:504-20; PMID:9588829; http://dx.doi.org/10.1016/S0923-2494(98)80144-2 43.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Infect Dis 1976; 133 Suppl:31-40; PMID:815449; http://dx.doi.org/ 10.1093/infdis/133.Supplement_1.S31 44.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Science 1974; 183:656-7; PMID:4810267; http://dx.doi.org/10.1126/science.183.4125.656 45.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Biochemistry 1997; 36:11051-4; PMID:9333321; http://dx.doi.org/10.1021/ bi971383p 46.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunologyand cell biology 1998; 76:280-7; PMID:9682972; http://dx.doi.org/10.1046/j.1440-1711.1998.00750.x 48.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2000; 164:6276-86;PMID:10843681; http://dx.doi.org/10.4049/ jimmunol.164.12.6276 49.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Infect Immun 2002; 70:5533-9; PMID:12228279; http://dx.doi.org/ 10.1128/IAI.70.10.5533-5539.2002 50.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Infect Immun 2003; 71:6850-6; PMID:14638772; http://dx.doi.org/ 10.1128/IAI.71.12.6850-6856.2003 51.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile entero- toxins is linked to their ADP-ribosyltransferase activity.Eur J Immunol 1992; 22:2277-81; PMID:1381311; http://dx.doi.org/10.1002/eji.1830220915 53.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
JImmunol 2000; 165:5750-9; PMID:11067933; http://dx.doi.org/10.4049/jimmunol.165.10.5750 54.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Mol Membr Biol 2004; 21:77-92; PMID:15204437; http://dx.doi.org/10.1080/ 09687680410001663267 55.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Biol Chem 2001; 276:22838- 43; PMID:11279243; http://dx.doi.org/10.1074/jbc.M101184200 56.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nature 1981; 292:413- 17; PMID:7019725; http://dx.doi.org/10.1038/ 292413a0 57.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Int J Med Microbiol 2000; 290:455-61; PMID:11111926; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Expert Rev Vaccines2007; 6:809-19; PMID:17931160; http://dx.doi.org/ 10.1586/14760584.6.5.809 61.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nature1998; 391:851; PMID:9495336; http://dx.doi.org/10.1038/36014 62.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2011; 186:5896-906; PMID:21490151; http://dx.doi.org/10.4049/jimmunol.1003789 66.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Proc Natl Acad Sci U S A 2010; 107:10638-43; PMID:20479237; http://dx.doi.org/ 10.1073/pnas.1002348107 67.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
PLoS One 2009; 4:e5190; PMID:19360100; http://dx.doi.org/10.1371/ journal.pone.0005190 68.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Infect Immun 2012; 80:2426-35; PMID:22526674; http://dx.doi.org/10.1128/ IAI.00181-12 69.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
BiochemBiophys Res Commun 1999; 261:377-80; PMID:10425193; http://dx.doi.org/10.1006/ bbrc.1999.1014 71.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2001; 19:1688-93; PMID:11166892; http://dx.doi.org/ 10.1016/S0264-410X(00)00406-0 72.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2005; 174:6292-8; PMID:15879128; http://dx.doi.org/10.4049/jimmunol.174.10.6292 73.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Scand J Immunol 2003; 57:229-38; PMID:12641651; http://dx.doi.org/ 10.1046/j.1365-3083.2003.01218.x 74.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2006; 24:897-903; PMID:16253404; http://dx.doi.org/10.1016/j.vaccine.2005.08.093 75.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Virol 2000;74:11598-607; PMID:11090158; http://dx.doi.org/ 10.1128/JVI.74.24.11598-11607.2000 76.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2002; 168:5448-54; PMID:12023338; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2001; 167:221-7; PMID:11418652; http://dx.doi.org/ 10.4049/jimmunol.167.1.221 79.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev 2004; 202:96-105; PMID:15546388; http://dx.doi.org/10.1111/j.0105-2896.2004.00214.x 80.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Cytokine Growth Factor Rev 2004; 15:367-77; PMID:15450252; http://dx.doi.org/10.1016/j.cytogfr.2004.03.009 www.tandfonline.com 2239 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Clin Immunol Immunopathol 1997; 83:18-20; PMID:9073529; http://dx.doi.org/ 10.1006/clin.1996.4306 82.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2002; 168:562-8; PMID:11777947; http://dx.doi.org/10.4049/ jimmunol.168.2.562 83.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Interferon Cytokine Res 1999; 19:77-84; PMID:10048771; http://dx.doi.org/ 10.1089/107999099314441 85.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Virology 2007; 369:153-67; PMID:17698160; http://dx.doi.org/10.1016/j.virol.2007.07.017 86.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vac- cine 2005; 23:1804-13; PMID:15734046; http://dx.doi.org/10.1016/j.vaccine.2004.11.010 88.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev 2003; 193:31-8; PMID:12752668; http://dx.doi.org/ 10.1034/j.1600-065X.2003.00044.x 90.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev1995; 146:211-21; PMID:7493755; http://dx.doi.org/ 10.1111/j.1600-065X.1995.tb00690.x 91.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Intern Med 2003; 253:402-10; PMID:12653868; http://dx.doi.org/ 10.1046/j.1365-2796.2003.01140.x 92.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Vaccine 2007;25:6392-8; PMID:17640779; http://dx.doi.org/ 10.1016/j.vaccine.2007.06.009 94.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
PLoS One 2012; 7: e33715; PMID:22442716; http://dx.doi.org/ 10.1371/journal.pone.0033715 95.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Expert Rev Vaccines 2009; 8:1205- 20; PMID:19722894; http://dx.doi.org/10.1586/ erv.09.82 96.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Immunol 2008; 180:7969-79; PMID:18523260; http://dx.doi.org/10.4049/jimmunol.180.12.7969 99.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/ 10.1158/1078-0432.CCR-08-1725 101.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Hum Gene Ther 2011; 22:809-19; PMID:21128743;http://dx.doi.org/10.1089/hum.2010.071 102.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Virol 2000; 74:6278-86; PMID:10864637; http://dx.doi.org/ 10.1128/JVI.74.14.6278-6286.2000 103.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Exp Med 2005; 201:233-40; PMID:15657292; http://dx.doi.org/10.1084/jem.20041257 104.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nat Immunol 2005; 6:1123-32; PMID:16200070; http://dx.doi.org/10.1038/ni1254 105.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nat Immunol 2005; 6:1133-41; PMID:16200068; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nature2007; 448:480-3; PMID:17581589; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nature 2007; 448:484-7; PMID:17581588; http://dx.doi.org/10.1038/nature05970 108.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Cell Res 2006; 16:902-7; PMID:17088898; http://dx.doi.org/ 10.1038/sj.cr.7310106 109.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
J Exp Med 2006; 203:2271-9; PMID:16982811; http://dx.doi.org/10.1084/ jem.20061308 110.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev 2013; 252:89-103; PMID:23405897; http://dx.doi.org/ 10.1111/imr.12035 111.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Proc Natl Acad Sci U S A 2010; 107:14292-7; PMID:20660725; http://dx.doi.org/10.1073/ pnas.1009234107 112.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Immunol Rev 2008; 223:87-113; PMID:18613831; http://dx.doi.org/10.1111/j.1600-065X.2008.00628.x 113.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Am J Pathol2013; 182:10-20; PMID:23159950; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Nat Immunol 2011; 12:255- 63; PMID:21278737; http://dx.doi.org/10.1038/ ni.1993 115.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Curr Opin Immunol 2013; 25:373-80; PMID:23669353; http://dx.doi.org/10.1016/j.coi.2013.03.011 116.,OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
Pro- tein Eng 1999; 12:173-8; PMID:10195289; http://dx.doi.org/10.1093/protein/12.2.173 117.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
"Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.Cell Microbiol 2004; 6:23-32; PMID:14678328; http://dx.doi.org/10.1046/j.1462-5822.2003.00338.x 118.",Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
AIDS Res Hum Retroviruses 1988; 4:369-79; PMID:2848557;http://dx.doi.org/10.1089/aid.1988.4.369 119.,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
AIDS 1990; 4:307-15; PMID:2190605; http://dx.doi.org/ 10.1097/00002030-199004000-00004 2240 Volume 11 Issue 9 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/06/17/khvi-11-09-1026498.PMC4635876.pdf
"Various payloadshave been delivered biolistically into tissue or cells in the © Palo Alto Research Center Inc. *Correspondence to: Fatemeh Nazly Pirmoradi; Email: Nazly.Pirmoradi@parc.comSubmitted: 12/26/2014; Revised: 02/23/2015; Accepted: 03/06/2015 http://dx.doi.org/10.1080/21645515.2015.1029211 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Nature 1987;327:70-3;http://dx.doi.org/10.1038/327070a0 2.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Vaccine 2000; 19:764-78;PMID:11115698; http://dx.doi.org/10.1016/S0264- 410X(00)00302-9 5.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Vaccine 2006; 24:4475-81; PMID:16150518; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Expert Rev Vaccines 2009; 8:1205-20; PMID:19722894; http://dx.doi.org/10.1586/erv.09.82 7.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Expert Rev Vaccines 2008; 7:1201-14; PMID:18844594; http://dx.doi.org/10.1586/14760584.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Cell Res 2002; 12:97-104; PMID:12118944; http://dx.doi.org/ 10.1038/sj.cr.7290115 10.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Expert Opin Drug Deliv 2007; 4:459-74; PMID:17880271; http://dx.doi.org/10.1517/17425247.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Expert Opin Biol Ther 2004; 4:889-900; PMID:15174971; http://dx.doi.org/10.1517/14712598.4.6.889 12.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Proc Natl Acad Sci U S A 1993;90:11478-82; PMID:8265577; http://dx.doi.org/ 10.1073/pnas.90.24.11478 13.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Trends Biotechnol 2007; 25:530-4; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Shock Waves 2002; 12:23-30; http://dx.doi.org/10.1007/s001930200126 17.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Exp Fluids2004; 37:128-36; http://dx.doi.org/10.1007/s00348- 004-0792-4 18.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Biomech2004; 37:1733-41; PMID:15388316; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
PLoS One 2010; 5:e11021;PMID:20544035; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Vaccine 2004; 23:681-6; PMID:15542190; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
ApplPhys Lett 2005; 87:014103; http://dx.doi.org/ 10.1063/1.1951044 22.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Eur J Pharm Biopharm 2012; 81:360-8; PMID:22484250; http://dx.doi.org/10.1016/j.ejpb.2012.03.008 26.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Invest Dermatol 2004; 122:739-46;PMID:15086561; http://dx.doi.org/10.1111/j.0022- 202X.2004.22320.x 27.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Vaccines 2013; 1:367-83; http://dx.doi.org/10.3390/vaccines 1030367 28.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Control Release 2010; 148:327-33;PMID:20850487; http://dx.doi.org/10.1016/j.jconrel.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Comp Immunol Microbiol Infect Dis 2008; 31:293-315; http://dx.doi.org/ 10.1016/j.cimid.2007.07.015 30.,OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Pharm Res 2002; 19:1673-9; PMID:12458673; http://dx.doi.org/10.1023/A:1020753329492 31.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Anat 1997; 190(Pt 4):601-11; PMID:9183682; http://dx.doi.org/10.1046/j.1469- 7580.1997.19040601.x 32.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Immunol 2007; 179:886-93; PMID:17617579; http://dx.doi.org/ 10.4049/jimmunol.179.2.886 33.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
Vet Pathol 2001;38:203-15; PMID:11280377; http://dx.doi.org/ 10.1354/vp.38-2-203 34.,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
J Control Release 2005;106:361-73; PMID:16002174; http://dx.doi.org/ 10.1016/j.jconrel.2005.05.023 1944 Volume 11 Issue 8 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/7c/81/khvi-11-08-1029211.PMC4635881.pdf
"2,3 Oxygenation prevents the inhibition of T cells and natural killer cells3 We also considered that oxygen may both directly kill tumor cells due to poten-tial toxic effects of reactive oxygen species © Stephen M Hat ﬁeld and Michail Sitkovsky *Corresponding to: Michail Sitkovsky; Email: m.sitkovsky@neu.eduSubmitted: 05/13/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/2162402X.2015.1052934 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
Nat Rev Immu- nol 2015; 15:45-56; http://dx.doi.org/10.1038/nri3790 2.,Non-OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
Nature 2001; 414:916-20; PMID:11780065; http://dx.doi.org/10.1038/414916a 5.,Non-OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
Proc Natl Acad Sci U S A 2006; 103:13132-7; PMID:16916931; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
Cancer Immunol Res 2014; 2:598-605; PMID:24990240; http://dx.doi.org/10.1158/2326-6066.CIR-14-0075 9.,Non-OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
Cancer Cell 2015; 27:435-6; PMID:25873169; http://dx.doi.org/10.1016/j.ccell.2015.03.014 www.tandfonline.com e1052934-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/fd/5a/koni-04-12-1052934.PMC4635883.pdf
"ListeriaKeywords: Listeria, LLO peptide, nano- particles, adjuvant, vaccine © Ricardo Calderon-Gonzalez, Marco Marradi, Isabel Garcia, Nikolai Petrovsky, and Carmen Alvarez- Dominguez *Correspondence to: Carmen Alvarez-Dominguez;Email: calvarez@humv.es Submitted: 06/01/2015Accepted: 06/15/2015 http://dx.doi.org/10.1080/21645515.2015.1063756 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Glia 2014; 62:233-46; PMID:24311463; http://dx.doi.org/10.1002/glia.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Emerg Infect Dis 2014; 20(12):2155-7; http://dx.doi.org/10.3201/ eid2012.140993 3.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Biomed Res Int 2014; 2014:358051; PMID:24822197; http://dx.doi.org/10.1155/2014/ 358051 5.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Front Cell Infect Microbiol 2014; 4(22):1-11; http://dx.doi.org/ 10.3389/fcimb.2014.00022 8.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
JVaccines Vaccin 2015; 6(266):1-8; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Biomaterials 2010;31(33):8749-58; PMID:20832111; http://dx.doi.org/10.1016/j.biomaterials.2010.07.093 11.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Bioconjug Chem 2015; 26(4):755-65; PMID:25734507; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
"Biochim Biophys Acta 2006; 1760(4):636-51; PMID:16529864; http://dx.doi.org/10.1016/j.bbagen.2005.12.001 15. de la Fuente JM, Barrientos AG, Rojas TC, Rojo J, Ca~nada J, Fern /C19andez A, Penades S. Gold glyconanopar- ticles as water-soluble polyvalent models to study 2502 Volume 11 Issue 10 Human Vaccines & Immunotherapeutics",Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Angew Chem Int Ed 2001; 40(12):2257-61; http://dx.doi.org/10.1002/1521-3773 (20010618)40:12%3c2257::AID-ANIE2257%3e3.0.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Chem Soc Rev 2013; 42:4728; PMID: 23288339; http://dx.doi.org/10.1039/c2cs35420a 17.,OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Vaccine 2015; 33(12):1465- 73; PMID:25659269; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Vaccine 2012; 30:2633-9; PMID:22365841; http://dx.doi.org/10.1016/j.vaccine.2012.02.026 19.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Vaccine 2012; 30(36):5407-16; PMID: 22717330; http://dx.doi.org/10.1016/j.vaccine.2012.06.009 20.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Vaccine 2014; 32(48):6469-77 PMID:25267153; http://dx.doi.org/ 10.1016/j.vaccine.2014.09.034 21.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
J Gen Virol 2011; 92(Pt 1):128-40;PMID:21169215; http://dx.doi.org/10.1099/ vir.0.023242-0 22.,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
Vaccine 2012; 30:5373-81; PMID:22728225; http://dx.doi.org/10.1016/j.vaccine.2012.06.021 www.tandfonline.com 2503 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/b7/1a/khvi-11-10-1063756.PMC4635887.pdf
"© Etienne Becht, Nicolas A Giraldo, Benoit Beuse- linck, Sylvie Job, Laetitia Marisa, Yann Vano,St/C19ephane Oudard, Jessica Zucman-Rossi, Pierre Lau- rent-Puig, Catherine Saut /C18es-Fridman, Aur /C19elien de Reyni /C18es, and Wolf Herman Fridman *Correspondence to: Wolf Herman Fridman; Email: herve.fridman@crc.jussieu.fr Submitted: 04/21/2015Revised: 05/04/2015Accepted: 05/06/2015 http://dx.doi.org/10.1080/2162402X.2015.1049804 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245 3.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782 4.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Lancet Oncol 2012; 13:239-46; PMID:22285168; http://dx.doi.org/ 10.1016/S1470-2045(11)70393-X 5.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
N Engl J Med 2010; 362:2380-8; PMID:20573926;http://dx.doi.org/10.1056/NEJMoa0909530 6.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nat Rev Cancer 2007; 7:345-56; PMID:17457302; http://dx.doi.org/10.1038/nrc2126 7.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306 8.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/ NEJMoa0804385 9.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
BMC Med Genomics2012; 5:66; PMID:23272949; http://dx.doi.org/ 10.1186/1755-8794-5-66 13.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nat Med 2013; 19:619-25; PMID:23584089; http://dx.doi.org/10.1038/nm.3175 14.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nat Med 2013; 19:614-8; PMID:23584090; http://dx.doi.org/ 10.1038/nm.3174 15.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
J Pathol 2013; 231:63-76; PMID:23836465; http://dx.doi.org/10.1002/path.4212 16.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
PLoS Med 2013; 10: e1001453; PMID:23700391; http://dx.doi.org/ 10.1371/journal.pmed.1001453 17.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Clin Cancer Res 2013; 19:462-8; PMID:23169436;http://dx.doi.org/10.1158/1078-0432.CCR-12-2625 18.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 19.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Science 2006; 313:1960-1964; PMID:17008531; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
J Transl Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205 21.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/ nature14011 22.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Clin Cancer Res 2014; 20:5064- 74; PMID:24714771; http://dx.doi.org/10.1158/1078- 0432.CCR-13-3271 23.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Trends Immunol 2014; 35:571-580; PMID:25443495; http://dx.doi.org/10.1016/j.it.2014.09.006 24.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Sci Transl Med 2014; 6:221ra13; PMID:24477000; http://dx.doi.org/10.1126/ scitranslmed.3007323 25.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Cancer Immunol Res 2014; 2:616-31; PMID:24942756; http://dx.doi.org/10.1158/2326- 6066.CIR-14-0027 26.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/ 10.1158/0008-5472.CAN-12-2606 27.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
J Clin Oncol 2013; 31:692-700; PMID:23182984;http://dx.doi.org/10.1200/JCO.2012.43.4589 28.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Leukemia 2004; 18:589-96; PMID:14712286; http://dx.doi.org/10.1038/sj.leu.2403240 29.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Clin Cancer Res 2013; 19:4079-4091; PMID:23785047;http://dx.doi.org/10.1158/1078-0432.CCR-12-3847 32.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Nature 2013; 499:43-9; PMID:23792563; http://dx.doi.org/10.1038/nature12222 33.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Cancer Res 2011; 71:5670-7; PMID:21846824; http://dx.doi.org/10.1158/0008- 5472.CAN-11-0268 34.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Cancer Immunol Immunother 2014 63:991- 7; PMID:25112529; http://dx.doi.org/10.1007/ s00262-014-1590-3 35.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Immunity 2013; 39:782-95;PMID:24138885; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
Sci Transl Med 2014; 6:228ra37; PMID:24648340;http://dx.doi.org/10.1126/scitranslmed.3007240 37.,Non-OADS,/arxiv_data1/oa_pdf/69/23/koni-04-12-1049804.PMC4635888.pdf
"*Correspondence to: George N Pavlakis; Email: george.pavlakis@nih.govSubmitted: 12/04/2014; Revised: 01/30/2015; Accepted: 02/12/2015 http://dx.doi.org/10.1080/21645515.2015.1020265 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Curr Opin Immunol2014; 27:26-32; PMID:24513968; http://dx.doi.org/ 10.1016/j.coi.2014.01.005 3.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Cancer Immunol Immunother 2014; 63:959-67; PMID:24878889; http://dx.doi.org/10.1007/s00262-014-1558-3 4.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Scand J Immunol 2013; 78:167-71; PMID:23672402; http://dx.doi.org/10.1111/sji.12060 5.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Curr Top Med Chem 2013; 13:2597-608; PMID:24066890; http://dx.doi.org/10.2174/15680266113136660185 7.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Immunity 2008; 29:319-24; PMID:18799140; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Expert Rev Vaccines 2013; 12:537-54; PMID:23659301; http://dx.doi.org/ 10.1586/erv.13.33 10.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Curr Opin Immunol 2011; 23:421-9; PMID:21530212; http://dx.doi.org/10.1016/j.coi.2011.03.008 11.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Mol Ther 2009; 17:585-92; PMID:19223870;http://dx.doi.org/10.1038/mt.2009.5 12.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Methods MolBio 2014; 1121:291-307; http://dx.doi.org/10.1007/ 978-1-4614-9632-8_26 13.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Infect Dis 2013; 208:818-29; PMID:23840043; http://dx.doi.org/ 10.1093/infdis/jit236 14.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Vaccine 2008; 26:2537-44; PMID:18400342; http://dx.doi.org/10.1016/j.vaccine.2008.03.003 15.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Gene Ther 2006; 13:1391- 402; PMID:16724093; http://dx.doi.org/10.1038/sj.gt.3302797 16.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
PLoS One 2010; 5:e8574; PMID:20052293; http://dx.doi.org/10.1371/journal.pone.0008574 17.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Vaccine 2010;28:7297-305; PMID:20817010; http://dx.doi.org/ 10.1016/j.vaccine.2010.08.079 1934 Volume 11 Issue 8 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
FEBS Lett 2003; 538:149-54;PMID:12633869; http://dx.doi.org/10.1016/S0014- 5793(03)00169-8 19.,OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Leukoc Biol 2008; 83:1530-40; PMID:18364435; http://dx.doi.org/ 10.1189/jlb.1107795 20.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Exp Med 2001; 193:233-8; PMID:11208863; http://dx.doi.org/10.1084/jem.193.2.233 22.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Int J Cancer 2001; 93:243-51; PMID:11410873; http://dx.doi.org/10.1002/ijc.1323 23.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Immunol 2007; 179:6704-14; PMID:17982060; http://dx.doi.org/10.4049/jimmunol.179.10.6704 24.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Nature 2009; 457:196-9; PMID:19005468; http://dx.doi.org/ 10.1038/nature07486 25.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Distinct effects of saracatinib on memory CD8CTc e l ld i f f e r e n t i a t i o n .JI m m u n o l2 0 1 2 ; 188:4323-33; PMID:22450814; http://dx.doi.org/ 10.4049/jimmunol.1101439 26.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
A composite MyD88/ CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efﬁcacy.J Clin Invest 2011; 121:1524-34; PMID:21383499; http://dx.doi.org/10.1172/JCI44327 27.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Vaccine 2012; 30:378-87;PMID:22085546; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Immunother 2007; 30:75-82; PMID:17198085; http://dx.doi.org/10.1097/01.cji.0000211316.15278.6e 30.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
CancerImmunol Immunother 2009; 58:1329-36; PMID:19156413; http://dx.doi.org/10.1007/s00262- 008-0648-531.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Eur J Immunol 2011; 41:18-25;PMID:21182072; http://dx.doi.org/10.1002/ eji.201040543 32.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Expert Rev Vaccines 2012; 11:1221-33; PMID:23176655; http://dx.doi.org/10.1586/erv.12.94 33.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Exp Med 1992; 176:1693-702; PMID:1460426; http://dx.doi.org/ 10.1084/jem.176.6.1693 34.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
"J Virol 2005; 79:8480-92; PMID:15956591; http://dx.doi.org/10.1128/JVI.79.13.8480-8492.2005 35. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischof- berger N, Boyer JD, et al.",OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
J Virol 2007; 81:1972- 9; PMID:17135321; http://dx.doi.org/10.1128/ JVI.01990-06 36.,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
Vaccine 2010; 28:4827-36; PMID:20451642; http://dx.doi.org/ 10.1016/j.vaccine.2010.04.064 www.tandfonline.com 1935 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/1f/e2/khvi-11-08-1020265.PMC4635890.pdf
"7However, how DCs in TME © Amol Suryawanshi and Santhakumar Manicassamy *Correspondence to: Santhakumar Manicassamy; Email: smanicassamy@gru.eduSubmitted: 05/14/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/2162402X.2015.1052932 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Ann Rev Immunol 2007; 25:267-96; PMID:17134371;http://dx.doi.org/10.1146/annurev.immunol.25.022106.,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Science 2010; 329:849-53; PMID:20705860; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
J Immunol2015; 194:3295-304; PMID:25710911; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Nat Rev Cancer 2008; 8:387-98; PMID:18432252; http://dx.doi.org/10.1038/nrc2389 5.,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Cancer Res 2015;75:656-65; PMID:25568183; http://dx.doi.org/ 10.1158/0008-5472.CAN-14-2377 6.,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Immunity 2011; 35:13-22; PMID:21777796; http://dx.doi.org/ 10.1016/j.immuni.2011.07.0027.,OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Cancer Res 2012; 72:5230-9; PMID:22902413; http://dx.doi.org/10.1158/0008-5472.CAN-12-1727 8 .,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
J Leukoc Biol 2014; 95:179-90; PMID:24023259; http://dx.doi.org/ 10.1189/jlb.0613330 9.,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
Nat Rev Cancer 2013; 13:11-26; PMID:23258168; http://dx.doi.org/10.1038/ nrc3419 www.tandfonline.com e1052932-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/8f/93/koni-04-12-1052932.PMC4635893.pdf
"© Elizabeth E Evans, Mark Paris, Ernest S Smith, and Maurice Zauderer *Correspondence to: Maurice Zauderer; Email: mzauderer@va.comSubmitted: 05/18/2015; Accepted: 05/20/2015 http://dx.doi.org/10.1080/2162402X.2015.1054599 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Mol Cancer 2010;9:251; PMID:20858260; http://dx.doi.org/10.1186/ 1476-4598-9-251 2.,Non-OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Journal of Experimental Medi- cine 2008 Jun 2; 205:1673-85; PMID:18559453; http://dx.doi.org/10.1084/jem.20072602 4.,Non-OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Neurobiol Dis 2014; 73:254-68; PMID:25461192; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Nat Cell Biol 2002 Sep; 4(9):720-4; PMID:12198496; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
J Interferon Cytokine Res 2009 Jun; 29 (6):313-26; PMID:19441883; http://dx.doi.org/10.1089/jir.2008.0027 9.,OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Immunity 2013 Jul 25; 39(1):11-26; PMID:23890060; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
Mol Cancer Ther 2015 Apr; 14(4):964-72; PMID:25657333; http://dx.doi.org/ 10.1158/1535-7163.MCT-14-0924 www.tandfonline.com e1054599-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/cb/26/koni-04-12-1054599.PMC4635900.pdf
"20 While IIVs alone are licensed for certain groups (children under 2 years, persons 50 years and above and pregnant women), both © Neisha Sundaram, Vidula Purohit, Christian Schaetti, Abhay Kudale, Saju Joseph, and Mitchell G Weiss *Corresponding author: Neisha Sundaram; Email: neisha.sundaram@unibas.chSubmitted: 04/16/2015; Revised: 05/26/2015; Accepted: 06/12/2015 http://dx.doi.org/10.1080/21645515.2015.1062956 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2010; 28:4895-902; PMID:20553769; http://dx.doi.org/10.1016/j.vaccine.2010.05.031 2.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/ index.html (accessed 20 Jan 2013) 3.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
J Sch Health 2011; 81:297-303; PMID:21592124; http://dx.doi.org/10.1111/j.1746-1561.2011.00594.x 4.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
PLoS One 2011; 6:e17713; PMID:21412418; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Inﬂuenza Other Respir Viruses 2013; 7 Suppl 2:97-104; PMID:24034493; http://dx.doi.org/10.1111/irv.120886.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2011; 29:4190-4; PMID:21497636; http://dx.doi.org/10.1016/j.vaccine.2011.03.107 9.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
BMC Infect Dis 2010;10:99; PMID:20403201; http://dx.doi.org/10.1186/ 1471-2334-10-99 10.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
N Engl J Med 2010; 362:e65; PMID:20484390; http://dx.doi.org/10.1056/NEJMp1005102 11.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2012; 30:1064-70; PMID:22178521; http://dx.doi.org/10.1016/j.vaccine.2011.12.03712.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2010; 28 Suppl 4:D3-13; PMID:20713258; http://dx.doi.org/10.1016/j.vaccine.2010.08.024 14.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Epidemiol Infect 2011; 139:27-40; PMID:20920380; http://dx.doi.org/10.1017/ S0950268810002037 15.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Inﬂuenza Other Respir Viruses 2013; 7 Suppl 2:54-8; PMID:24034485; http://dx.doi.org/10.1111/irv.12082 16.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
http://mohfw-h1n1.nic.in/August2010.html (accessed 20 Feb 2014) 17.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
PMID:20479875; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Hum Vaccin Immunother 2013; 9:125-7; PMID:23047369; http://dx.doi.org/10.4161/hv.22421 19.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"The Indian Express, 2009 Aug 4. http://indianexpress.com/article/news-archive/web/ﬁrst-india-h1n1-death-is-girl-in-pune/ 20.",Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2011; 29 Suppl 1:A16-A21; PMID:21684421; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
N Engl J Med 2009; 361:2405-13; PMID:19745216; http://dx.doi.org/10.1056/NEJMoa0907413 24.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Lancet 2010; 375:56- 66; PMID:20018364; http://dx.doi.org/10.1016/S0140-6736(09)62003-1 26.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Vaccine 2013; 31:1503-9; PMID:23318149; http://dx.doi.org/10.1016/j.vaccine.2012.12.082 27.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"DNA, 2010 Aug 18. http://www.dnaindia.",OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"The Indian Express, 2010 Apr 19. http://indianexpress.com/article/cities/pune/2-weeks-on-docs-heal th-workers-continue-to- shun-h1n1-vaccine/ 32.",Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
BMJ Open 2013; 3:e002573; PMID:23408082; http://dx.doi.org/10.1136/ bmjopen-2013-002573 33.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
BMJ Open 2014; 4:e006350; PMID:25492273; http://dx.doi.org/10.1136/ bmjopen-2014-006350 34.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
PLoS One 2013; 8:e55918; PMID:23690913; http://dx.doi.org/10.1371/journal.pone.0055918 36.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Indian J Public Health 2010; 54:161-4; PMID:21245588; http://dx.doi.org/10.4103/0019- 557X.75741 37.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Hum Vaccin 2011; 7:89-95; PMID:21263225; http://dx.doi.org/10.4161/ hv.7.1.13460 38.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
J Infect 2012; 65:90-3; PMID:22406971; http://dx.doi.org/ 10.1016/j.jinf.2012.03.007 40.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
BMC Public Health 2005; 5:56; PMID:15929800; http://dx.doi.org/10.1186/1471- 2458-5-56 42.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Soc Sci Med 1987; 25:307-18; PMID:3629304; http://dx.doi.org/ 10.1016/0277-9536(87)90233-4 44.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Lancet 2011; 378:526-35; PMID:21664679; http://dx.doi.org/ 10.1016/S0140-6736(11)60678-8 46.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Sociol Ruralis 1967; 7:30-48;http://dx.doi.org/10.1111/j.1467-9523.1967.tb01044.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Soc Sci Med 1995;41:617-32; PMID:7502096; http://dx.doi.org/ 10.1016/0277-9536(95)00034-5 51.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"The Indian Express, 2010 Jun 25. http://indianexpress.com/article/cities/pune/h1n1-6-schoolkids-infected-since-june-10/ 52.",Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Health Educ Q 1984; 11:1-47;PMID:6392204; http://dx.doi.org/10.1177/ 109019818401100101 54.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
J Soc Clin Psychol 1996; 15:1-8; http://dx.doi.org/10.1521/jscp.1996.15.1.1 55.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Lancet 2010; 376:572-3;PMID:20728739; http://dx.doi.org/10.1016/S0140- 6736(10)60881-1 60.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"The Indian Express, 2015 Mar 21. http://indianexpress.com/article/india/india-others/swine-ﬂu-deaths-at-1895-cases-near-32k-mark/ 64.",Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Lan- cet 2015; 385:e21; PMID:25765694; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Indian Pediatr 2013; 50:867-74; PMID:24096845; http://dx.doi.org/10.1007/s13312-013-0230-x 66.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Transcult Psychiatry 1997; 34:235-63; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Anthropol Med 2001; 8:5-29; http://dx.doi.org/10.1080/13648470120070980 68.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
BMC Public Health 2013; 13:60; PMID:23339647; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Hum Vaccin 2011; 7:1299-308; PMID:22108036; http://dx.doi.org/10.4161/ hv.7.12.18012 70.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
Epidemiol Infect 2013; 141:639-50; PMID:22564277; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/03/khvi-11-10-1062956.PMC4635903.pdf
"ﬁocruz.br Submitted: 02/09/2015Accepted: 02/20/2015 http://dx.doi.org/10.1080/21645515.2015.1022700 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
"New York, Springer, 2011, p. 109-35;http://dx.doi.org/10.1007/978-1-4419-1339-5 2.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 15997317; http://dx.doi.org/10.1590/ S0034-89102005000300012 7.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 11463410; http://dx.doi.org/10.1016/S0140-6736(01)05327-2 8 .,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Lancet 2001; 358: 91-7.PMID 11463409; http://dx.doi.org/10.1016/S0140- 6736(01)05326-0 9.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
J Clin Virol 2015; 64:160–73; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Virology 2001; 290: 309-19; http://dx.doi.org/10.1006/viro.2001.1168 11.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Lancet 2004; 364: 936; http://dx.doi.org/ 10.1016/S0140-6736(04)17017-7 12.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Procedia Vaccinol 2010; 2:178-183; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 24456625; http://dx.doi.org/10.1016/j.vaccine.2014.01.015 14.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine 2013; 31: 5798-805; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 22000363; http://dx.doi.org/10.3201/ eid1710.101789 16.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine 2007; 25: 8480-5; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 18598196; http://dx.doi.org/10.1086/590187 18.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Clin Vacc Immunol 2010; 17: 118-26; http://dx.doi.org/10.1128/CVI.00369-0919.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
J Clin Virol 2006; 36: 156-8; http://dx.doi.org/10.1016/j.jcv.2006.02.005 20.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 24837504; http://dx.doi.org/10.1016/j.vaccine.2014.05.003 22.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
"Springer, New York, 2011, p. 109-35; http://dx.doi.org/10.1007/978-1-4419-1339-5.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
J Pediatr (Rio J)2011; 87: 269-72.PMID 21461453; http://dx.doi.org/ 10.2223/JPED.2067 25.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID: 22627101; http://dx.doi.org/10.1016/j.trstmh.2012.04.002 28.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID: 19191654; http://dx.doi.org/10.1086/ 597006 29.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
J Thorac Oncol 2014; 9 (9 Suppl 2): S137-42; http://dx.doi.org/10.1097/ JTO.0000000000000299.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID 25192973; http://dx.doi.org/ 10.1016/j.vaccine.2014.08.051 31.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine2009; 27: 5974-81; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Hum Vaccin Immunother 2013; 9: 1-10; http://dx.doi.org/10.416/hv.22982 33.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID: 21106799; http://dx.doi.org/10.1128/ JCM.01775.10 36.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PMID: 21385635; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
PLoS ONE 2011; 6: e27753; http://dx.doi.org/ 10.1371/journal.pone.0027753 38.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine 2012; 30: 5038-58; http://dx.doi.org/10.1016/j.vaccine.2012.04.067 39.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
J Glob Infect Dis 2009; 1: 111- 116; http://dx.doi.org/10.4103/0974-777X56257 40.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine 2013; 31: 1819-29; http://dx.doi.org/10.1016/j.vaccine.2013.01.054 42.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
mBio 2014; 5: e01253-14; http://dx.doi.org/ 10.1128/mBio.01253-14 43.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
N Engl J Med 2011; 364:1326-33; http://dx.doi.org/10.1056/NEJMoa1009303 44. WHO.,OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
Vaccine 2005; 23: 3908-14; http://dx.doi.org/10.1016/j.vaccine.2005.12.052 www.tandfonline.com 2187 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/khvi-11-09-1022700.PMC4635904.pdf
"The anti-body slowed the growth of subcutaneous © Xiaohu Zheng, Zhigang Tian, and Haiming Wei *Correspondence: Haiming Wei; Email: ustcwhm@ustc.edu.cnSubmitted: 05/13/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/2162402X.2015.1052931 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
"Nature Reviews Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236 2 .W e i n e rL M ,S u r a n aR ,W a n gS .M o n o c l o n a la n t i - bodies: versatile platforms for cancer immunother- apy.",Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
Nature Reviews Immunology 2010; 10:317-27;PMID:20414205; http://dx.doi.org/10.1038/nri2744 3.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
Cancer Research 2015; 75:1080-90; PMID:25600649; http://dx.doi.org/ 10.1158/0008-5472.CAN-14-1831 4.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
BMC Cancer 2008; 8:156; PMID:18513434; http://dx.doi.org/10.1186/1471-2407-8-156 6.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
The Journal of Molecular Diagnostics: JMD2003; 5:237-42; PMID:14573783; http://dx.doi.org/ 10.1016/S1525-1578(10)60480-1 7.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
Infection and Immunity 2013; 81:285-91; PMID:23132494; http://dx.doi.org/10.1128/IAI.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
Seminars in Cell & Developmental Biology 2011; 22:705-12; PMID:21983031; http://dx.doi.org/10.1016/j.semcdb.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
Oncogene 2007; 26:2658-66; PMID:17057737; http://dx.doi.org/10.1038/sj.onc.,OADS,/arxiv_data1/oa_pdf/2d/08/koni-04-12-1052931.PMC4635906.pdf
"Two-dose PHiD-CV catch-up regimen in the second year oflife was well-tolerated and immunogenic for all vaccine pneumococcal serotypes and NTHi protein D when administered to Malian children © Alassane Dicko, Yahia Dicko, Amadou Barry, Youssoufa Sidibe, Almahamoudou Mahamar, Gaoussou Santara, Amagana Dolo, Aminata Diallo, Ogobara Doumbo, Fakrudeen Sha ﬁ, Nancy Fran ¸cois, Juan Pablo Yarzabal, Ana Strezova, Dorota Borys, and Lode Schuerman *Correspondence to: Alassane Dicko; Email: adicko@icermali.orgSubmitted: 12/05/2014; Revised: 01/20/2015; Accepted: 02/04/2015 http://dx.doi.org/10.1080/21645515.2015.1016679 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
2013 [http://www.who.int/immunization/monitoring_ surveillance/burden/estimates/Pneumo_hib/en/] 2.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
"PLoS Med 2010, 7(10); PMID:20957191; http://dx.doi.org/10.1371/journal.pmed.1000348 4.",Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
PLoS One 2013; 8(3):e60432; PMID:23555971; http://dx.doi.org/10.1371/journal.pone.0060432 6.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Hum Vaccin 2011; 7(5):511-22; PMID:21441782; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Pediatr Infect Dis J 2011; 30(8):e130- 41; PMID:21540760; http://dx.doi.org/10.1097/ INF.0b013e31821d1790 9.,OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
J Epidemiol Community Health 2012; 66(3):210-17; PMID:20884668; http://dx.doi.org/ 10.1136/jech.2010.111880 10.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Effec tiveness of the ten-val- ent pneumococcal Haemophilus inﬂuenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.Lancet 2013; 381(9862):214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6 13.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
BMC Public Health 2011;11:882-93; PMID:22112189; http://dx.doi.org/10.1186/ 1471-2458-11-882 15.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Hum Vaccin Immun-other 2013; 9:382-88; PMID:23291945; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Pediatr Infect Dis J 2009; 28(4 Suppl):S77- 88; PMID:19325450; http://dx.doi.org/10.1097/ INF.0b013e318199f609 17.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Pediatr Infect Dis J 2009; 28(10):e276-82; PMID:20118683; http://dx.doi.org/ 10.1097/INF.0b013e3181b48ca318.,OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Pediatr Infect Dis J 2010; 29(6):e47-56; PMID:20508478; http://dx.doi.org/ 10.1097/INF.0b013e3181dffabf 19.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
"Vaccine 1998, 16(9-10):921-27; PMID:9682338; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Hum Vaccin 2005; 1(3):112-17; PMID:17012870; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Expert Rev Vaccines 2011; 10(7):951-80;PMID:21806394; http://dx.doi.org/10.1586/erv.11.76 24.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Clin Vaccine Immunol 2006; 13(3):356-60; PMID:16522777; http://dx.doi.org/10.1128/ CVI.13.3.356-360.200627.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI.,Non-OADS,/arxiv_data1/oa_pdf/a0/bc/khvi-11-09-1016679.PMC4635909.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/ licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/31/83/bhv188.PMC4635923.pdf
http://neuromorpho.org/neuroMorpho/index.,Non-OADS,/arxiv_data1/oa_pdf/31/83/bhv188.PMC4635923.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/ licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/22/a1/bhv198.PMC4635924.pdf
Supplementary Material Supplementary material can be found at: http://www.cercor.,Non-OADS,/arxiv_data1/oa_pdf/22/a1/bhv198.PMC4635924.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/ licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/69/bhv202.PMC4635925.pdf
Supplementary Material Supplementary material can be found at: http://www.cercor.,Non-OADS,/arxiv_data1/oa_pdf/c4/69/bhv202.PMC4635925.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/ licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/8a/bhv209.PMC4635926.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/ licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/75/bhv212.PMC4635927.pdf
"Stimulus Material and Procedure Auditory stimuli were presented binaurally over tubal insertearphones (VIASYS, CareFusion Corporation, 3750 Torry View Court, San Diego, CA 92130, USA, http://www.carefusion.de/ medical-products/carefusion-brands/viasys/ , last accessed on 9 September 2015).",OADS,/arxiv_data1/oa_pdf/c4/75/bhv212.PMC4635927.pdf
"As a region of interest (ROI), the primary auditory cortex (AI) was chosen and the respective MNI coordinates of Brodmann Area 41 and 42 (BA 41, 42) were identi ﬁed with an anatomical brain atlas (AFNI TTatlas, http://afni.nimh.nih.gov/afni/doc/ misc/afni_ttatlas/ , last accessed on 9 September 2015).",OADS,/arxiv_data1/oa_pdf/c4/75/bhv212.PMC4635927.pdf
Supplementary Material Supplementary material can be found at: http://www.cercor.,Non-OADS,/arxiv_data1/oa_pdf/c4/75/bhv212.PMC4635927.pdf
"© Qi Zhu, Huizhen Zheng, Hongying Qu, Huihong Deng, Jikai Zhang, Wenjun Ma, Yongjie Lin, Xin Xie, Quan Qiu, and Zhuhang Huang *Correspondence to: Huizhen Zheng; Email: address:zhzgdcdc@163.comSubmitted: 11/04/2014; Revised: 12/31/2014; Accepted: 01/27/2015 http://dx.doi.org/10.1080/21645515.2015.1016672 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Curr Pedi-atric Rev 2009; 5:207–28; http://dx.doi.org/10.2174/ 157339609791317315 2.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
(Accessed at http://www.cdc.gov/shingles/about/over view.html.),Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Geriatr Nurs 2000; 21:132–7; PMID:10864692; http://dx.doi.org/ 10.1067/mgn.2000.108260 6.,OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
BMC Infect Dis 2013; 13:1–10; PMID:23280237; http://dx.doi.org/10.1186/1471-2334-13-1 7.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
BMJ Open 2014; 4: e004833; PMID:24916088; http://dx.doi.org/ 10.1136/bmjopen-2014-004833 8.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Am J Hematol 2007; 82:403–4; PMID:17133426; http://dx.doi.org/10.1002/ajh.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
J Infect Dis 1995; 171:701–4;PMID:7876622; http://dx.doi.org/10.1093/infdis/ 171.3.701 15.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
J Clin Virol 2012; 55:153–7; PMID:22824229; http://dx.doi.org/10.1016/j.jcv.2012.06.020 16.,OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
J Clin Virol 2010; 48:S2–S7; PMID:20510263; http://dx.doi.org/10.1016/S1386- 6532(10)70002-0 17.,OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Lan- cet 2012; 380:1715–6; http://dx.doi.org/10.1016/S0140-6736(11)60893-3 18.,OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Rev Epidemiol Sante Publique 2010; 58:393– 401; PMID:21094001; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Clin Infect Dis 2001; 33:62; PMID:11389496; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
Canad Med Assoc J 2010; 182:1731–6; PMID:20921251; http://dx.doi.org/10.1503/cmaj.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
PLoS Med 2013; 10:e1001420;PMID:23585738; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
(Accessed at http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/khvi-11-08-1016672.PMC4635933.pdf
"© Leonard Moise, Andres Gutierrez, Farzana Kibria, Rebecca Martin, Ryan Tassone, Rui Liu, Frances Terry, Bill Martin, and Anne S De Groot *Correspondence to: Anne S De Groot; Email AnnieD@EpiVax.comSubmitted: 04/06/2015; Accepted: 06/07/2015 http://dx.doi.org/10.1080/21645515.2015.1061159 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b1/20/khvi-11-09-1061159.PMC4635942.pdf
Computational immunology Google search term results were input into the Wordleword cloud generator (http://www.wordle.net/) that sizes terms by fre- quency.,OADS,/arxiv_data1/oa_pdf/b1/20/khvi-11-09-1061159.PMC4635942.pdf
"National Cancer Institute, Available at, http://www.can cer.gov/clinicaltrials/search.",Non-OADS,/arxiv_data1/oa_pdf/b1/20/khvi-11-09-1061159.PMC4635942.pdf
"7,8In addition, we © Tao Wang, Gerald M Feldman, Meenhard Herlyn, and Russel E Kaufman *Correspondence to: Tao Wang; Email: tao.wang@fda.hhs.govSubmitted: 05/13/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/2162402X.2015.1052929 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Nature 2010, 467:596-9; PMID:20823850; http://dx.doi.org/ 10.1038/nature09454 2.",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Nature 2010, 464:427-30; PMID:20179705; http://dx.doi.org/10.1038/nature08902 3.",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"NEngl J Med 2012, 366:207-15; PMID:22256804; http://dx.doi.org/10.1056/NEJMoa11053584.",OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Pigment Cell Melanoma Res 2012, 25:493-505;PMID:22498258; http://dx.doi.org/10.1111/j.1755- 148X.2012.01005.x 7.",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Pigment CellMelanoma Res 2012, 25:896; PMID:22498258; http://dx.doi.org/10.1111/j.1755-148X.2012.01005.x 9.",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Cancer discovery 2014, 4:1214-29;PMID:25256614; http://dx.doi.org/10.1158/2159- 8290.CD-13-1007 1 0 .",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"Nat Chem Biol 2009, 5:484-93; PMID:19465931; http://dx.doi.org/10.1038/ nchembio.183 www.tandfonline.com e1052929-3 OncoImmunology",Non-OADS,/arxiv_data1/oa_pdf/e1/b1/koni-04-12-1052929.PMC4635944.pdf
"http://dx.doi.org/10.1590/S1806-37132015000400001Treatment of lymphangioleiomyomatosis and Camões Treatment of lymphangioleiomyomatosis and Camões Rogério Rufino1 1 Disciplina de Pneumologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.",Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
Rufino R http://dx.doi.org/10.1590/S1806-371320150004000015.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2008;358(2):140-51. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
J Bras  Pneumol 2015;41(3):275-80. http://dx.doi.org/10.1590/ S1806-37132015000004553 7.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2014;370(22):2071-82. http://dx.doi.org/10.1056/ NEJMoa1402584 9.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2014;43(5):1525-8.  http://dx.doi.org/10.1183/09031936.00224513 10.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2015;44(4):428-36.  http://dx.doi.org/10.1016/j.semarthrit.2014.09.002 11.,OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2015;7:249-57. http://dx.doi.org/10.2147/CLEP.S50780 3.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2014;10:691-700. http://dx.doi.org/10.2147/ TCRM.S50784 4.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
2015;191(12):1354-66. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/1806-3713-jbpneu-41-04-00295.PMC4635947.pdf
"http://dx.doi.org/10.1590/S1806-37132015000400002the degree of quadriceps muscle weakness, the  equations were statistically equivalent, although  the equation proposed by Neder et al.",OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
Chiavegato LD http://dx.doi.org/10.1590/S1806-3713201500040000210.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
1997;10(2):447-23. http://dx.doi.org/10.1183/09031 936.97.10020417 11.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2010;36(1):81-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2011;37(5):576-83. http://dx.doi.org/10.1590/ S1806-37132011000500003 13.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2011;37(5):607-14. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2013;17(6):556-63.  http://dx.doi.org/10.1590/S1413-35552012005000122 15.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
1999;32(6):719-27. http://dx.doi.org/10.1590/ s0100-879x1999000600007 17.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2014;40(5):504-12. http://dx.doi.org/10.1590/ S1806-37132014000500006Chest.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2015;147(3):673-84. http://dx.doi.org/10.1378/ chest.14-1079 2.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2011;37(3):380-8. http://dx.doi.org/10.1590/ S1806-37132011000300016 3.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2014;189(9):15-62.  http://dx.doi.org/10.1164/rccm.201402-0373ST 4.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
"[Epub ahead of print]  http://dx.doi.org/10.1016/j.arbr.2015.04.027 5. van Zeller M, Mota PC, Amorim A, Viana P, Martins P,  Gaspar L, et al.",Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2012;32(5):278-83. http://dx.doi.org/10.1097/ HCR.0b013e3182631314 6.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2013;14:46.  http://dx.doi.org/10.1186/1465-9921-14-46 7.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
2014;19(1):138-43. http://dx.doi.org/10.1111/resp.12181 8.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
1999;29(2):116-26. http://dx.doi.org/10.2519/ jospt.1999.29.2.116 J Bras Pneumol.,Non-OADS,/arxiv_data1/oa_pdf/54/0f/1806-3713-jbpneu-41-04-00297.PMC4635948.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000057Functional improvement in patients with idiopathic  pulmonary fibrosis undergoing single lung transplantation* Melhora funcional em portadores de fibrose pulmonar idiopática  submetidos a transplante pulmonar unilateral Adalberto Sperb Rubin1,2, Douglas Zaione Nascimento1, Letícia Sanchez1,  Guilherme Watte2, Arthur Rodrigo Ronconi Holand1,   Derrick Alexandre Fassbind1, José Jesus Camargo1,2 Abstract Objective: To evaluate the changes in lung function in the first year after single lung transplantation in  patients with idiopathic pulmonary fibrosis (IPF).",Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
"Rubin AS, Nascimento DZ, Sanchez L, Watte G, Holand ARR, Fassbind DA, Camargo JJ http://dx.doi.org/10.1590/S1806-37132015000000057The patients who died before the first year  of follow-up and those who were unable to  undergo lung function assessment at the end of  the first year after transplantation were excluded.",Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
"Functional improvement in patients with idiopathic pulmonary   fibrosis undergoing single lung transplantation http://dx.doi.org/10.1590/S1806-37132015000000057third month and the first year after transplantation  (Figure 2), a total of 24 deaths having occurred  (30%).",Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
"Rubin AS, Nascimento DZ, Sanchez L, Watte G, Holand ARR, Fassbind DA, Camargo JJ http://dx.doi.org/10.1590/S1806-37132015000000057Pêgo-Fernandes et al.",Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
Functional improvement in patients with idiopathic pulmonary   fibrosis undergoing single lung transplantation http://dx.doi.org/10.1590/S1806-37132015000000057Sociedade Brasileira de Pneumologia e Tisiologia.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2003;29(6):371-8.  http://dx.doi.org/10.1590/S0102-35862003000600009 4.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2003;126(2):469-75.  http://dx.doi.org/10.1016/S0022-5223(03)00600-7 5.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2001;164(1):103-8. http://dx.doi.org/10.1164/ ajrccm.164.1.2007077 7.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2012;366(21):1968- 77. http://dx.doi.org/10.1056/NEJMoa1113354 8.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2010;104(3):426-33. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2011;146(10):1204-9. http://dx.doi.org/10.1001/ archsurg.2011.239 10.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
1986;314(18):1140-5. http://dx.doi.org/10.1056/ NEJM198605013141802 11.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2009;28(10):1031-49.  http://dx.doi.org/10.1016/j.healun.2009.08.004 13.,OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2011;183(6):788-824. http://dx.doi.org/10.1164/ rccm.2009-040GL 2.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
"Rubin AS, Nascimento DZ, Sanchez L, Watte G, Holand ARR, Fassbind DA, Camargo JJ http://dx.doi.org/10.1590/S1806-3713201500000005724.",Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2011;39(5):726-31.  http://dx.doi.org/10.1016/j.ejcts.2010.08.034 26.,OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
1998;53(1):43-9. http://dx.doi.org/10.1136/ thx.53.1.43 27.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2000;118(1):115-22. http://dx.doi.org/10.1378/ chest.118.1.115 28.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2009;64(6):519-25. http://dx.doi.org/10.1590/ S1807-59322009000600006 29.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2014;370(22):2071-82. http://dx.doi.org/10.1056/ NEJMoa1402584Transplantation.,OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2011;91(11):1297-1303. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2011;184(2):159-71. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2003;168(5):543-8.  http://dx.doi.org/10.1164/rccm.200209-1112OC 19.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2002;165(2):277-304. http://dx.doi.org/10.1164/ ajrccm.165.2.ats01 20.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2007;33(4):397-406. http://dx.doi.org/10.1590/ S1806-37132007000400008 22.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
1993;55(5):1048- 50. http://dx.doi.org/10.1097/00007890-199305000-00019 23.,Non-OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
2010;42(8):3211-3. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/51/83/1806-3713-jbpneu-41-04-00299.PMC4635949.pdf
"http://dx.doi.org/10.1590/S1806-37132015000004515Analysis of three different equations for predicting quadriceps  femoris muscle strength in patients with COPD* Análise de três diferentes fórmulas de predição de força muscular do  quadríceps femoral em pacientes com DPOC Aline Gonçalves Nellessen¹, Leila Donária¹,   Nidia Aparecida Hernandes¹, Fabio Pitta¹ Abstract Objective: To compare equations for predicting peak quadriceps femoris (QF) muscle force; to determine the  agreement among the equations in identifying QF muscle weakness in COPD patients; and to assess the differences  in characteristics among the groups of patients classified as having or not having QF muscle weakness by each  equation.",OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Nellessen AG, Donária L, Hernandes NA, Pitta F http://dx.doi.org/10.1590/S1806-37132015000004515they were unable to perform the tests proposed  in the study.",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Analysis of three different equations for predicting quadriceps   femoris muscle strength in patients with COPD http://dx.doi.org/10.1590/S1806-37132015000004515that were normally distributed are expressed as  mean and standard deviation, and otherwise as  median and interquartile range (25-75% percentile).",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Nellessen AG, Donária L, Hernandes NA, Pitta F http://dx.doi.org/10.1590/S1806-37132015000004515obtained with the equations of Neder et al.,(16)  Decramer et al.,(12) or Seymour et al.",OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Analysis of three different equations for predicting quadriceps   femoris muscle strength in patients with COPD http://dx.doi.org/10.1590/S1806-37132015000004515consideration, which hinders its use in clinical  practice because it requires the estimation of  fat-free body mass (by bioelectrical impedance  or dual-energy X-ray absorptiometry).",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Nellessen AG, Donária L, Hernandes NA, Pitta F http://dx.doi.org/10.1590/S1806-37132015000004515One possible explanation for the fact that  patients classified as not having QF muscle  weakness by the equations of Neder et al.",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
Analysis of three different equations for predicting quadriceps   femoris muscle strength in patients with COPD http://dx.doi.org/10.1590/S1806-37132015000004515severity.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2010;36(1):81-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2014;189(9):e15- 62. http://dx.doi.org/10.1164/rccm.201402-0373ST 10.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2000;94(9):859-67. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
1997;10(2):417-23. http://dx.doi.org/10.1183/09031 936.97.10020417 13.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2011;31(1):11-24. http://dx.doi.org/10.1097/ HCR.0b013e3181ebf302 15.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2000;20(6):353- 60. http://dx.doi.org/10.1097/00008483-200011000-00004 16.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
1999;29(2):116-26. http://dx.doi.org/10.2519/ jospt.1999.29.2.116 17.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2005;26(2):319-38. http://dx.doi.org/10.1183/09031936.05.00034805 18.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2007;33(4):397-406. http://dx.doi.org/10.1590/ S1806-37132007000400008 19.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
1998;12(4):960-6. http://dx.doi.org/10.1183/090319 36.98.12040960 21.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Global Strategy for the Diagnosis, Management, and  Prevention of Chronic Obstructive Pulmonary Disease;  2014 Available from: http://www.goldcopd.org/Guidelines/ guidelines-resources.html 2.",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2003;21(2):347-60. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2011;37(3):380-8. http://dx.doi.org/10.1590/ S1806-37132011000300016 4.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2013;114(9):1222-34. http://dx.doi.org/10.1152/ japplphysiol.00981.2012 6.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2007;8:25. http://dx.doi.org/10.1186/1465-9921-8-25 8.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"Nellessen AG, Donária L, Hernandes NA, Pitta F http://dx.doi.org/10.1590/S1806-37132015000004515and South America.",Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2009;103(3):421-6.  http://dx.doi.org/10.1016/j.rmed.2008.09.019 28.,OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2011;37(1):150-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2014;44(6):1428-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2004;59(8):673-8. http://dx.doi.org/10.1136/ thx.2003.020636 32.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
PM R. 2011;3(5):472-9.  http://dx.doi.org/10.1016/j.pmrj.2010.10.025Arch Phys Med Rehabil.,OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2007;88(1):32-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2013;23(6):1283-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2014;69(6):525-31. http://dx.doi.org/10.1136/thoraxjnl-2013-204388 25.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
1977;33(1):159- 74. http://dx.doi.org/10.2307/2529310 26.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
2005;21(5):1565-73. http://dx.doi.org/10.1590/ S0102-311X2005000500030 27.,Non-OADS,/arxiv_data1/oa_pdf/b9/15/1806-3713-jbpneu-41-04-00305.PMC4635950.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000025Cocaine-induced pulmonary changes: HRCT findings* Cocaine-induced pulmonary changes: HRCT findings Renata Rocha de Almeida1, Gláucia Zanetti1,2, Arthur Soares Souza Jr.3,   Luciana Soares de Souza4, Jorge Luiz Pereira e Silva5, Dante Luiz Escuissato6,  Klaus Loureiro Irion7, Alexandre Dias Mançano8, Luiz Felipe Nobre9,   Bruno Hochhegger10, Edson Marchiori1,11 Abstract Objective:  To evaluate HRCT scans of the chest in 22 patients with cocaine-induced pulmonary disease.",Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000025All scans were analyzed for the following:  ground-glass opacities, consolidations, interlobular  septal thickening, the crazy-paving pattern,  nodules, small parenchymal nodules, centrilobular  nodules, the tree-in-bud pattern, cavitation, the  halo sign, paraseptal emphysema, apical bullae,  bullous emphysema, masses, and architectural  distortion.",OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"Cocaine-induced pulmonary changes: HRCT findings http://dx.doi.org/10.1590/S1806-37132015000000025hemopneumothorax occurred in 1 patient,  respectively.",Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000025Discussion Cocaine is the second most widely used illicit  drug (second only to marijuana) in Brazil and  in the world, as well as being associated with  numerous health problems, such as those related to  the respiratory system.",Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"Cocaine-induced pulmonary changes: HRCT findings http://dx.doi.org/10.1590/S1806-37132015000000025batteries, sometimes combined with different  organic solvents.",Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000025and 2 cases of pneumothorax, 1 of which was  associated with hemothorax.",Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
Cocaine-induced pulmonary changes: HRCT findings http://dx.doi.org/10.1590/S1806-371320150000000252002;22 Spec No:S119-35.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
http://dx.doi.org/10.1148/ radiographics.22.suppl_1.g02oc01s119 9.,OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
1987;136(5):1250-2. http://dx.doi.org/10.1164/ ajrccm/136.5.1250 10.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
1990;142(2):462-7. http://dx.doi.org/10.1164/ ajrccm/142.2.462 11.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2008;246(3):697-722.  http://dx.doi.org/10.1148/radiol.2462070712 12.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2002;35(2):125-8. http://dx.doi.org/10.1590/ S0100-39842002000200016 13.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2010;36(1):99-123. http://dx.doi.org/10.1590/ S1806-37132010000100016 14.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
http://dx.doi.org/10.1590/ S0102-311X2008001600007 15.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2012;142(5):1348- 51. http://dx.doi.org/10.1378/chest.12-0482 16.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2008;42(4):664-71. http://dx.doi.org/10.1590/ S0034-89102008000400012 17.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
1989;172(2):459- 62. http://dx.doi.org/10.1148/radiology.172.2.2748826 18.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2013;90(3):542- 51. http://dx.doi.org/10.1007/s11524-012-9780-9 19.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2012;19(33):5647-57. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2012;19(33):5612-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
Available from: http://www.unodc.org/documents/ data-andanalysis/WDR2012/WDR_2012_web_small.pdf 3.,OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
Available from: http://dssbr.org/site/2013/10/estudo-da- fiocruz-estima-alcance-do-crack-nas-capitais-brasileiras 5.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2007;27(4):941-56. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2001;7(2):43-61.  http://dx.doi.org/10.1097/00063198-200103000-00001 7.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2012;19(33):5624-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
http://dx.doi.org/10.1590/S1806-3713201500000002529.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2010;3(4):435-7. http://dx.doi.org/10.1007/ s12245-010-0205-9 30.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2010;339(1):65-7. http://dx.doi.org/10.1097/ MAJ.0b013e3181c371da 31.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2010;188(2):165-71. http://dx.doi.org/10.1007/ s00408-010-9230-y 32.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
http://dx.doi.org/10.4187/respcare.02402 34.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2007;13(3):159-69. http://dx.doi.org/10.1097/ MCP.0b013e3280f3bff4 35.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2014;108(1):1-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2011;106(6):1191-2.  http://dx.doi.org/10.1111/j.1360-0443.2011.03427.x 24.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
1994;25(2):203-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2009;37(3):324-32. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
2014;192(2):225- 33. http://dx.doi.org/10.1007/s00408-013-9553-6 J Bras Pneumol.,Non-OADS,/arxiv_data1/oa_pdf/b3/07/1806-3713-jbpneu-41-04-00323.PMC4635952.pdf
"http://dx.doi.org/10.1590/S1806-37132015000004462Clinical characteristics of children and adolescents   with severe therapy-resistant asthma in Brazil* Características clínicas de crianças e adolescentes   brasileiros com asma grave resistente a terapia Andrea Mendonça Rodrigues1, Cristian Roncada1, Giovana Santos2,   João Paulo Heinzmann-Filho1, Rodrigo Godinho de Souza2,   Mauro Henrique Moraes Vargas1, Leonardo Araújo Pinto3, Marcus Herbert Jones3,  Renato Tetelbom Stein3, Paulo Márcio Pitrez3 Abstract Objective: To describe the clinical characteristics, lung function, radiological findings, and the inflammatory cell  profile in induced sputum in children and adolescents with severe therapy-resistant asthma (STRA) treated at a  referral center in southern Brazil.",Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
http://dx.doi.org/10.1590/S1806-37132015000004462β2 agonist use; d) reduced lung function that  cannot be reversed with treatment; and e) need  for continuous oral corticosteroid use.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
Clinical characteristics of children and adolescents with severe therapy-resistant asthma in Brazil http://dx.doi.org/10.1590/S1806-37132015000004462was administered more than five consecutive  times (once at each clinical visit).,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
http://dx.doi.org/10.1590/S1806-37132015000004462Sputum induction was performed in 18 patients  but was successful in only 13 (73%).,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
"Clinical characteristics of children and adolescents with severe therapy-resistant asthma in Brazil http://dx.doi.org/10.1590/S1806-37132015000004462allergens were uncommon, a finding that was  reported by our research group in a previous study  of children with asthma in the same region.",Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
http://dx.doi.org/10.1590/S1806-37132015000004462the management of severe asthma in children.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
Clinical characteristics of children and adolescents with severe therapy-resistant asthma in Brazil http://dx.doi.org/10.1590/S1806-37132015000004462References 1.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
1998;351(9111):1225- 32. http://dx.doi.org/10.1016/S0140-6736(97)07302-9 3.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2014;18(11):1269-78.  http://dx.doi.org/10.5588/ijtld.14.0170 4.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2009;64(5):822.  http://dx.doi.org/10.1111/j.1398-9995.2008.01672.x 5.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2010;376(9743):814-25. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2014;43(4):1216. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2004;59(10):862-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2009;34(5):1052-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2009;64(6):476-83. http://dx.doi.org/10.1136/ thx.2008.106609 14.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
http://dx.doi.org/10.1590/S1806-37132015000004462function.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2004;170(4):426- 32. http://dx.doi.org/10.1164/rccm.200308-1178OC 24.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
http://dx.doi.org/10.1542/peds.2009-2382 29.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2010;22(6):758- 64. http://dx.doi.org/10.1097/MOP.0b013e3283404201 30.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2011;364(11):1005-15. http://dx.doi.org/10.1056/ NEJMoa1009705 31.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2013;42(5):1224-33. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2008;43(10):1020-4. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
Available from: http://www.lungfunction.org 17.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2010;36(2):159-66.  http://dx.doi.org/10.1590/S1806-37132010000200002 19.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2000;162(6):2341-51. http://dx.doi.org/10.1164/ ajrccm.162.6.ats9-00 20.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
2003;124(4):1318-24. http://dx.doi.org/10.1378/ chest.124.4.1318 23.,Non-OADS,/arxiv_data1/oa_pdf/4b/2f/1806-3713-jbpneu-41-04-00343.PMC4635954.pdf
"http://dx.doi.org/10.1590/S1806-37132015000004468Sleep-disordered breathing in patients with cystic fibrosis* Distúrbios respiratórios do sono em pacientes com fibrose cística Jefferson Veronezi1,2, Ana Paula Carvalho3, Claudio Ricachinewsky4,   Anneliese Hoffmann4, Danielle Yuka Kobayashi5, Otavio Bejzman Piltcher6,   Fernando Antonio Abreu e Silva7, Denis Martinez1,2,8 Abstract Objective: To test the hypothesis that disease severity in patients with cystic fibrosis (CF) is correlated with an  increased risk of sleep apnea.",Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
"Veronezi J, Carvalho AP, Ricachinewsky C, Hoffmann A,   Kobayashi DY, Piltcher OB, Abreu e Silva FA, Martinez D http://dx.doi.org/10.1590/S1806-37132015000004468Blood samples were collected between 10:00  a.m. and 12:00 p.m. for determination of IL-1β  levels.",OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
Sleep-disordered breathing in patients with cystic fibrosis http://dx.doi.org/10.1590/S1806-37132015000004468for confounding factors.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
"Veronezi J, Carvalho AP, Ricachinewsky C, Hoffmann A,   Kobayashi DY, Piltcher OB, Abreu e Silva FA, Martinez D http://dx.doi.org/10.1590/S1806-37132015000004468useful in raising the suspicion of sleep apnea, a  condition that can worsen the clinical picture  of CF.",Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
Sleep-disordered breathing in patients with cystic fibrosis http://dx.doi.org/10.1590/S1806-37132015000004468which we found for the children in the present  study (4.7 ±  2.8 vs. 4.9 ±  2.0).,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
"Veronezi J, Carvalho AP, Ricachinewsky C, Hoffmann A,   Kobayashi DY, Piltcher OB, Abreu e Silva FA, Martinez D http://dx.doi.org/10.1590/S1806-371320150000044684.",Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2013;19(6):652-61. http://dx.doi.org/10.1097/ MCP.0b013e3283659e9f 5.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2002;19(3):504-10. http://dx.doi.org/10.1183/09031 936.02.00088702 6.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2001;163(1):129- 34. http://dx.doi.org/10.1164/ajrccm.163.1.2005130 7.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2011;87(1):63-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2012;16(4):1041-8. http://dx.doi.org/10.1007/ s11325-011-0599-5 9.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2007;2(2):161-69. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2012;12:3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2009;373(9678):1891-904. http://dx.doi.org/10.1016/ S0140-6736(09)60327-5 14.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
Available from:  http://www.who.int/childgrowth/ 16.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2008;108(5):832-9. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
1958;96(1):6-15. http://dx.doi.org/10.1001/ archpedi.1958.02060060008002 18.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2001;164(1):16-30. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2012;47(11):1123-30.  http://dx.doi.org/10.1002/ppul.22537 J Bras Pneumol.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
Sleep-disordered breathing in patients with cystic fibrosis http://dx.doi.org/10.1590/S1806-3713201500000446825.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2007;3:7. http://dx.doi.org/10.1186/1745-9974-3-7 28.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2012;97(11):960-6.  http://dx.doi.org/10.1136/archdischild-2011-300440 30.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2008;34(6):356-61.  http://dx.doi.org/10.1590/S1806-37132008000600004 31.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
http://dx.doi.org/10.1542/peds.113.6.e564.19.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2011;7(5):531-48. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2009;135(2):330-6.  http://dx.doi.org/10.1378/chest.08-1859 21.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2005;6(2):123-30.  http://dx.doi.org/10.1016/j.sleep.2004.08.005 23.,OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
2009;13(2):123-31. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/30/1806-3713-jbpneu-41-04-00351.PMC4635955.pdf
"http://dx.doi.org/10.1590/S1806-37132015000004453Reflex cough PEF as a predictor of successful   extubation in neurological patients* Pico de fluxo de tosse reflexa como preditor de sucesso   na extubação em pacientes neurológicos Fernanda Machado Kutchak1,2, Andressa Maciel Debesaitys2,   Marcelo de Mello Rieder2,3, Carla Meneguzzi2, Amanda Soares Skueresky3,   Luiz Alberto Forgiarini Junior3,4, Marino Muxfeldt Bianchin5 Abstract Objective: To evaluate the use of reflex cough PEF as a predictor of successful extubation in neurological  patients who were candidates for weaning from mechanical ventilation.",Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
"Reflex cough PEF as a predictor of successful extubation in neurological patients http://dx.doi.org/10.1590/S1806-37132015000004453physical therapy team immediately before the  SBT, with the head of the bed elevated 45°.",Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
http://dx.doi.org/10.1590/S1806-371320150000044530.001).,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
"Reflex cough PEF as a predictor of successful extubation in neurological patients http://dx.doi.org/10.1590/S1806-37132015000004453 Reflex cough PEF Accuracy: 0.81 (95% CI: 0.73-0.89) Accuracy: 0.57 (95% CI: 0.47-0.67)SensitivitySensitivity 1 − specificity 1 − specificityGlasgow Coma Scale 0.0 0.2 0.4 0.6 0.8 1.0 0.00.0 0.20.2 0.40.4 0.60.6 0.80.8 1.01.0 0.00.20.40.60.81.0Table 2 - Ventilatory, hemodynamic, and gas exchange parameters measured within 30 min after initiation  of a spontaneous breathing trial.a  Variable Extubation success Extubation failure pb (n = 90) (n = 45) SBP, mmHg 138 ± 22 140 ± 16 0.411 DBP, mmHg 80 ± 11 81 ± 8.90 0.677 HR, bpm 89 ± 12 88 ± 12 0.838 RR, breaths/min 23 ± 8.90 25 ± 3.80 0.359 Arterial blood gases, pH 7.40 ± 0.31 7.40 ± 0.03 0.436 PaCO2, mmHg 40 ± 6.20 (5.37 ± 0.83) 39 ± 5.47 (5.16 ± 0.73) 0.177 PaO2, mmHg 117 ± 35 (15.60 ± 4.67) 125 ± 31 (16.67 ± 4.13) 0.243 SaO2, % 98 ± 1.51 98 ± 1.75 0.230 PaO2/FiO2346 ± 116 356 ± 112 0.507 SBP: systolic blood pressure; and DBP: diastolic blood pressure.",Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
http://dx.doi.org/10.1590/S1806-37132015000004453patients.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
Reflex cough PEF as a predictor of successful extubation in neurological patients http://dx.doi.org/10.1590/S1806-371320150000044536.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
"2008;26(2):543-63, x. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2011;15(3):490-7. http://dx.doi.org/10.1007/ s12028-010-9369-7 9.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2011;37(5):669-79. http://dx.doi.org/10.1590/ S1806-37132011000500016 10.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2008;36(11):2986-92. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2000;161(5):1450-8.  http://dx.doi.org/10.1164/ajrccm.161.5.9902018 13.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2006;5(2):108-14. http://dx.doi.org/10.1385/ NCC:5:2:108 18.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
1997;112(1):186-92. http://dx.doi.org/10.1378/ chest.112.1.186 19.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2006;61(8):699- 705. http://dx.doi.org/10.1136/thx.2005.057901 20.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
1993;19(4):204-8. http://dx.doi.org/10.1007/ BF01694771 4.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
http://dx.doi.org/10.1590/S1806-37132015000004453Paulo: Escola de Enfermagem da Universidade de São  Paulo; 2000.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2001;163(3 Pt 1):658-64. http://dx.doi.org/10.1164/ ajrccm.163.3.2003060 27.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
Available from: http://www.scielo.br/scielo.php?script=sci_ arttext&pid=S0103-507X2006000400006&lng=en 28.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2010;137(4):777- 82. http://dx.doi.org/10.1378/chest.07-2808 30.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2010;23(3):495-502. http://dx.doi.org/10.1590/ S0103-51502010000300016Crit Care Med.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2000;161(5):1530-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
http://dx.doi.org/10.1378/ chest.120.6_suppl.375S 22.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2011;26(5):502-9.  http://dx.doi.org/10.1016/j.jcrc.2010.12.015 23.,OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
2002;28(5):535-46. http://dx.doi.org/10.1007/ s00134-002-1268-8 25.,Non-OADS,/arxiv_data1/oa_pdf/cf/7c/1806-3713-jbpneu-41-04-00358.PMC4635956.pdf
"http://dx.doi.org/10.1590/S1806-37132015000004531Identifying activating mutations in the EGFR gene: prognostic  and therapeutic implications in non-small cell lung cancer* Identificação de mutações ativadoras no gene EGFR: implicações no  prognóstico e no tratamento do carcinoma pulmonar de células não pequenas Gabriel Lima Lopes1, Edoardo Filippo de Queiroz Vattimo2,  Gilberto de Castro Junior2,3 Abstract Lung cancer is the leading cause of cancer-related deaths worldwide.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Lopes GL, Vattimo EFQ, Castro Jr G http://dx.doi.org/10.1590/S1806-37132015000004531among these is the Ras/Raf/mitogen-activated  protein kinase (MAPK) pathway, in which the  adaptor protein Grb2 binds to phosphorylated  tyrosine residues of EGFR, thus activating the  Son of sevenless protein.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Identifying activating mutations in the  EGFR  gene: prognostic and   therapeutic implications in non-small cell lung cancer http://dx.doi.org/10.1590/S1806-37132015000004531involving 731 patients with advanced NSCLC  that had previously been treated with first- or  second-line platinum-based chemotherapy, was  conducted between August of 2001 and January of  2003.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Lopes GL, Vattimo EFQ, Castro Jr G http://dx.doi.org/10.1590/S1806-37132015000004531all of whom were nonsmokers or former light  smokers, were randomized to first-line treatment  with gefitinib or with carboplatin plus paclitaxel.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Identifying activating mutations in the  EGFR  gene: prognostic and   therapeutic implications in non-small cell lung cancer http://dx.doi.org/10.1590/S1806-371320150000045315.6 months and 67% vs. 23%, respectively).",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Lopes GL, Vattimo EFQ, Castro Jr G http://dx.doi.org/10.1590/S1806-37132015000004531of EGFR-TKIs in patients with localized or locally  advanced disease.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Identifying activating mutations in the  EGFR  gene: prognostic and   therapeutic implications in non-small cell lung cancer http://dx.doi.org/10.1590/S1806-37132015000004531RFLP The RFLP technique is based on the use of  restriction enzymes, which cleave sequences of  genetic material at specific sites.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Lopes GL, Vattimo EFQ, Castro Jr G http://dx.doi.org/10.1590/S1806-371320150000045314.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2002;346(2):92-8. http://dx.doi.org/10.1056/ NEJMoa011954 5.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;304(5676):1497-500. http://dx.doi.org/10.1126/ science.1099314 6.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;350(21):2129-39. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1965;12(3):394-407.  http://dx.doi.org/10.1016/0012-1606(65)90005-9 8.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2000;19(56):6550- 65. http://dx.doi.org/10.1038/sj.onc.1204082 9.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1997;16(2):281- 94. http://dx.doi.org/10.1093/emboj/16.2.281 10.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"1984;311(5985):483-5. http://dx.doi.org/10.1038/311483a0 11. van der Geer P, Pawson T. The PTB domain: a new  protein module implicated in signal transduction.",OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1995;20(7):277-80. http://dx.doi.org/10.1016/ S0968-0004(00)89043-X 12.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1993;73(3):611-20. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;30(2):193-204.  http://dx.doi.org/10.1016/j.ctrv.2003.07.007 15.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1984;307(5951):521-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;10(4):1212-8.  http://dx.doi.org/10.1158/1078-0432.CCR-03-0564 18.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2005;10(7):461-6. http://dx.doi.org/10.1634/ theoncologist.10-7-461 19.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"2013;73(13):1503-15. http://dx.doi.org/10.1007/ s40265-013-0111-6as RAS mutations, anaplastic lymphoma kinase  translocations, and HER-2 amplification.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
Available from: http://globocan.iarc.fr 3.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
Identifying activating mutations in the  EGFR  gene: prognostic and   therapeutic implications in non-small cell lung cancer http://dx.doi.org/10.1590/S1806-37132015000004531non-small-cell lung cancer (INTEREST): a randomised  phase III trial.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;22(9):1589-97. http://dx.doi.org/10.1200/ JCO.2004.08.163 33.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2008;56(3):97-103. http://dx.doi.org/10.1007/ s11748-007-0193-8 34.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2006;54(1):25-33. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
http://dx.doi.org/10.6061/ clinics/2012(05)03 39.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2008;27(34):4702-11. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2012;13(5):391-5. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2009;361(10):947-57.  http://dx.doi.org/10.1056/NEJMoa0810699 43.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2002;16(5):1041-63. http://dx.doi.org/10.1016/ S0889-8588(02)00055-2 21.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004 Dec 1;22(23):4863.  http://dx.doi.org/10.1200/JCO.2003.10.038 23.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;22(5):777- 84. http://dx.doi.org/10.1200/JCO.2004.08.001 25.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;22(5):785-94. http://dx.doi.org/10.1200/ JCO.2004.07.215 26.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2007;25(12):1545-52.  http://dx.doi.org/10.1200/JCO.2005.05.1474 28.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2005;353(2):123-32. http://dx.doi.org/10.1056/ NEJMoa050753 29.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2004;44(2):221-30. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2005;366(9496):1527- 37. http://dx.doi.org/10.1016/S0140-6736(05)67625-8 31.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"Lopes GL, Vattimo EFQ, Castro Jr G http://dx.doi.org/10.1590/S1806-37132015000004531Cancer.",Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2013;80(3):242-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
http://dx.doi.org/10.1093/ annonc/mdu349.2 55.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2008;359(4):366-77. http://dx.doi.org/10.1056/NEJMoa0800668 59.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
1977;74(12):5463-7. http://dx.doi.org/10.1073/ pnas.74.12.5463 60.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2007;13(17):4954-5. http://dx.doi.org/10.1158/1078-0432.CCR-07-1387 61.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2006;12(13):3915-21.  http://dx.doi.org/10.1158/1078-0432.CCR-05-2324 62.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;136(9):1341-7. http://dx.doi.org/10.1007/s00432-010-0785-z 64.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;362(25):2380-8. http://dx.doi.org/10.1056/ NEJMoa0909530 44.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;11(2):121-8. http://dx.doi.org/10.1016/S1470-2045(09)70364-X 45.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2011;12(8):735-42. http://dx.doi.org/10.1016/S1470-2045(11)70184-X 46.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2012;13(3):239-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2013;31(27):3327-34. http://dx.doi.org/10.1200/ JCO.2012.44.2806 48.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2014;15(2):213-22. http://dx.doi.org/10.1016/ S1470-2045(13)70604-1 49.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2015;16(2):141-51. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2011;29(21):2866-74. http://dx.doi.org/10.1200/ JCO.2010.33.4235 51.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2009;361(10):958- 67. http://dx.doi.org/10.1056/NEJMoa0904554 52.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2011;19(8):1079-95. http://dx.doi.org/10.1007/ s00520-011-1197-6 53.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
Identifying activating mutations in the  EGFR  gene: prognostic and   therapeutic implications in non-small cell lung cancer http://dx.doi.org/10.1590/S1806-3713201500000453170.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2013;368(25):2385-94.  http://dx.doi.org/10.1056/NEJMoa1214886 71.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2014;514(7521):262. http://dx.doi.org/10.1038/nature13385 73.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;28(2):357-60. http://dx.doi.org/10.1200/ JCO.2009.24.7049 75.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;11(6):521-9. http://dx.doi.org/10.1016/ S1470-2045(10)70112-1assay.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2006;12(1):43-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2005;7(3):396-403. http://dx.doi.org/10.1016/ S1525-1578(10)60569-7 66.,OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2006;8(3):335-41. http://dx.doi.org/10.2353/ jmoldx.2006.050104 67.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2007;53(1):62-70. http://dx.doi.org/10.1373/ clinchem.2006.074831 68.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2010;8:135. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
2011;6(2):244-85. http://dx.doi.org/10.1097/ JTO.0b013e318206a221 J Bras Pneumol.,Non-OADS,/arxiv_data1/oa_pdf/a0/3f/1806-3713-jbpneu-41-04-00365.PMC4635957.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000034Stereotactic body radiotherapy in lung cancer: an update* Radioterapia estereotáxica extracraniana   em câncer de pulmão: atualização Carlos Eduardo Cintra Vita Abreu1, Paula Pratti Rodrigues Ferreira1,   Fabio Ynoe de Moraes1, Wellington Furtado Pimenta Neves Jr1,   Rafael Gadia2, Heloisa de Andrade Carvalho1,3 Abstract For early-stage lung cancer, the treatment of choice is surgery.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034will eventually result in toxicity.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Abreu CECV, Ferreira PPR, Moraes FY, Neves Jr WFP, Gadia R, Carvalho HA http://dx.doi.org/10.1590/S1806-37132015000000034event profiles were found to be different across  studies, and the data constituted evidence for the  use of SBRT in patients with peripheral lesions.",OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034In the Netherlands, Haasbeek et al.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Abreu CECV, Ferreira PPR, Moraes FY, Neves Jr WFP, Gadia R, Carvalho HA http://dx.doi.org/10.1590/S1806-37132015000000034thoracotomy without previous histological  confirmation.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034has been observed, indicating the possibility of  a paradigm change in the near future.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Abreu CECV, Ferreira PPR, Moraes FY, Neves Jr WFP, Gadia R, Carvalho HA http://dx.doi.org/10.1590/S1806-37132015000000034respectively.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034DLCO can be less than significant in patients with  severe COPD, they can be significant in patients  with normal lung function or mild to moderate  COPD.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Abreu CECV, Ferreira PPR, Moraes FY, Neves Jr WFP, Gadia R, Carvalho HA http://dx.doi.org/10.1590/S1806-37132015000000034control probability model parameters from 3-D dose  distributions of non-small cell lung cancer patients.",OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
1999;24(1):31-7. http://dx.doi.org/10.1016/ S0169-5002(99)00019-7 7.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
1999;52(2):137-48. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2002;54(2):348- 56. http://dx.doi.org/10.1016/S0360-3016(02)02958-9 9.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
1995;34(6):861- 70. http://dx.doi.org/10.3109/02841869509127197 11.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;94(1):1- 11. http://dx.doi.org/10.1016/j.radonc.2009.12.008 14.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;81(5):1352-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Basel: Karger;  2007. p. 368-85. http://dx.doi.org/10.1159/000106047 16.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available  from: http://www.rtog.org/ClinicalTrials/ProtocolTable/ StudyDetails.aspx?study=0236patients who are unwilling to undergo  surgery.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;61(2):69- 90. http://dx.doi.org/10.3322/caac.20107 2.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;62(1):10-29. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2007;132(1):193-9. http://dx.doi.org/10.1378/ chest.06-3096 4.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
1995;60(2):466-72. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034Radiat Oncol Biol Phys.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;28(35):5153-9. http://dx.doi.org/10.1200/ JCO.2010.30.0731 30.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2009;93(3):408-13. http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;80(3):692-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2003;124(5):1946-55.  http://dx.doi.org/10.1378/chest.124.5.1946 35.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2014;4:151. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;6(12):2036-43. http://dx.doi.org/10.1097/ JTO.0b013e31822e71d8 37.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;186(5):274-9.  http://dx.doi.org/10.1007/s00066-010-2072-y17.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available from: http://www.rtog.org/ClinicalTrials/ ProtocolTable/StudyDetails.aspx?study=0813 18.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;80(5):1343-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2006;45(7):787-95.  http://dx.doi.org/10.1080/02841860600904862 24.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;13(8):802-9.  http://dx.doi.org/10.1016/S1470-2045(12)70242-5 25.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2007;8(8):488- 92. http://dx.doi.org/10.3816/CLC.2007.n.033 26.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2009;91(3):296-300. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"Abreu CECV, Ferreira PPR, Moraes FY, Neves Jr WFP, Gadia R, Carvalho HA http://dx.doi.org/10.1590/S1806-37132015000000034tomography.",Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2005;128(4):2490-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;101(2):250-4.  http://dx.doi.org/10.1016/j.radonc.2011.09.017 54.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2014;146(4):1021-8.  http://dx.doi.org/10.1378/chest.13-2924 56.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2002;21(3):527-33. http://dx.doi.org/10.1016/ S1010-7940(02)00024-6 57.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2006;12(4):283-8.  http://dx.doi.org/10.1097/00130404-200607000-00006 58.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2008;86(5):1632-8; discussion 1638-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2013;119(18):3402-10. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;116(2):406-14. http://dx.doi.org/10.1002/ cncr.24759 62.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2013;17(5):845- 53. http://dx.doi.org/10.1093/icvts/ivt262 63.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;101(2):240-4. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;3:39.  http://dx.doi.org/10.1186/1756-8722-3-39 41.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2009;91(3):301-6. http://dx.doi.org/10.1016/j.radonc.2009.03.005 42.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2008;72(4):967-71. http://dx.doi.org/10.1016/j.ijrobp.2008.08.001 43.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2010;5:81. http://dx.doi.org/10.1186/1748-717X-5-81 44.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2006;66(1):117-25.  http://dx.doi.org/10.1016/j.ijrobp.2006.04.013 45.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2009;74(1):47-54. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
http://dx.doi.org/10.1016/j.ijrobp.2011.01.038 47.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2011;101(2):255-9. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"2012;35(7- 8):408-12. http://dx.doi.org/10.1159/000340064 50. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh  JH, Schreurs AJ, Stallaert RA, et al.",OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2002;359(9315):1388-93. http://dx.doi.org/10.1016/ S0140-6736(02)08352-6 51.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Stereotactic body radiotherapy in lung cancer: an update http://dx.doi.org/10.1590/S1806-37132015000000034therapy for early- stage peripheral non-small cell lung  cancer: an analysis of RTOG 0236.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2014;88(5):1092-9. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2013;143(1):130-7. http://dx.doi.org/10.1378/ chest.12-0207 73.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;82(1):e107- 10. http://dx.doi.org/10.1016/j.ijrobp.2011.01.037 74.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2009;4(7):838-44.  http://dx.doi.org/10.1097/JTO.0b013e3181a99ff6 75.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2008;72(2):404-9.  http://dx.doi.org/10.1016/j.ijrobp.2007.12.051 76.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;82(3):1149-56. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available from: https://www.rtog.org/ClinicalTrials/ ProtocolTable/StudyDetails.aspx?study=0813 78.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available from: https://www.rtog.org/ ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=091564.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;83(1):348-53. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2014;90(3):603-11. http://dx.doi.org/10.1016/j.ijrobp.2014.05.055 66.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available from:  https://clinicaltrials.gov/ct2/show/NCT00687986 67.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
Available  from: https://clinicaltrials.gov/ct2/show/NCT00840749 68.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2015;16(6)630-7. http://dx.doi.org/10.1016/ S1470-2045(15)70168-3 70.,OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
2012;7(3):542-51.  http://dx.doi.org/10.1097/JTO.0b013e31824165d7 71.,Non-OADS,/arxiv_data1/oa_pdf/5a/5c/1806-3713-jbpneu-41-04-00376.PMC4635958.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000076Dense consolidations Consolidação densa Edson Marchiori1,2, Gláucia Zanetti2,3, Bruno Hochhegger4,5 1.",Non-OADS,/arxiv_data1/oa_pdf/c3/db/1806-3713-jbpneu-41-04-00388.PMC4635959.pdf
"http://dx.doi.org/10.1590/S1806-37132015000000010Streptococcus pneumoniae -associated pneumonia   complicated by purulent pericarditis: case series* Pneumonia por Streptococcus pneumoniae  complicada   por pericardite purulenta: uma série de casos  Catia Cillóniz1, Ernesto Rangel2, Cornelius Barlascini3,   Ines Maria Grazia Piroddi4, Antoni Torres1, Antonello Nicolini4 Abstract Objective: In the antibiotic era, purulent pericarditis is a rare entity.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"Cillóniz C, Rangel E, Barlascini C, Piroddi IMG, Torres A, Nicolini A http://dx.doi.org/10.1590/S1806-37132015000000010On the sixth day, thoracic ultrasound showed  volume loss of the right hemithorax with minimal  pleural effusion.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"Streptococcus pneumoniae -associated pneumonia   complicated by purulent pericarditis: case series http://dx.doi.org/10.1590/S1806-37132015000000010a four-day history of flu with cough and fever  (39.4°C), having recently complained of dyspnea  and progressive edema of the lower extremities.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"Cillóniz C, Rangel E, Barlascini C, Piroddi IMG, Torres A, Nicolini A http://dx.doi.org/10.1590/S1806-37132015000000010fluid.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"Streptococcus pneumoniae -associated pneumonia   complicated by purulent pericarditis: case series http://dx.doi.org/10.1590/S1806-37132015000000010aggressive, long-term therapy.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"Cillóniz C, Rangel E, Barlascini C, Piroddi IMG, Torres A, Nicolini A http://dx.doi.org/10.1590/S1806-3713201500000001013.",Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2010;42(10):791-3. http://dx.doi.org/10.3109/00365 548.2010.486002 15.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2002;37(10):1404-8. http://dx.doi.org/10.1053/ jpsu.2002.35401 16.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
1993;22(6):1661-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
1996;3(11):1084-90. http://dx.doi.org/10.1016/ S0929-693X(96)89513-3 19.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2006;42(8):1135-40. http://dx.doi.org/10.1086/502680 21.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2014;7:21. http://dx.doi.org/10.1186/s12245-014-0021-8 23.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2009;88(1):52- 65. http://dx.doi.org/10.1097/MD.0b013e318194432b2.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2002;17(4):251-4. http://dx.doi.org/10.1053/ jcrc.2002.36758 5.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
2006;12(4):338- 44. http://dx.doi.org/10.1111/j.1469-0691.2006.01363.x 6.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
http://dx.doi.org/10.1016/j.ijcard.2007.02.042 12.,OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
1975;59(1):68-78. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/32/1806-3713-jbpneu-41-04-00389.PMC4635960.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/2d/iev136.PMC4635999.pdf
"After initiation of carbidopa/levodopa 25/100 two tablets three times a day, therewas improvement in bradykinesia as well as tremor reduction in handwriting.Freely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/83/ac/tre-05-345-7378-1.PMC4636028.pdf
"J Neurol Neurosurg Psychiatry 1979;42:1106–1114, doi: http://dx.doi.org/10.1136/jnnp.",Non-OADS,/arxiv_data1/oa_pdf/83/ac/tre-05-345-7378-1.PMC4636028.pdf
"Int J Neurosci 2012;112:114–118, doi: http://dx.doi.org/10.3109/00207454.2011.635827.",OADS,/arxiv_data1/oa_pdf/83/ac/tre-05-345-7378-1.PMC4636028.pdf
"Neurology 2014;82, Supplement P3.079.Battista JP, Greene PE Improvement of Primary Writing Tremor in Parkinson’s Disease Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2",Non-OADS,/arxiv_data1/oa_pdf/83/ac/tre-05-345-7378-1.PMC4636028.pdf
1InvoluntaryFreely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Botulinum Toxin in Blepharospasm and Hemifacial Spasm Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Botulinum Toxin in Blepharospasm and Hemifacial Spasm Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Botulinum Toxin in Blepharospasm and Hemifacial Spasm Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services6,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services7,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Botulinum Toxin in Blepharospasm and Hemifacial Spasm Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services8,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services9,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Mov Disord 2013;28:926–943, doi: http://dx.doi.org/10.1002/mds.25567.",OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Neurology 1995; 45:897–902, doi: http://dx.doi.org/10.1212/WNL.45.5.897.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm.Arch Ophthalmol 2006;124:116–119, doi: http://dx.doi.org/10.1001/archopht.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"J Neurosurg 2008;109:416–420, doi: http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Qual Life Res 2011;20:1519– 1523, doi: http://dx.doi.org/10.1007/s11136-011-9890-y.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Eur J Neurol 2011;18:5–18, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Toxicon 2013;67:94–114, doi: http://dx.doi.org/10.1016/j.toxicon.2012.12.004.",OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Surv Ophthalmol 2011;56:54–67, doi: http://dx.doi.org/10.1016/j.survophthal.2010.",OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Eur Neurol 2000;43:9–12, doi: http://dx.doi.org/10.1159/000008121.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Neurotox Res 2009;15:224–231, doi: http://dx.doi.org/10.1007/ s12640-009-9023-3.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Botulinum Toxin in Blepharospasm and Hemifacial Spasm Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services10,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Am J Phys Med Rehabil 2015;94:229–238, doi: http://dx.doi.org/10.1097/PHM.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Parkinsonism Relat Disord 2008;14:407–414, doi: http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"J Neural Transm 2010;117:759–763, doi: http://dx.doi.org/10.1007/ s00702-010-0409-4.",OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Dermatol Surg 2009;35:1–8, doi: http://dx.doi.org/10.1111/j.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"Curr Med Res Opin 2009;25:1573–1584, doi: http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services11,Non-OADS,/arxiv_data1/oa_pdf/bf/4f/tre-05-338-7370-1.PMC4636029.pdf
"The patient is treated with primidone 250 mg/day, which has resulted in a substantial (i.e., 50%) reduction in her jaw tremor.Freely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/36/59/tre-05-354-7421-1.PMC4636030.pdf
"Eur J Neurol 2013;20:949–954, doi:http://dx.doi.org/10.1111/ene.12123.",Non-OADS,/arxiv_data1/oa_pdf/36/59/tre-05-354-7421-1.PMC4636030.pdf
"Mov Disord 2006;21:1872–1878, doi:http://dx.doi.org/10.1002/mds.",Non-OADS,/arxiv_data1/oa_pdf/36/59/tre-05-354-7421-1.PMC4636030.pdf
"21069.Hernandez NC, Louis ED Broken Teeth in Essential Tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2",Non-OADS,/arxiv_data1/oa_pdf/36/59/tre-05-354-7421-1.PMC4636030.pdf
"In PD patients, tremor is predominantly present at rest compared to posture or task-specificmovement.1–3Tremor causes difficulty in performing daily activities and significantly affects quality of life.4Levodopa remains the most potent drug for managing PD symptoms yet it results in significant complications such as “wearing off” motor fluctuations and dyskinesia,Freely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services6,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services7,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services8,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services9,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services10,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services11,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Effective management of upper limb Parkinsonian tremor Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services12,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"J Neurol Neurosurg Psychiatry 2008;79:368–376, doi:http://dx.doi.org/10.1136/jnnp.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Parkinsonism Relat Disord 2001;8:67–73, doi:http://dx.doi.org/10.1016/S1353-8020(00)00077-8.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"J Neural Transm 2006;113:845–853, doi:http://dx.doi.org/10.1007/s00702-005-0354-9.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Exp Aging Res 2007;33: 59–76, doi:http://dx.doi.org/10.1080/03610730601006370.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Neurology 2002;58:11–17, doi:http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Parkinsonism Relat Disord 2009;15:S3–S8, doi:http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Expert Rev Neurother 2015;15:1–7, doi:http://dx.doi.org/10.1586/14737175.2015.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Cochrane Database Syst Rev 2003;2:CD003735, doi:http://dx.doi.org/10.1586/14737175.2015.1001747.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Expert Opin Pharmacother 2005;6:419–428, doi:http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Lancet Neurol 2006;5:525–535, doi:http://dx.doi.org/10.1016/S1474-4422(06) 70471-9.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"11.Rahimi F, Debicki D, Roberts-South AC, Bee C, Bapat P, Jog S. Dynamic decomposition of motion in essential and parkinsonian tremor.Can J Neurol Sci 2015;42:116–124, doi:http://dx.doi.org/10.1017/cjn.2015.12.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Mov Disord 2013;29: 835–838, doi:http://dx.doi.org/10.1002/mds.25739.13.Pacchetti C, Mancini F, Bulgheroni M, et al.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Parkinsonism Relat Disord 2011;17:S34–S39, doi:http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Clin Biomech 2011;26:811–818, doi:http://dx.doi.org/ 10.1016/j.clinbiomech.2011.04.007.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"J Child Neurol 2011;26:822–829, doi:http://dx.doi.org/10.1177/ 0883073810392997.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"JAMA 2014;311:1670–1683, doi:http://dx.doi.org/10.1001/jama.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Conf Proc IEEE Eng Med Biol Soc 2011;2011: 470–473, doi:http://dx.doi.org/10.1109/IEMBS.2011.6090067.",OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
"Neurology 2012;79:92–99, doi:http://dx.doi.org/10.1212/WNL.0b013e31825dcdd9.Effective management of upper limb Parkinsonian tremor Rahimi F, Samotus O, Lee J, et al.",Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services13,Non-OADS,/arxiv_data1/oa_pdf/69/bc/tre-05-348-7425-1.PMC4636031.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/tcrm-11-1657.PMC4636086.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2015:11 1657–1661Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1657Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S6491 5New developments in the management of  schizophrenia and bipolar disorder: potential  use of cariprazine Felix-Martin werner1,2 Rafael Coveñas2 1euro Akademie Pößneck, Higher  vocational School for elderly Care  and Occupational Therapy, Pößneck,   Germany; 2institute of Neurosciences  of Castilla y León (iNCYL),   Laboratory of Neuroanatomy  of the Peptidergic Systems  (Lab.",Non-OADS,/arxiv_data1/oa_pdf/ad/fe/tcrm-11-1657.PMC4636086.pdf
"14), University of  Salamanca, c/Pintor Fernando Gallego, 1,  37007 Salamanca, Spain Tel +34 923 29 44 00 Fax +34 923 29 45 49 email felixm-werner@versanet.d e Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2015 Volume: 11 Running head verso: Werner and Coveñas Running head recto: New developments in management of schizophrenia and bipolar disorder DOI: http://dx.doi.org/10.2147/TCRM.S64915",Non-OADS,/arxiv_data1/oa_pdf/ad/fe/tcrm-11-1657.PMC4636086.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/ad/fe/tcrm-11-1657.PMC4636086.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/tcrm-11-1657.PMC4636086.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 5863–5872Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5863Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S9299 8Efficacy and tolerability of oral oxycodone and  oxycodone/naloxone combination in opioid-naïve  cancer patients: a propensity analysis Marzia lazzari1 Maria T eresa greco2,3 claudio Marcassa4 simona Finocchi1 clarissa caldarulo1 Oscar corli2 1emergency care, critical care  Medicine, Pain Medicine and  anesthesiology Department, Tor  Vergata Polyclinic, University of rome,   rome, 2Oncology Department, Pain  and Palliative care research Unit,   Mario n egri irccs, 3Department  of clinical sciences and community,   University of Milan, Milan, 4cardiology,   Fondazione Maugeri irccs Veruno,   novara, italyBackground:  World Health Organization step III opioids are required to relieve  moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side  effects.",Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
"Keywords:  cancer pain, analgesia, oxycodone, naloxone, propensity analysis Background World Health Organization (WHO) guidelines for pharmacological management of  cancer pain consider that opioid analgesics are an established therapy for moderate-to- severe cancer pain.1 The European Association of Palliative Care (EAPC) recommends  the use of morphine, oxycodone (OXY), and hydromorphone as first-line options for  therapy with a strong opioid.2,3 In a recent study assessing the effectiveness of four  strong opioids (morphine, buprenorphine, OXY, and fentanyl) in cancer patients,  the efficacy and tolerability profiles of these drugs were found to be broadly similar,  although some variability in response among different opioids was seen.4 In particular,  a series of systematic reviews on the use of opioids in cancer pain reported that OXY, correspondence: Marzia lazzari Tor Vergata Polyclinic, University of  rome “Tor Vergata”, Viale Oxford 81,  00133 rome, italy Tel +39 06 2090 0638 Fax +39 06 2090 4846 email marzialaz@hotmail.i t Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Lazzari et al Running head recto: Oxycodone and oxycodone/naloxone in cancer patients DOI: http://dx.doi.org/10.2147/DDDT.S92998",Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
Available from: http://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/db/18/dddt-9-5863.PMC4636087.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b4/cf/ott-8-3203.PMC4636088.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 3203–3209OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3203Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9162 6correlation of c-X-c chemokine receptor 2   upregulation with poor prognosis and  recurrence in human glioma liu Yang1 Zenghui liu1 ronghua Wu2 Qi Yao1 Zhikai gu1 Mei liu2 1Department of neurosurgery,   affiliated hospital of nantong  University, 2Jiangsu Key laboratory  of neuroregeneration, co-innovation  center of neuroregeneration,   nantong University, nantong, Jiangsu,   People’s republic of chinaAbstract:  C-X-C chemokine receptor 2 (CXCR2), a member of the G-protein-coupled receptor  family, is an interleukin-8 receptor and results in the activation of neutrophils.",Non-OADS,/arxiv_data1/oa_pdf/b4/cf/ott-8-3203.PMC4636088.pdf
"C-X-C chemokine receptor 2 (CXCR2), an interleukin-8 (IL8) receptor, possesses  tumorigenic and proangiogenic properties that are similar to CXCR1,7 and it medi - ates neutrophil migration to sites of inflammation.8 In a previous study, glioblastoma  cells secreted IL8 and were reported to induce permeability mediated through its correspondence: Mei liu Jiangsu Key laboratory of  neuroregeneration, co-innovation  center of neuroregeneration,  nantong University, no 19 Qixiu  road, nantong, Jiangsu 226001,  People’s republic of china Tel +86 513 8505 1852 Fax +86 513 8551 1585 email liumei@ntu.edu.c n Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Y ang et al Running head recto: CXCR2 upregulation in human glioma DOI: http://dx.doi.org/10.2147/OTT.S91626",Non-OADS,/arxiv_data1/oa_pdf/b4/cf/ott-8-3203.PMC4636088.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b4/cf/ott-8-3203.PMC4636088.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b4/cf/ott-8-3203.PMC4636088.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 2039–2047Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2039Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S9524 2T ear film osmolarity and dry eye disease: a review  of the literature Richard Potvin1 Sarah Makari1 Christopher J Rapuano2 1Science in vision, Akron, NY, USA;   2wills eye Hospital, Philadelphia, PA,   USAObjective:  To evaluate the evidence in the peer-reviewed literature regarding the use of tear  osmolarity as a physiological marker to diagnose, grade severity, and track therapeutic response  in dry eye disease (DED).",Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
"It is Correspondence: Richard Potvin Science in vision, 6197 Dye Road,  Akron, NY, USA 14001 Tel +1 407 697 6008 Fax +1 716 442 5110 email rick@scienceinvision.co m Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Potvin et al Running head recto: Tear film osmolarity literature review DOI: http://dx.doi.org/10.2147/OPTH.S95242 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
Or use: http://youtu.be/qgiLxbEIrG Evideo abstract,Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
Available from: http://www.essentialevidenceplus.com/product/ebm_loe.,Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
"Available from: http://www.essentialevidenceplus.com/ product/ebm_loe.cfm?show =guideline s. Accessed September 16, 2015.",Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/84/8b/opth-9-2039.PMC4636089.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/49/09/copd-10-2357.PMC4636090.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2015:10 2357–2363International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2357OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S9174 2Prevalence of chronic obstructive pulmonary  disease in asymptomatic smokers raúl h sansores Mónica Velázquez-Uncal Oliver Pérez-Bautista Jaime Villalba-Caloca ramcés Falfán-Valencia alejandra ramírez-Venegas Tobacco smoking and COPD research  Department, national Institute of  respiratory Diseases, Ismael Cosio  Villegas, Mexico City, MexicoBackground:  Physicians do not routinely recommend smokers to undergo spirometry unless  they are symptomatic.",Non-OADS,/arxiv_data1/oa_pdf/49/09/copd-10-2357.PMC4636090.pdf
"Correspondence: alejandra ramírez- Venegas Departamento de Investigación en  Tabaquismo y ePOC, Instituto nacional  de enfermedades respiratorias,  Ismael Cosio Villegas, Tlalpan #4502,  14080 Mexico City, Mexico email aleravas@hotmail.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Sansores et al Running head recto: COPD in asymptomatic smokers DOI: http://dx.doi.org/10.2147/COPD.S91742",Non-OADS,/arxiv_data1/oa_pdf/49/09/copd-10-2357.PMC4636090.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/49/09/copd-10-2357.PMC4636090.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/49/09/copd-10-2357.PMC4636090.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pStem Cells and Cloning: Advances and Applications 2015:8 149–162Stem Cells and Cloning: Advances and Applications Dove press submit your manuscript | www.dovepress.co m Dove press  149Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/SCCAA.S6437 3From bench to bedside: use of human   adipose-derived stem cells vaughan Feisst1 Sarah Meidinger1 Michelle B Locke2 1Dunbar Laboratory, School of  Biological Sciences, 2Department  of Surgery, Faculty of Medicine and  Health Sciences, The University of  Auckland, Auckland, New Zealand Correspondence: Michelle B Locke   Department of Surgery, Faculty of  Medicine and Health Sciences, The  University of Auckland, South Auckland  Clinical Campus, 2nd Floor, esme Green  Building, c/- Middlemore Hospital, Private  Bag 93311, Otahuhu, Auckland 1640,   New Zealand   Tel +64 2196 3533   email m ichelle.",Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
"Available  from: http://ir.cytori.com/investor-relations/News/news-details/2013/ Cytoris-Celution-System-Approved-in-Australia-for-Processing- and-Delivering -Adipose-Derived-Regenerative-Cells/default.asp x.  Accessed April 24, 2015.",Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
Available from: http://www.who.int/ mediacentre/factsheets/fs384/en /.,Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
"Stem Cells and Cloning: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journa lStem Cells and Cloning: Advances and Applications is an international,  peer-reviewed, open access journal.",Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f3/fb/sccaa-8-149.PMC4636091.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c6/ff/ott-8-3185.PMC4636092.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 3185–3192OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3185Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8245 3combination of cetuximab and PP242 synergistically  suppress the progression of wild-type K ras  colorectal carcinoma lei cheng1,* Zuguang Xia2,3,* Xinyu Bian1 guangchao li4 Jing hu1 Ya cao5 Qing Wang1 Xiaoping Qian1 1comprehensive cancer center  of Drum -Tower hospital, Medical  school of n anjing University,   clinical cancer institute of nanjing  University, nanjing, 2Department of  Medical Oncology, Fudan University  shanghai cancer center, shanghai,   3Department of Oncology, shanghai  Medical college, Fudan University,   shanghai, 4school of Bioscience  and Bioengineering, south china  University of T echnology, guangzhou,   guangdong, 5Department of Biological  science and Technology and state  Key laboratory of Pharmaceutical  Biotechnology, school of life sciences,   nanjing University, nanjing, People’s  republic of china *These authors contributed equally  to this workAbstract:  Mammalian target of rapamycin (mTOR) has been shown to be overactive in  human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to  show clinical efficacy against colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/c6/ff/ott-8-3185.PMC4636092.pdf
"Recently, changes in these pathways were also linked to  anti-EGFR MoAb resistance.10 It was reported that mutations in KRAS, BRAF, and  PIK3CA were associated with anti-EGFR MoAb resistance, and testing for these muta - tions was a potentially cost-effective way to improve survival in mCRC patients.11,12 correspondence: Xiaoping Qian comprehensive cancer center  of Drum-Tower hospital, Medical  school of nanjing University, clinical  cancer institute of nanjing University,  321 Zhongshan road, nanjing 210008,  People’s republic of china email qianxiaoping211@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Cheng et al Running head recto: Wild-type KRAS colorectal carcinoma DOI: http://dx.doi.org/10.2147/OTT.S82453",Non-OADS,/arxiv_data1/oa_pdf/c6/ff/ott-8-3185.PMC4636092.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c6/ff/ott-8-3185.PMC4636092.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c6/ff/ott-8-3185.PMC4636092.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pThe Application of Clinical Genetics 2015:8 257–267The Application of Clinical Genetics Dove press submit your manuscript | www.dovepress.co m Dove press  257OriG inAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TACG.S9021 5ROCK2  and MYLK  variants under hypobaric  hypoxic environment of high altitude associate  with high altitude pulmonary edema and  adaptation Priyanka Pandey1,2 Ghulam Mohammad1,3 Y ogendra singh1,2 MA Qadar Pasha1,2 1Functional Genomics Unit, Csir- institute of Genomics and integrative  Biology, Delhi, 2Department of  Biotechnology, University of Pune,   Ganeshkhind, Pune, Maharashtra,   3Department of Medicine, snM  hospital, leh, ladakh, Jammu and  Kashmir, india Correspondence: MA Qadar Pasha   Csir-institute of Genomics and  integrative Biology, Mall road,   Delhi 110 007, india   email qpasha@igib.res.i nObjective:  To date, a major class of kinases, serine–threonine kinase, has been scantly inves - tigated in stress-induced rare, fatal (if not treated early), and morbid disorder, high altitude  pulmonary edema (HAPE).",Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
"Acknowledgments The authors thank the director of CSIR-Institute of Genom - ics and Integrative Biology, Delhi, for providing necessary  facilities and constant encouragement; the Council of Sci - entific and Industrial Research (CSIR; http://www.csir.res.",Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
The Application of Clinical Genetics 2015:8submit your manuscript | www.dovepress.co m Dove press Dove press 266Pandey et al the University Grants Commission (UGC; http://www.ugc.,Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
"Available from: http://diyhpl.us/~bryan/irc/protocol-online/protocol- cache/TFSEARCH.htm l. Accessed January 1, 2014.",OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
"The Application of Clinical Genetics Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/the-application-of-clinical-genetics-journa lThe Application of Clinical Genetics is an international, peer-reviewed  open access journal that welcomes laboratory and clinical findings in  the field of human genetics.",Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/33/tacg-8-257.PMC4636093.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/60/d1/ott-8-3193.PMC4636094.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 3193–3202OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3193Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9424 6impact of more detailed categorization of  shrinkage or progression ratio at initial imaging  response after sorafenib treatment in advanced  hepatocellular carcinoma patients Y oshiyuki Wada Yuko Takami Masaki Tateishi T omoki ryu Kazuhiro Mikagi hideki saitsu Department of hepato-Biliary- Pancreatic surgery, clinical research  institute, national hospital  Organization Kyushu Medical center,   Fukuoka, JapanBackground:  Sorafenib therapy improves survival in unresectable hepatocellular carcinoma  (HCC) patients without an objective response.",Non-OADS,/arxiv_data1/oa_pdf/60/d1/ott-8-3193.PMC4636094.pdf
"Keywords:  sorafenib, hepatocellular carcinoma, liver, response, imaging, chemotherapy Introduction Hepatocellular carcinoma (HCC) is the third-most common cause of cancer mortal - ity worldwide.1,2 HCC is often diagnosed at an advanced stage, or the patients have  advanced liver cirrhosis at the time of diagnosis and are thus considered unsuitable  for potentially curative approaches, such as resection, liver transplantation, or other  locoregional therapies.3 Sorafenib is a molecularly targeted multikinase inhibitor that  suppresses both signal transduction of tumor growth and angiogenesis by inhibit - ing Raf kinase and VEGF- and PDGF-receptor kinase.4 Two large-scale Phase III  clinical studies – the SHARP5 and Asia-Pacific studies6 – demonstrated that sorafenib  significantly prolonged time to progression and improved overall survival in patients correspondence: Yoshiyuki Wada Department of hepato-Biliary-Pancreatic  surgery, clinical research institute,  national hospital Organization Kyushu  Medical center, 1-8-1 Jigyohama,  chuo-ku, Fukuoka 810-8563, Japan Tel +81 92 852 0700 Fax +81 92 857 8802 email yoshiwada@kyumed.j p Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Wada et al Running head recto: Initial imaging response after sorafenib treatment in HCC DOI: http://dx.doi.org/10.2147/OTT.S94246",Non-OADS,/arxiv_data1/oa_pdf/60/d1/ott-8-3193.PMC4636094.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/60/d1/ott-8-3193.PMC4636094.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/60/d1/ott-8-3193.PMC4636094.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/eb/c1/ce-10-099.PMC4636095.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCore Evidence 2015:10 99–109Core Evidence Dove press submit your manuscript | www.dovepress.co m Dove press  99REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CE.S5845 7Clinical utility of tadalafil in the treatment of  pulmonary arterial hypertension: an evidence- based review Adam M Henrie James J Nawarskas Joe R Anderson College of Pharmacy, University of  New Mexico, Albuquerque, NM, USA Correspondence: Joe R Anderson   College of Pharmacy, University of New  Mexico, MSC09  5360, Albuquerque,  NM 87131-0001, USA   Tel +1 505 272 3664  Email ja nderson@salud.unm.ed uAbstract:  Pulmonary arterial hypertension (PAH) is a chronic and disabling condition  characterized by an elevated pulmonary vascular resistance and an elevated mean pulmo - nary arterial pressure.",Non-OADS,/arxiv_data1/oa_pdf/eb/c1/ce-10-099.PMC4636095.pdf
"Core Evidence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/core-evidence-journa lCore Evidence is an international, peer-reviewed open-access journal  evaluating the evidence underlying the potential place in therapy of  drugs throughout their development lifecycle from preclinical to post - launch.",Non-OADS,/arxiv_data1/oa_pdf/eb/c1/ce-10-099.PMC4636095.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/eb/c1/ce-10-099.PMC4636095.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/39/fc/dddt-9-5873.PMC4636096.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 5873–5875Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5873LeTTeropen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S9337 1Evaluation of the efficacy and safety of three dosing  regimens of agalsidase alfa enzyme replacement  therapy was underpowered Alberto Ortiz1,2 Maria Dolores Sanchez- Niño1,2 1Department of Nephrology, IIS- Fundacion Jimenez Diaz, School of  Medicine, Universidad Autónoma de  Madrid, 2Department of Nephrology,   Instituto reina Sofia de Investigación  Nefrológica, Madrid, SpainDear editor We read with interest the report by Golá ň et al on the “Evaluation of the efficacy and  safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in  adults with Fabry disease”.1 Based on the reported results, the authors conclude that no  efficacy or safety differences were found when the approved every-other-week (EOW)  dosage of agalsidase alfa was increased to weekly administration.",Non-OADS,/arxiv_data1/oa_pdf/39/fc/dddt-9-5873.PMC4636096.pdf
"We  suggest that the conclusion be modified to state that no efficacy or safety differences  were found when the approved EOW dosage of agalsidase alfa was increased to weekly  administration, but the study was underpowered to detect such differences.Correspondence: Alberto Ortiz Unidad de Dialisis, IIS-Fundacion  Jimenez Diaz, Av reyes católicos 2,  28040 Madrid, Spain email aortiz@fjd.e s Journal name: Drug Design, Development and Therapy Article Designation: Letter Y ear: 2015 Volume: 9 Running head verso: Ortiz and Sanchez-Niño Running head recto: Underpowered evaluation of agalsidase alfa enzyme replacement therapy DOI: http://dx.doi.org/10.2147/DDDT.S9337 1",Non-OADS,/arxiv_data1/oa_pdf/39/fc/dddt-9-5873.PMC4636096.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/39/fc/dddt-9-5873.PMC4636096.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/39/fc/dddt-9-5873.PMC4636096.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0a/95/dddt-9-5771.PMC4636097.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 5771–5783Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5771Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S9227 6reductive metabolism of oxymatrine is catalyzed  by microsomal cYP3a4 Wenqin liu1,2,* Jian shi1,2,* lijun Zhu2 lingna Dong1 Feifei luo2 Min Zhao2 Ying Wang2 Ming hu2,3 linlin lu2 Zhongqiu liu1,2 1Department of Pharmaceutics, school  of Pharmaceutical sciences, southern  Medical University, guangzhou,   guangdong, People’s republic of  china; 2international institute for  Translational chinese Medicine,   guangzhou University of chinese  Medicine, guangzhou, guangdong,   People’s republic of china;   3Department of Pharmacological and  Pharmaceutical sciences, college of  Pharmacy, University of houston,   houston, TX, Usa *These authors contributed equally  to this workAbstract:  Oxymatrine (OMT) is a pharmacologically active primary quinolizidine alkaloid with  various beneficial and toxic effects.",Non-OADS,/arxiv_data1/oa_pdf/0a/95/dddt-9-5771.PMC4636097.pdf
"Our group has demonstrated that the oral absolute bioavailability of OMT was correspondence: Zhongqiu liu; linlin lu international institute for Translational  chinese Medicine, guangzhou University  of chinese Medicine, guangzhou,  guangdong 510006, People’s republic  of china Tel +86 20 3935 8061; +86 20 3935 7902 Fax +86 20 3935 8071; +86 20 3935 8071 email liuzq@gzucm.edu.c n;   lllu@gzucm.edu.c nJournal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Liu et al Running head recto: Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4 DOI: http://dx.doi.org/10.2147/DDDT.S92276",Non-OADS,/arxiv_data1/oa_pdf/0a/95/dddt-9-5771.PMC4636097.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/0a/95/dddt-9-5771.PMC4636097.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0a/95/dddt-9-5771.PMC4636097.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d0/b2/opth-9-2033.PMC4636098.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 2033–2037Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2033Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S9148 6reassessment of pneumatic retinopexy for  primary treatment of rhegmatogenous retinal  detachment eyal Cohen1,* amir Zerach1,* Michael Mimouni2 adiel Barak1 1Department of Ophthalmology,   T el aviv sourasky Medical Center,   sackler Faculty of Medicine, Tel aviv  University, T el aviv, 2Department of  Ophthalmology, rambam health Care  Campus, haifa, israel *These authors contributed equally   to this workBackground:  Pneumatic retinopexy (PR) remains a popular technique for the treatment of  rhegmatogenous retinal detachment (RRD).",Non-OADS,/arxiv_data1/oa_pdf/d0/b2/opth-9-2033.PMC4636098.pdf
"The incidence of rhegmatogenous retinal detachment (RRD)  has significant geographic variations ranging between 6.3 and 17.9 per 100,000 people  per year.1 In current clinical practice, scleral buckling, pars plana vitrectomy (PPV), and  pneumatic retinopexy (PR) are used to treat RRD2 with reported primary success rates of  95%, 71%–92%, and 64%, respectively.3 PR is both safe4 and cost-effective.5 It is used  in 14%–17% of cases of RRD making it the second most popular primary modality after  PPV.6 The classic indications for PR are retinal breaks confined to the superior clock-hours,  retinal break or breaks within 1–2 clock-hours, absence of proliferative retinopathy grade  C or D, a cooperative patient who can be positioned, and clear media.7 In addition, in  cases with other relative indications, PR was shown to have satisfactory results.7 In spite Correspondence: Michael Mimouni Department of Ophthalmology, rambam  health Care Campus, POB 9602,  haifa 31096, israel Tel +972 52 329 2429 Fax +972 4 854 2142 email michael@intername.co.i l Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Cohen et al Running head recto: Reassessment of pneumatic retinopexy DOI: http://dx.doi.org/10.2147/OPTH.S91486",Non-OADS,/arxiv_data1/oa_pdf/d0/b2/opth-9-2033.PMC4636098.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d0/b2/opth-9-2033.PMC4636098.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d0/b2/opth-9-2033.PMC4636098.pdf
2015;5(3):1-6.   http://dx.doi.org/10.4322/acr.2015.011 a Internal Medicine Division - Hospital Universitário - University of São Paulo - São Paulo/SP – Brazil.,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
Autopsy and Case Reports  2015;5(3):1-6The pedagogical value of autopsy 62007 ;17(Suppl 2 ):97-103. http://dx.doi.org/10.1017/ S1047951107001205 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2007 ;369(9571 ):1471 -80. http://dx.doi.org/10.1016/ S0140-6736(07)60376-6 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2014 ;4(2):1-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
1983 ;308(17):1000 -5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2007 ;93(11):1414 -9. http://dx.doi.org/10.1136/ hrt.2006.103093 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2003 ;289(21):2849 - 56. http://dx.doi.org/10.1001/jama.289.21.2849 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2005 ;14(6):408-13. http://dx.doi.org/10.1136/ qshc.2004.011973 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2003 ;24(6):330-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2013 ;462(4):371- 80. http://dx.doi.org/10.1007/s00428-013-1387-3 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
2000 ;23(10):792-4. http://dx.doi.org/10.1002/ clc.4960231021 .,Non-OADS,/arxiv_data1/oa_pdf/38/9f/autopsy-05-03001.PMC4636099.pdf
"2015;5(3):7-9.   http://dx.doi.org/10.4322/acr.2015.012 a Pathology Laboratory - Instituto do Coração - Hospital das Clínicas - University of São Paulo, São Paulo/SP – Brazil.",Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
2012 ;54(6):845-52.  http://dx.doi.org/10.1093/cid/cir956 .,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
2009 ;48(11):1534 -40. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
1975 ;9(6):269-82. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
1995 ;113(2):802-13. http://dx.doi.org/10.1590/S1516- 31801995000200011 .,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
1983 ;52(1):147- 51. http://dx.doi.org/10.1016/0002-9149(83)90085-1 .,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
2007 ;88(4):496-8. http://dx.doi.org/10.1590/ S0066-782X2007000400022 .,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
2003 ;60(1):96-107. http://dx.doi.org/10.1016/S0008- 6363(03)00361-4 .,Non-OADS,/arxiv_data1/oa_pdf/08/0c/autopsy-05-03007.PMC4636100.pdf
"2015;5(3):11-20. http://dx.doi.org/10.4322/acr.2015.015 ABSTRACT Lemierre’s syndrome (LS), described in detail in 1936, used to be a life-threatening entity until the advent of antibiotics.",Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2011 ;23(8):633-41. http://dx.doi.org/10.1097/ MEG.0b013e3283484795 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2015 ;39(4):497-504. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2005 ;14(2):467- 75. http://dx.doi.org/10.1158/1055-9965.EPI-04-0551 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
1997 ;350(9082 ):928. http://dx.doi.org/10.1016/S0140- 6736(97)05261-6 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
1936 ;227(5874 ):701-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2012 ;12(10):808-15. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2005 ;41(8):1208 - 9. http://dx.doi.org/10.1086/444565 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
1989 ;68(2):85-94. http://dx.doi.org/10.1097/00005792- 198903000-00002 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2002 ;81(6):458-65.  http://dx.doi.org/10.1097/00005792-200211000-00006 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2011 ;1(3):53-8. http://dx.doi.org/10.4322/ acr.2011.009 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2004 ;350(10):1037 - 42. http://dx.doi.org/10.1056/NEJMcps032253 .,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2015 ;28(3):425-30.   http://dx.doi.org/10.3122/jabfm.2015.03.140131 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2000 ;2(2):168-73.  http://dx.doi.org/10.1007/s11908-000-0030-z .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2013 ;64(1):75-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2007 ;132(5):1706 -9. http://dx.doi.org/10.1378/ chest.07-0631 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2010 ;28(10):701-5. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2014 ;371(21):2018 -27.   http://dx.doi.org/10.1056/NEJMcpc1310001 .,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2015 ;33(5):733.e3 -4. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2010 ;19(116):141-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2006 ;35(11):1021 -5.   http://dx.doi.org/10.1016/j.ijom.2006.06.021 .,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2011 ;3(1):237-41. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
2008 ;66(8):1720 -5.   http://dx.doi.org/10.1016/j.joms.2007.12.002 .,OADS,/arxiv_data1/oa_pdf/af/1d/autopsy-05-03011.PMC4636101.pdf
"2015;5(3):21-26. http://dx.doi.org/10.4322/acr.2015.019 ABSTRACT Congenital cystic adenomatoid malformation (CCAM) is an hamartomatous congenital pulmonary airway malformation  with incidence ranging between 1:10,000 and 1:35,000 newborns.",Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
http://dx.doi.org/10.1136/ adc.2007.130542 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2004 ;78(1):337-9. http://dx.doi.org/10.1016/ S0003-4975(03)01289-X .,OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
1999 ;2(5):454-63. http://dx.doi.org/10.1007/ s100249900149 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
1998 ;194(3):209-11. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
1977 ;8(2):155- 71. http://dx.doi.org/10.1016/S0046-8177(77)80078-6 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
1986 ;17(12):1290 -3. http://dx.doi.org/10.1016/S0046- 8177(86)80576-7 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2003 ;27(8):1139 -46.  http://dx.doi.org/10.1097/00000478-200308000-00012 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
http://dx.doi.org/10.1111/his.12515.,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
J Pediatr Surg 2015;50:1004-8. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2008 ;24(9):987-91. http://dx.doi.org/10.1007/s00383- 008-2201-1 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2004 ;35(5):565-70. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
1996 ;31(6):805-8. http://dx.doi.org/10.1016/S0022- 3468(96)90138-4 .,Non-OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2004 ;39(4):603-6. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8e/b9/autopsy-05-03021.PMC4636102.pdf
2015;5(3):27-32. http://dx.doi.org/10.4322/acr.2015.014 ABSTRACT Chagas disease (CD) — a tropical parasitic disease caused by the protozoan Trypanosoma cruzi  — is a major health problem  in Latin America.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2010 ;115(1-2):5-13. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;84(4):575-80. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
1991 ;58(1):102-14. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2001 ;31(5-6):555-61. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2009 ;361(1):11-21. http://dx.doi.org/10.1056/ NEJMoa0810457 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;11(10):2144 -52. http://dx.doi.org/10.1111/j.1600- 6143.2011.03643.x .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;364(7):689-90. http://dx.doi.org/10.1056/ NEJMc1011678 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
1996 ;271(1):250-7.  http://dx.doi.org/10.1074/jbc.271.1.250 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2010 ;56(1):157-67. http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2009 ;361(1):11-21. http://dx.doi.org/10.1056/ NEJMoa0810457 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;22(6):1137 -43. http://dx.doi.org/10.1681/ ASN.2010090967 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;26(8):2526 -32. http://dx.doi.org/10.1093/ndt/ gfr247 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2011 ;6(6):1286 -91. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2012 ;82(7):797-804. http://dx.doi.org/10.1038/ ki.2012.209 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
http://dx.doi.org/10.1371/ journal.pone.0062151 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2014 ;2014 (143274 ):1-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
1979 ;66(1):82- 90. http://dx.doi.org/10.1016/0002-9343(79)90486-8 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2012 ;27(1):231-4. http://dx.doi.org/10.1093/ ndt/gfr285 .,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
2013 ;28(7):1839 -44. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/aa/e5/autopsy-05-03027.PMC4636103.pdf
"2015;5(3):33-36. http://dx.doi.org/10.4322/acr.2015.016 ABSTRACT Dengue is endemic in more than 100 countries in Southeast Asia, the Americas, the western Pacific, Africa and the eastern  Mediterranean regions.",Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2009 ;108(8):595-8. http://dx.doi.org/10.1016/S0929- 6646(09)60379-X .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2005 ;21(1):34-9.  http://dx.doi.org/10.1016/S1607-551X(09)70274-8 .,OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2002 ;22(2):160-6. http://dx.doi.org/10.7705/ biomedica.v22i2.1155 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2012 ;42(1):30-2.  http://dx.doi.org/10.1016/j.medmal.2011.09.008 .,OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2012 ;55(1):79-82. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2014 ;69(3):210- 3. http://dx.doi.org/10.1179/2295333714Y.0000000019 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2008 ;13(5):286-8. http://dx.doi.org/10.1179/102453308X316095 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2014 ;53(8):899-902. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2012 ;44(9):708- 9. http://dx.doi.org/10.3109/00365548.2011.652667 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2007 ;7(12):814-22. http://dx.doi.org/10.1016/S1473- 3099(07)70290-6 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2015 ;69:91-5. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2012 ;366(15):1423 -32. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
2002 ;100(7):2367 -73. http://dx.doi.org/10.1182/ blood-2002-01-0172 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
1966 ;252(1):68-74.  http://dx.doi.org/10.1097/00000441-196607000-00010 .,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/autopsy-05-03033.PMC4636104.pdf
"2015;5(3):37-41. http://dx.doi.org/10.4322/acr.2015.020 ABSTRACT Acute Hemorrhagic Edema of Infancy (AHEI) is a rare leukocytoclastic vasculitis, clinically characterized by the classical  triad: palpable purpuric skin lesions, edema and fever, and is commonly misdiagnosed as Henoch-Schönlein purpura.",Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2013 ;30(6):e149 -52. http://dx.doi.org/10.1111/ pde.12004 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2013 ;4(2):106-8. http://dx.doi.org/10.4103/2229- 5178.110630 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2007 ;47(1):69-71. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
1990 ;86(4 Pt 1 ):473-83.  http://dx.doi.org/10.1016/S0091-6749(05)80202-7 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2009 ;48(3):323-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2008 ;59(4):684-95. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2009 ;21(4):411-8.  http://dx.doi.org/10.1097/BOR.0b013e32832c49f2 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
1913 ;61(1):18-9. http://dx.doi.org/10.1001/ jama.1913.04350010020008 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2005 ;18(2):160-75.  http://dx.doi.org/10.1111/j.1529-8019.2005.05014.x .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
1995 ;12(3):224-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2013 ;6:197-9. http://dx.doi.org/10.2147/CCID.S51525 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2011 ;86(6):1181 -4.  http://dx.doi.org/10.1590/S0365-05962011000600019 .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
2004 ;43(1):48-51.  http://dx.doi.org/10.1111/j.1365-4632.2004.01820.x .,Non-OADS,/arxiv_data1/oa_pdf/4b/d1/autopsy-05-03037.PMC4636105.pdf
"2015;5(3):43-47. http://dx.doi.org/10.4322/acr.2015.021 ABSTRACT Syphilis still remains a major health concern worldwide because of the possibility of serious medical and psychological  consequences, long-term disability, and death.",Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2013 ;73(2):131-58. http://dx.doi.org/10.1007/ s40265-013-0007-5 .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
Available from: http://www.who.int/iris/ bitstream/10665/75181/1/9789241503839_eng.pdf 5.,OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2013 ;185(6):499-503. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2015 ;17(5):481. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2010 ;16(5):e157 -68.  http://dx.doi.org/10.1111/j.1755-5949.2010.00183.x .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2013 ;54(3):284- 5. http://dx.doi.org/10.1016/j.psym.2012.07.002 .,OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
Available from: http://emedicine.medscape.com/ article/1169231 10.,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2012 ;33(1):99-102. http://dx.doi.org/10.1007/ s10072-011-0563-y .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2014 ;26(3):233-40. http://dx.doi.org/10.1176/appi.,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2013 ;40(12):917-22.  http://dx.doi.org/10.1097/OLQ.0000000000000049 .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
1982 ;11(1):35-40. http://dx.doi.org/10.1002/ ana.410110107 .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2014 ;36(3):169-72.  http://dx.doi.org/10.1590/2237-6089-2013-0063 .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2004 ;38(7):1001 -6. http://dx.doi.org/10.1086/382532 .,Non-OADS,/arxiv_data1/oa_pdf/90/78/autopsy-05-03043.PMC4636106.pdf
2015;5(3):49-53. http://dx.doi.org/10.4322/acr.2015.018 ABSTRACT Gastrointestinal metastases from breast cancer are rare and generally occur several years after the diagnosis of the primary  lesion.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1997 ;45(2):181- 92. http://dx.doi.org/10.1023/A:1005845100512 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1968 ;13(10):868-73. http://dx.doi.org/10.1007/ BF02237571 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1961 ;14(2):426-31. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2014 ;232(1):23-31. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1992 ;38(2):130-5. http://dx.doi.org/10.1016/S0016- 5107(92)70377-0 .,OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1992 ;38(2):136-41. http://dx.doi.org/10.1016/S0016- 5107(92)70378-2 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2005 ;12(11):886-94. http://dx.doi.org/10.1245/ ASO.2005.03.030 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2000 ;89(11):2214 -21. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2010 ;17(4):303-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1996 ;39(4):556-61. http://dx.doi.org/10.1136/ gut.39.4.556 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
1996 ;77(1):113-20. http://dx.doi.org/10.1002/(SICI)1097- 0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2007 ;31(8):1597 -601. http://dx.doi.org/10.1007/ s00268-007-9099-y .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2007 ;5:1-6. http://dx.doi.org/10.1186/1477-7819-5-75 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2009 ;69(1):174-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2001 ;76(2):205-7. http://dx.doi.org/10.1016/S0025-6196(11)63129-7 .,OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2011 ;93(5):49- 50. http://dx.doi.org/10.1308/147870811X582800 .,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2011 ;43(10):823-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/fd/autopsy-05-03049.PMC4636107.pdf
2015;5(3):55-60. http://dx.doi.org/10.4322/acr.2015.013 ABSTRACT Sickle cell anemia (SCA) is a hemoglobin disorder that occurs more commonly among Afro-descendants.,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2013 ;71(6):1027 - 33. http://dx.doi.org/10.1016/j.joms.2012.12.004 .,OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2005 ;129(4):482-90.  http://dx.doi.org/10.1111/j.1365-2141.2005.05476.x .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1996 ;82(2):225-8. http://dx.doi.org/10.1016/S1079- 2104(96)80261-7 .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1977 ;43(4):538-45. http://dx.doi.org/10.1016/0030- 4220(77)90106-2 .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1999 ;57(2):171-8.  http://dx.doi.org/10.1016/S0278-2391(99)90234-3 .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2004 ;92(1):68-72. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1993 ;51(8):912-6. http://dx.doi.org/10.1016/S0278- 2391(10)80114-4 .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1991 ;72(1):25-8. http://dx.doi.org/10.1016/0030- 4220(91)90184-E .,OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
1997 ;35(3):190-2. http://dx.doi.org/10.1016/S0266- 4356(97)90562-3 .,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2011 ;6(4):227-34. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2014 ;52(7):629-31. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/44/2f/autopsy-05-03055.PMC4636108.pdf
2015;5(2):1-4. http://dx.doi.org/10.4322/acr.2015.010 Due to a desktop publishing error the Editorial was published with the following errors: •	 Missing competing interests disclosure paragraph.,Non-OADS,/arxiv_data1/oa_pdf/8c/f9/autopsy-05-03061.PMC4636109.pdf
No writing assistance was utilized in the production of this manuscript.Erratum: missing competing interests in editorial http://dx.doi.org/10.4322/acr.2015.017,Non-OADS,/arxiv_data1/oa_pdf/8c/f9/autopsy-05-03061.PMC4636109.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
17 http://repository.edm-forum.org/egems/vol3/iss1/17 DOI: 10.13063/2327-9214.1169,Non-OADS,/arxiv_data1/oa_pdf/eb/11/egems1169.PMC4636110.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ad/ea/hmer-7-071.PMC4636165.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pHepatic Medicine: Evidence and Research 2015:7 71–79Hepatic Medicine: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  71ORiginal REsEaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/HMER.S8944 7association of cytokine gene polymorphisms   with hepatitis c virus infection in a population  from Rio de Janeiro, Brazil gustavo Milson Fabrício- silva1 Bruno silva Poschetzky2 Renata de Mello Perez2 Ronaldo carneiro dos  santos2 luciana Tricai cavalini3 luís cristóvão Porto1 1Histocompatibility and  cryopreservation laboratory,   2gastroenterology service, internal  Medicine Department, 3information  Technology and Healthy Education  Department, Rio de Janeiro state  University, Rio de Janeiro, Brazil correspondence: luís cristóvão Porto   laboratório de Histocompatibilidade e  criopreservação, UERJ, av.",Non-OADS,/arxiv_data1/oa_pdf/ad/ea/hmer-7-071.PMC4636165.pdf
"A P-value ,0.05 was considered to be significant using Prism  software Version 5.0 (GraphPad Software, Inc., La Jolla, CA,  USA – http://www.graphpad.co m).",OADS,/arxiv_data1/oa_pdf/ad/ea/hmer-7-071.PMC4636165.pdf
"Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hepatic-medicine-evidence-and-research-journa lHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pedi - atric hepatology in the clinic and laboratory including the following  topics: Pathology, pathophysiology of hepatic disease; Investigation  and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/ad/ea/hmer-7-071.PMC4636165.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/ea/hmer-7-071.PMC4636165.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2015:8 277–281International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  277Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S8996 8synergistic effect of regenerating agent plus cord  blood serum eye drops for the treatment of  resistant neurotrophic keratitis: a case report   and a hypothesis for pathophysiologic mechanism Giuseppe Giannaccare1 Michela Fresina1 aldo Vagge2 piera Versura1 1ophthalmology Unit, DIM es,   s orsola-Malpighi teaching Hospital,   University of Bologna, Bologna, Italy;   2eye Clinic, DiN oGMI, University of  Genoa, Genoa, Italy Correspondence: Giuseppe Giannaccare   ophthalmology Unit, DIMes,   s orsola-Malpighi teaching Hospital,   University of Bologna, Via pelagio   palagi n 9, 40138 Bologna, Italy   email giuseppe.giannaccare@gmail.co mAbstract:  This report describes a case of a 72-year-old Caucasian woman presenting with a  large neurotrophic keratitis with a large persistent epithelial defect, with a longest linear diameter  of 7 mm and greatest perpendicular width of 5 mm, affecting epithelium, Bowman membrane,  and anterior stroma.",Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
Available from: http://clinicaltrials.gov/show/NCT0222714 7.,Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
Available  from: http://clinicaltrials.gov/show/NCT0175645 6.,Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT0179431 2.,Non-OADS,/arxiv_data1/oa_pdf/d6/c5/imcrj-8-277.PMC4636166.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cc/3c/ijwh-7-871.PMC4636167.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2015:7 871International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  871Erratumopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/IJWH.S9924 3Randomized comparative trial of cervical block protocols for pain  management during hysteroscopic removal of polyps and myomas [Erratum] Lukes AS, Roy KH, Presthus JB, et al.",Non-OADS,/arxiv_data1/oa_pdf/cc/3c/ijwh-7-871.PMC4636167.pdf
"This error was made by Dove Medical Press, not the authors  of the paper.Journal name: International Journal of Women’s Health Article Designation: Erratum Y ear: 2015 Volume: 7 Running head verso: Lukes et al Running head recto: Randomized comparative trial of cervical block protocols DOI: http://dx.doi.org/10.2147/IJWH.S99243 International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/cc/3c/ijwh-7-871.PMC4636167.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.Dove pres s,Non-OADS,/arxiv_data1/oa_pdf/cc/3c/ijwh-7-871.PMC4636167.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 6825–6834International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6825OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9383 5an in vitro and in vivo study of gemcitabine-loaded  albumin nanoparticles in a pancreatic cancer  cell line Xinzhe Yu,1,* Yang Di,2,*  chao Xie,3 Yunlong song,4  hang he,2 hengchao li,1  Xinming Pu,5 Weiyue lu,3  Deliang Fu,2 chen Jin1 1Pancreatic surgery Department,   huashan hospital, 2Pancreatic Disease  Institute, Fudan University, 3school of  Pharmacy & Key laboratory of smart  Drug Delivery, Fudan University,   4school of Pharmacy, The second  Military Medical University, 5The  state Key laboratory of Molecular  engineering of Polymers, Department  of Macromolecular science, Fudan  University, shanghai, People’s  republic of china *These authors contributed equally  to this workBackground and objectives:  Gemcitabine (Gem) is far from satisfactory as the first-line  regimen for pancreatic cancer, and the emergence of albumin nanoparticles offers new hope  for the delivery of Gem.",Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
"According to the statistics, pancreatic cancer is the fourth, fifth, and  seventh leading cause of cancer-related deaths in the USA, the European Union, and  People’s Republic of China, respectively.1–3 Although great progress has been made  for other cancers, pancreatic cancer still has a poor prognosis, with a dismal 5-year  survival rate ,5%.4 Surgery is the only effective cure, but only 20% of patients are  eligible for this approach, and chemotherapy remains the standard treatment for most  patients with pancreatic cancer.5 Currently, gemcitabine (Gem) (2 ′,2′-difluoro-2 ′-deoxycytidine) is recommended  as the first-line regimen for advanced pancreatic cancer.6 However, because of its  low molecular weight and high solubility in water, the clinical benefits of Gem are  compromised by its short plasma half-life and relative low concentration around  tumor sites.7 Furthermore, in order to achieve optimal clinical efficacy, a schedule correspondence: chen Jin Pancreatic surgery Department, huashan  hospital, Fudan University, shanghai  200040, People’s republic of china Tel +86 136 0198 1174 email galleyking@hotmail.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Yu et al Running head recto: Gem-loaded albumin nanoparticles in pancreatic cancer cell line DOI: http://dx.doi.org/10.2147/IJN.S93835 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
Or use: http://youtu.be/vPWpgACyn8 wVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/43/aa/ijn-10-6825.PMC4636168.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c8/b3/ijn-10-6835.PMC4636169.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 6835–6846International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6835OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9375 2Nanoencapsulation of natural triterpenoid celastrol  for prostate cancer treatment Vanna sanna1,2 Jean christopher  chamcheu3 Nicolino Pala1 hasan Mukhtar3 Mario sechi1,2 Imtiaz ahmad siddiqui3 1Department of chemistry and  Pharmacy, University of sassari,   sassari, Italy; 2laboratory of  Nanomedicine, University of sassari,   sassari, Italy; 3Department of  Dermatology, University of Wisconsin,   Madison, WI, UsaAbstract:  Celastrol (CL), a triterpenoid extracted from the Chinese herb Tripterygium wilfordii ,  has recently attracted interest for its potential antitumor effects.",Non-OADS,/arxiv_data1/oa_pdf/c8/b3/ijn-10-6835.PMC4636169.pdf
"Previously, Y ang et al first  reported that CL directly inhibits the chymotrypsin-like activity of proteasome in  androgen-independent PC3 (androgen receptor [AR]-negative) and androgen-dependent  LNCaP (AR-positive) prostate tumor cells, accompanied by suppression of AR pro - tein expression, and induction of apoptosis.9 More recently, Dai et al demonstrated  that CL suppresses androgen-independent prostate cancer proliferation, invasion, and  angiogenesis by inducing the apoptotic machinery and attenuating constitutive NF-kB correspondence: Vanna sanna Department of chemistry and Pharmacy,  laboratory of Nanomedicine, University  of sassari, Via Vienna 2, 07100, sassari,  Italy Tel +39 079 998 619 Fax +39 079 228 720 email vsanna@uniss.i t  Imtiaz ahmad siddiqui Department of Dermatology, Medical  sciences center, University of  Wisconsin – Madison, 1300 University  avenue, Madison, WI 53706, Usa Tel +1 608 262 6389 Fax +1 608 263 5223 email iasiddiqui@wisc.ed u Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Sanna et al Running head recto: Nanoencapsulation of celastrol for prostate cancer treatment DOI: http://dx.doi.org/10.2147/IJN.S93752",Non-OADS,/arxiv_data1/oa_pdf/c8/b3/ijn-10-6835.PMC4636169.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/c8/b3/ijn-10-6835.PMC4636169.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/b3/ijn-10-6835.PMC4636169.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f4/58/ijwh-7-865.PMC4636170.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2015:7 865–870International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  865RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S7563 7Mayer-Rokitansky-Kuster-Hauser syndrome: a  review Laura Londra Farah S Chuong Lisa Kolp Division of Reproductive  endocrinology and Infertility,   Department of Gynecology and  Obstetrics, Johns Hopkins University,   Baltimore, MD, USAAbstract:  The congenital aplasia or severe hypoplasia of mullerian structures is infrequent.",Non-OADS,/arxiv_data1/oa_pdf/f4/58/ijwh-7-865.PMC4636170.pdf
"Interestingly, the HOX genes are also associated  with the normal development of the kidneys, bone, and vascular structures, which  would reinforce the hypothesis of dysregulation of developmental genes involved in  the embryonic origin of the female reproductive tract.4–6 Due to the difficulty in classifying the various clinical presentations, multiple  authors have proposed systems that either reflect the embryologic correlate of the  abnormality7 or the predominance of particular clinical findings.8 In general, it is  accepted the existence of a typical form (fallopian tubes, ovaries, and renal sys - tem normally developed), atypical form (with malformations in the ovary or renal  system), and the MURCS association (mullerian, renal, and cervico thoracic somite  malformations).2,9 The latter refers to associated anomalies in the renal system and  in the axial skeleton, although vascular anomalies have also been described.10 In this  review, we will describe the most commonly recommended diagnostic modalities Correspondence: Laura Londra Division of Reproductive endocrinology  and Infertility, Department of Gynecology  and Obstetrics, Johns Hopkins University,  Baltimore, 10751 Falls Road, Suite 280  Lutherville, MD 21093, USA email llondra1@jhmi.ed uJournal name: International Journal of Women’s Health Article Designation: Review Y ear: 2015 Volume: 7 Running head verso: Londra et al Running head recto: Mayer-Rokitansky-Kuster-Hauser syndrome DOI: http://dx.doi.org/10.2147/IJWH.S75637",Non-OADS,/arxiv_data1/oa_pdf/f4/58/ijwh-7-865.PMC4636170.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/f4/58/ijwh-7-865.PMC4636170.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f4/58/ijwh-7-865.PMC4636170.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 6847–6861International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6847OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9066 0graphene oxide-silver nanocomposite as a  promising biocidal agent against methicillin- resistant Staphylococcus aureus ana carolina Mazarin de  Moraes1 Bruna araujo lima2 andreia Fonseca de Faria1 Marcelo Brocchi2 Oswaldo luiz alves1 1laboratory of solid state chemistry,   Institute of chemistry, University of  campinas, campinas, são Paulo, Brazil;   2Department of genetics, evolution  and Bioagents, Institute of Biology,   University of campinas, campinas,   são Paulo, BrazilBackground:  Methicillin-resistant Staphylococcus aureus  (MRSA) has been responsible for  serious hospital infections worldwide.",Non-OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
"Transmission of the microbe occurs mostly  through direct contact with wounds, respiratory and feeding tubes, urinary catheters,  and indwelling devices.3correspondence: ana carolina Mazarin  de Moraes; Oswaldo luiz alves laboratory of solid state chemistry,  Institute of chemistry, University of  campinas, PO Box 6154, 13083-970  campinas, são Paulo, Brazil Tel +55 19 3521 3394 Fax +55 19 3521 3023 email anacmmo@gmail.co m;   oalves@iqm.unicamp.b r Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: de Moraes et al Running head recto: Antibacterial activity of graphene oxide-silver nanocomposite DOI: http://dx.doi.org/10.2147/IJN.S90660",Non-OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
"Available from: http://apps.who.int/medicinedocs/ documents/s16211e/s16211e.pd f. Accessed February 2, 2015.",OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
"Available from:  http://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.pd f.  Accessed February 2, 2015.",OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/68/ijn-10-6847.PMC4636171.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1e/82/ijn-10-6789.PMC4636172.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 6789–6809International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6789OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7948 9Plga-encapsulated tea polyphenols enhance  the chemotherapeutic efficacy of cisplatin against  human cancer cells and mice bearing Ehrlich  ascites carcinoma Madhulika  Singh1 Priyanka Bhatnagar2 sanjay Mishra1 Pradeep Kumar2 Yogeshwer  Shukla1 Kailash chand gupta1,2 1CSIR-Indian  Institute of Toxicology  research, lucknow, 2csIr-Institute  of Genomics  and Integrative  Biology,  Delhi University campus, Delhi, IndiaAbstract:  The clinical success of the applicability of tea polyphenols awaits efficient systemic  delivery and bioavailability.",Non-OADS,/arxiv_data1/oa_pdf/1e/82/ijn-10-6789.PMC4636172.pdf
"To this end, anticancer drugs are  now frequently being combined with dietary phytochemicals in an effort to enhance  their antitumor efficacy while lowering their toxic effects.4,5Correspondence: Yogeshwer Shukla CSIR-Indian Institute of Toxicology  Research, PO Box 80, MG Marg,  lucknow 226001, India Tel +91 52 2262 0207 Fax +91 52 2262 8227 email yogeshwer_shukla@hotmail.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Singh et al Running head recto: Cancer chemosensitization using nanosized tea polyphenols DOI: http://dx.doi.org/10.2147/IJN.S79489",Non-OADS,/arxiv_data1/oa_pdf/1e/82/ijn-10-6789.PMC4636172.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/1e/82/ijn-10-6789.PMC4636172.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1e/82/ijn-10-6789.PMC4636172.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/51/3c/hmer-7-051.PMC4636173.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pHepatic Medicine: Evidence and Research 2015:7 51–70Hepatic Medicine: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  51REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/HMER.S5586 4interferon-free combination therapies for the  treatment of hepatitis C: current insights Jacinta A Holmes Alexander J Thompson Department of Gastroenterology,   St vincent’s Hospital, University of  Melbourne, Fitzroy, victoria, Australia Correspondence: Jacinta A Holmes   Department of Gastroenterology,   St vincent’s Hospital, University   of Melbourne, Level 4, Daly wing,   35 victoria Parade, Fitzroy,   victoria, Australia   Tel +61 3 9231 3580   Fax +61 3 9231 3590   Email Jacinta.",Non-OADS,/arxiv_data1/oa_pdf/51/3c/hmer-7-051.PMC4636173.pdf
"Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hepatic-medicine-evidence-and-research-journa lHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pedi - atric hepatology in the clinic and laboratory including the following  topics: Pathology, pathophysiology of hepatic disease; Investigation  and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/51/3c/hmer-7-051.PMC4636173.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/51/3c/hmer-7-051.PMC4636173.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a1/30/ndt-11-2833.PMC4636174.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 2833–2836Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2833Case repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/NDT .S9236 6Double encephalitis with herpes simplex virus  type II and cytomegalovirus in an elder Chinese:  a case report Chaobiao Xue1,2 shaoxian Chen1 Qi Lin1 Houshi Zhou1 Chuming Huang1 Jiyuan Lin1 Weihang Xie1 Kai Chen1 Dongming Zhou1 Wan Ma1 Feiyu Ma1 Haiyun Xu2 1outpatient Department, shantou  Central Hospital, affiliated  shantou Hospital of sun Yat- sen University, 2Mental Health  Center, shantou University Medical  College, shantou,  Guangdong,   people’s  republic of ChinaAbstract:  Herpes simplex encephalitis is a rare disease.",Non-OADS,/arxiv_data1/oa_pdf/a1/30/ndt-11-2833.PMC4636174.pdf
"Then, the patient was referred to the Shantou Central  Hospital, Affiliated Shantou Hospital of Sun Y at-sen University on October 15.Correspondence: Feiyu Ma Shantou Central Hospital, Affiliated  shantou Hospital of sun Yat-sen  University, 114 Waima road,  shantou, Guangdong 515065,  people’s republic of China Tel +86 754 8890 3165 email mafeiyu12345@163.co m  Haiyun Xu Mental Health Center, shantou University  Medical College, North Taishan  road, shantou, Guangdong 515065,  people’s republic of China Tel +86 754 8890 0728 email hyxu@stu.edu.c n Journal name: Neuropsychiatric Disease and Treatment Article Designation: Case report Y ear: 2015 Volume: 11 Running head verso: Xue et al Running head recto: Double encephalitis with HSV -II and CMV DOI: http://dx.doi.org/10.2147/NDT.S92366",Non-OADS,/arxiv_data1/oa_pdf/a1/30/ndt-11-2833.PMC4636174.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/a1/30/ndt-11-2833.PMC4636174.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/30/ndt-11-2833.PMC4636174.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/23/1a/imcrj-8-273.PMC4636175.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2015:8 273–275International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  273Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S9269 3a case of choroidal osteoma in a 10-year-old child Madhusmita Behera1 Manmath Kumar Das2 1Rotary Narayana Nethralaya,    Kolkata, India; 2Vitreo-Retina   services, CL Gupta eye Institute,   Moradabad, India Correspondence: Madhusmita Behera   Rotary Narayana Nethralaya, CN-5,   salt Lake, Kolkata, West Bengal, India   email: madhusmita.behera@rediffmail.",Non-OADS,/arxiv_data1/oa_pdf/23/1a/imcrj-8-273.PMC4636175.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/23/1a/imcrj-8-273.PMC4636175.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/23/1a/imcrj-8-273.PMC4636175.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/72/db/ijn-10-6811.PMC4636176.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 6811–6823International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6811OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8664 0Detection of fluorescent organic nanoparticles  by confocal laser endomicroscopy in a rat model  of Barrett’s esophageal adenocarcinoma elisa Dassie,1,2,* Diletta  arcidiacono,2,3,* Iga  Wasiak,4 Nunzio Damiano,5  Luigi Dall’Olmo,6  cinzia giacometti,7  sonia Facchin,3 Mauro  cassaro,7 ennio guido,8  Franca De lazzari,8 Oriano  Marin,9,10 T omasz ciach,4  Suzanne Fery-Forgues,11,12  alfredo alberti,1,2  Giorgio Battaglia,13  stefano realdon13 1Department of Molecular Medicine,  University of Padua, 2Venetian Institute of  Molecular Medicine, 3Department of Surgery,  Oncology and Gastroenterology, University  of Padua, Padua, Italy; 4Faculty of chemical  and Process Engineering, Warsaw University  of T echnology, Warsaw, Poland; 5Department  of Biomedical sciences, University of  Padua, Padua, 6Department of Emergency  Medicine, “ santi giovanni e Paolo” hospital,  Venice, 7Anatomic Pathology Unit, ULSS  15, alta Padovana, camposampiero,  8Gastroenterology Unit, Sant’Antonio  hospital, 9Interdepartmental research  Centre for Innovative Biotechnologies  (crIBI), University of Padua, 10Proteomics  Facility, azienda Ospedaliera di Padova,  Padua, 11cNrs, IT aV-Usr 3505, T oulouse,  France; 12Université de T oulouse, IT aV-Usr   3505, T oulouse, France; 13endoscopy Unit,  Veneto Institute of Oncology (IOV-IRCCS),  Padua, Italy *These authors contributed equally  to this workAbstract:  For many years, novel strategies for cancer detection and treatment using nanoparticles  (NPs) have been developed.",Non-OADS,/arxiv_data1/oa_pdf/72/db/ijn-10-6811.PMC4636176.pdf
"Keywords:  confocal laser endomicroscopy, Barrett’s esophagus, diagnostics, esophageal  adenocarcinoma, fluorescent nanoparticles, heptapeptide Introduction Esophageal adenocarcinoma (EAC) is a major public health concern, particularly in  Western countries, due to its high mortality and incidence rising by at least sixfold in  the past three decades.1 Prognosis is still very poor, with a 5-year survival rate below  20%.2 The steps involved in the progression from gastroesophageal reflux disease, its  predisposing condition, to Barrett’s esophagus (BE), its premalignant disorder, and  to cancer, are not yet fully understood.3 While BE is found in 5%–10% of patients  with chronic gastroesophageal reflux disease, most patients do not progress to EAC.4  Moreover, most EAC are diagnosed incidentally and often in advanced stages hardly  amenable to cure.5 Periodic endoscopic surveillance is the only currently avail - able measure to diagnose early gastric cancer in high-risk populations who have correspondence: elisa Dassie Department of Molecular Medicine,  University of Padua, Via gabelli 9, 35121  Padua, Italy Tel +39 049 792 3224 Fax +39 049 792 3250 email dassie.elisa@ymail.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Dassie et al Running head recto: Nanoparticles for esophagus cancer detection by CLE DOI: http://dx.doi.org/10.2147/IJN.S86640",Non-OADS,/arxiv_data1/oa_pdf/72/db/ijn-10-6811.PMC4636176.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/72/db/ijn-10-6811.PMC4636176.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/db/ijn-10-6811.PMC4636176.pdf
"Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav Correspondence to: Erin E Longbrake Washington University in St. Louis, Department ofNeurology, 660 S. Euclid Ave., Campus Box 8111, St. Louis, MO 63110, USA.",Non-OADS,/arxiv_data1/oa_pdf/0e/ad/10.1177_2055217315596994.PMC4636217.pdf
"Grades oflymphopenia were assigned according to thecommon terminology criteria for adverse events (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_ 2010-06-14_QuickReference_5x7.pdf): grade 1 ¼ ALC of 800 to the lower limit of normal, grade 2¼ALC 500–799, grade 3 ¼ALC<500.",OADS,/arxiv_data1/oa_pdf/0e/ad/10.1177_2055217315596994.PMC4636217.pdf
"Exclusion linkage analysis localized the Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > Received 1 July 2014 | Accepted 28 October 2015 | Published 31 October 2015© 2015 Molecular Vision 1261Mutations in GRM6  identified in consanguineous Pakistani  families with congenital stationary night blindness Muhammad Asif Naeem,1 Alexander D. H. Gottsch,2 Inayat Ullah,1 Shaheen N. Khan,1 Tayyab Husnain,1  Nadeem H. Butt,3 Zaheeruddin A. Qazi,4 Javed Akram,3,5 Sheikh Riazuddin,1,3,5 Radha Ayyagari,6 J.",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1262 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
"Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1263disease phenotype to chromosome 5q, whereas bidirectional  sequencing of GRM6  identified causal mutations that segre - gated with the disease phenotype in the respective families.",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1264 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1265of odds (LOD) scores were calculated using ILINK from the  LINKAGE Program Package.,OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1266Table  3.,Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1267In silico analysis:  The degree of evolutionary conservation of  positions at which mutations exist in other GRM6 orthologs  was examined using the UCSC genome browser .,OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
"Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1268of affected individuals in both the families show signs of  tilted optic disc, while the macula and vasculature are normal.",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
"Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1269if the mutant protein escapes NMD, the mutant protein would  lack the terminal 432 residues, including the seven transmem - brane domains and the intracellular G-protein binding region  [28].",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
"Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1270MA, Koenekoop RK, Bergen AA, Kamermans M, Gregg  RG.",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
"Molecular Vision  2015; 21:1261-1271 <http://www.molvis.org/molvis/v 21/1261 > © 2015 Molecular Vision  1271Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R.",Non-OADS,/arxiv_data1/oa_pdf/ef/ca/mv-v21-1261.PMC4636350.pdf
Available: http://medical.nema.org/ 2.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
"^, Radiological Society of North America 2009 Scientific Assemblyand Annual Meeting ,November 29 - December 4, 2009 ,Chicago IL.http://archive.rsna.org/2009/8011488.html Accessed September 10, 2014 8.",Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.idoimaging.com/ 9.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.schoech.de/diploma/toolkits.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.dclunie.com/medical-image-faq/ html/part8.html#DICOMDeidentifiers 11.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://plastimatch.org/dicom_ comparison.html 12.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://ingenium.home.xs4all.nl/dicom.html 13.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://mircwiki.rsna.org /index.php?title=CTP-The_ RSNA_Clinical_Trial_Processor 14.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.dicomworks.com 16.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.dvtk.org/ 17.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://gdcm.sourceforge.net/wiki/index.php/Main_Page 18.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.pixelmed.com 2 0 .,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://santec.tudor.lu/project/optimage/dicom/start 21.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.kuhp.kyoto-u.ac.jp/~diag_rad/intro/tech/ dicom_tools.html 22.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.oracle.com/technetwork/java/ install-jai-imageio-1-0-01-139659.html 27.,OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://www.dcm4che.org/ 29.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
Available: http://dicom.offis.de/dcmtk.php.en 31.,Non-OADS,/arxiv_data1/oa_pdf/bb/f1/330_2015_Article_3794.PMC4636522.pdf
At: http://www.mrisafety.com/ .,Non-OADS,/arxiv_data1/oa_pdf/b0/04/330_2015_Article_3807.PMC4636525.pdf
At: http://www.acr.org/ Quality-Safety/Resources/BIRADS/MRI.,Non-OADS,/arxiv_data1/oa_pdf/b0/04/330_2015_Article_3807.PMC4636525.pdf
National Institute for Public Health and the Environment (RIVM).http://www.rivm.nl/dsresource?,Non-OADS,/arxiv_data1/oa_pdf/64/14/330_2015_Article_3764.PMC4636526.pdf
http://www.orpha.net/consor/ cgi-bin/OC_Exp.php?Expert=55880 .,OADS,/arxiv_data1/oa_pdf/64/14/330_2015_Article_3764.PMC4636526.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommerc ial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits anynoncommercial use, distribution, and reproduction in any medium,provided you give appropriate credit to the original author(s) and thesource, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/bb/12/330_2015_Article_3770.PMC4636534.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/6c/f1/atr-04-03-23167.PMC4636540.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/5e/0b/atr-04-03-22602.PMC4636541.pdf
"To view please visit the journal (http://dx.doi.org/ 10.1136/bmjdrc-2015- 000137) Received 22 July 2015 Revised 2 October 2015Accepted 9 October 2015 1Department of Endocrinology and Metabolism, National Cerebral and Cardiovascular Center, Osaka, Japan 2Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan Correspondence to Dr Ichiro Kishimoto; kishimot@hsp.ncvc.go.jpABSTRACT Objective: To examine a relationship between statin intensity and heart failure (HF) incidence in diabetes.",Non-OADS,/arxiv_data1/oa_pdf/27/7b/bmjdrc-2015-000137.PMC4636543.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/c2/2e/atr-04-03-25439.PMC4636544.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-009873).,Non-OADS,/arxiv_data1/oa_pdf/fb/3f/bmjopen-2015-009873.PMC4636598.pdf
"All analyses were performed using SAS V .9.2, except the regression with spline functions, which was per-formed in the R system for statistical computation (http://www.cran.r-project.org).",OADS,/arxiv_data1/oa_pdf/fb/3f/bmjopen-2015-009873.PMC4636598.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/fb/3f/bmjopen-2015-009873.PMC4636598.pdf
http://www.johnforester.com/ Articles/Facilities/Pucher%20Revs.htm (accessed 19 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/80/e2/bmjopen-2015-008052.PMC4636599.pdf
http://www.cihi.ca/CIHI-ext-portal/ internet/en/document/types+of+care/hospital+care/acute+care/dad_metadata (accessed 19 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/80/e2/bmjopen-2015-008052.PMC4636599.pdf
http://www.cihi.,Non-OADS,/arxiv_data1/oa_pdf/80/e2/bmjopen-2015-008052.PMC4636599.pdf
http://www12.statcan.gc.ca/nhs-enm/2011/as-sa/fogs-spg/Pages/CSDSelector.cfm?lang=E&level=4#PR59 (accessed 19 Jan 2015).,OADS,/arxiv_data1/oa_pdf/80/e2/bmjopen-2015-008052.PMC4636599.pdf
"Canadian Motor Vehicle Traffic Collision Statistics, 2006 to 2011. http://www.tc.gc.ca/eng/motorvehiclesafety/tp-index-45.htm (accessed 9 May2015).",OADS,/arxiv_data1/oa_pdf/80/e2/bmjopen-2015-008052.PMC4636599.pdf
(cited 23 October 2013) http://www.gov.hk/en/about/abouthk/factsheets/docs/ population.pdf 10.,OADS,/arxiv_data1/oa_pdf/ac/cb/bmjopen-2015-008607.PMC4636600.pdf
(cited 17 September 2013)http://www.tco.gov.hk/english/legislation/legislation_sa.html 14.,Non-OADS,/arxiv_data1/oa_pdf/ac/cb/bmjopen-2015-008607.PMC4636600.pdf
(cited 28 December 2013)http://hk.apple.nextmedia.com/supplement/service/art/20120701/ 16474054 16.,Non-OADS,/arxiv_data1/oa_pdf/ac/cb/bmjopen-2015-008607.PMC4636600.pdf
(cited 28 December 2013)https://www.housingauthority.gov.hk/en/common/pdf/about-us/ publications-and-statistics/HIF.pdf 17.,Non-OADS,/arxiv_data1/oa_pdf/ac/cb/bmjopen-2015-008607.PMC4636600.pdf
(cited 14 September 2013) http://www.housingauthority.gov.hk/en/public-housing/estate-management/marking-scheme-for-estate-management-enforcement/index.html 18.,Non-OADS,/arxiv_data1/oa_pdf/ac/cb/bmjopen-2015-008607.PMC4636600.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009186).,Non-OADS,/arxiv_data1/oa_pdf/d9/a9/bmjopen-2015-009186.PMC4636601.pdf
"The professional English-language scientific editing staff at BioScience Writers, LLC (http://www.biosciencewriters.com/ verify; validation code: 3E6C2C5E-43DA-40E7-85B9-DC07299ABBA0) provided English translation services and scientific editing.",Non-OADS,/arxiv_data1/oa_pdf/d9/a9/bmjopen-2015-009186.PMC4636601.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009218).,Non-OADS,/arxiv_data1/oa_pdf/7f/f9/bmjopen-2015-009218.PMC4636602.pdf
http://nicotinepolicy.net/documents/letters/MargaretChan.pdf (accessed Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/7f/f9/bmjopen-2015-009218.PMC4636602.pdf
https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Chan-letter-June16%20PST%20FINAL%20with%20129%20sigs.pdf (accessed Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/7f/f9/bmjopen-2015-009218.PMC4636602.pdf
http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10-en.pdf?ua=1 (accessed Aug 2015).,OADS,/arxiv_data1/oa_pdf/7f/f9/bmjopen-2015-009218.PMC4636602.pdf
2007. http://www.statistics.gov.uk.statbase/product.asp?=6725 (30 March2009).,OADS,/arxiv_data1/oa_pdf/d2/f5/bmjopen-2015-008981.PMC4636603.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 008796).,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
"and Nielsen (http://www.ncppanel.com/content/ ncp/ncphome.html), and access can be purchased.",OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
"Washington DC, 2013. http://www.ftc.gov/ os/2013/05/130521smokelesstobaccoreport.pdf 11.",Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
2015. http://www.rankingthebrands.,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
2008. http://www.gallup.com/poll/109048/us-smoking-rate-still-coming-down.aspx (accessed 11 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
2010. http://www.wsj.com/news/articles/SB10001424052748703314904575399632882251718 (accessed 12 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
2012. http://www.thecommunityguide.org/index.html 21.,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
October 29; http://www.washingtonpost.com/business/economy/australias-plain-packaging-stubs-out-cigarette-branding-prompting-backlash/2013/10/29/317e58cc-3ccd-11e3-a94f-b58017bfee6c_story.html (accessed21 Jun 2014).,Non-OADS,/arxiv_data1/oa_pdf/17/4e/bmjopen-2015-008796.PMC4636604.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009446).,Non-OADS,/arxiv_data1/oa_pdf/f1/1a/bmjopen-2015-009446.PMC4636607.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f1/1a/bmjopen-2015-009446.PMC4636607.pdf
http://www.espad.org/Uploads/ESPAD_reports/2011/ FULL%20REPORT%20-%20Supplement%20to%20The%202011%20ESPAD%20Report%20-%20WEB.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/f1/1a/bmjopen-2015-009446.PMC4636607.pdf
http://www.bhas.ba/17.,Non-OADS,/arxiv_data1/oa_pdf/f1/1a/bmjopen-2015-009446.PMC4636607.pdf
"France, 2007. http://www.who.int/violence_injury_prevention/other_injury/falls/en/ 40.",Non-OADS,/arxiv_data1/oa_pdf/0d/14/bmjopen-2015-008460.PMC4636608.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 008614).,Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
2 April 2012. http://www.who.int/healthsystems/ topics/financing/MexicoCityPoliticalDeclarationUniversalHealthCoverage.pdf (accessed 24 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
Hu Resour Health 2010;8:8. http://www.human-resources-health.com/content/8/1/8 (accessed 21 Aug 2014).,Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
Hum Resour Health 2009;7:31. http://www.human-resources-health.com/content/7/1/31 (accessed 21 Aug 2014).,Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
"Geneva, Switzerland: the Global Health Workforce Alliance, 2013. http://www.who.int/workforcealliance/knowledge/resources/CHWsResearch_Agenda_by2015.pdf (accessed 16 Sep 2014).",Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
http://devdata.worldbank.org/ AAG/uga_aag.pdf (accessed 16 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
http://esa.un.org/unpd/wpp/Excel-Data/population.htm (accessed 16 Sep 2014).,OADS,/arxiv_data1/oa_pdf/b1/5a/bmjopen-2015-008614.PMC4636609.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-008190).,Non-OADS,/arxiv_data1/oa_pdf/7f/55/bmjopen-2015-008190.PMC4636611.pdf
"4 A prior ethnography by the ﬁrst two authors (the InfoRehab project; https://uwaterloo.ca/geriatric-health-systems-research-group/ research/inforehab) explored patient, family and caregiver engagement withhealthcare providers as older adults Stolee P, et al.BMJ Open 2015; 5:e008190.",Non-OADS,/arxiv_data1/oa_pdf/7f/55/bmjopen-2015-008190.PMC4636611.pdf
"The CFHI (http://www.cfhi-cass.ca/ 2 Stolee P, et al.BMJ Open 2015; 5:e008190.",Non-OADS,/arxiv_data1/oa_pdf/7f/55/bmjopen-2015-008190.PMC4636611.pdf
http://www.ramesesproject.org/media/Realist_reviews_training_materials.pdf 15. International Association for Public Participation (IAP2).,Non-OADS,/arxiv_data1/oa_pdf/7f/55/bmjopen-2015-008190.PMC4636611.pdf
2007. http://c.ymcdn.com/sites/www.iap2.org/resource/resmgr/imported/IAP2%20Spectrum_vertical.pdf (accessed 20 Sept2013).,Non-OADS,/arxiv_data1/oa_pdf/7f/55/bmjopen-2015-008190.PMC4636611.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-007807).,Non-OADS,/arxiv_data1/oa_pdf/d8/7d/bmjopen-2015-007807.PMC4636612.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d8/7d/bmjopen-2015-007807.PMC4636612.pdf
2012. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012003136 5.,Non-OADS,/arxiv_data1/oa_pdf/d8/7d/bmjopen-2015-007807.PMC4636612.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 007362).,Non-OADS,/arxiv_data1/oa_pdf/4b/69/bmjopen-2014-007362.PMC4636613.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/4b/69/bmjopen-2014-007362.PMC4636613.pdf
doi:10.1136/ bmjopen-2015-009567 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009567).,Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
http://www.hscic.gov.uk/catalogue/PUB13085/ pss-exp-eng-12 –13-fin-rpt.pdf (accessed Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
"Health and Social Care Information Centre, 2013. https://www.gov.uk/government/publications/nhs-continuing-healthcare (accessed Dec 2014).",Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
2013. https://www.gov.,Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
2013. http://www.england.nhs.uk/wp-content/uploads/2013/05/nv-narrative-cc.pdf (accessed Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
"London: The Nuffield Trust, 2010. http://www.nuffieldtrust.org.uk/sites/files/nuffield/publication/where_next_for_integrated_care_organisations_in_the_english_nhs_230310.pdf (accessed May 2015).",Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
"Maidenhead: Open University Press, 2008. http://www.euro.who.int/__data/assets/pdf_file/0006/96468/E91878.pdf (accessed 13 Apr 2015).",Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
http://www.ijic.org/index.php/ijic/article/view/843/1890(accessed Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/f8/14/bmjopen-2015-009567.PMC4636614.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-008214).,Non-OADS,/arxiv_data1/oa_pdf/fb/ac/bmjopen-2015-008214.PMC4636615.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009523).,Non-OADS,/arxiv_data1/oa_pdf/0b/ba/bmjopen-2015-009523.PMC4636616.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/0c/43/bmjopen-2015-009518.PMC4636617.pdf
(CADTH Therapeutic Review).http://www.cadth.ca/media/pdf/NOAC_Therapeutic_Review_final_report.pdf 9.,Non-OADS,/arxiv_data1/oa_pdf/0c/43/bmjopen-2015-009518.PMC4636617.pdf
Trial registration number: The study protocol has been registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) under registration numberCRD42014009677.,Non-OADS,/arxiv_data1/oa_pdf/32/6c/bmjopen-2015-008440.PMC4636618.pdf
METHODS The protocol of this review has been registered in PROSPERO (CRD42014009677) (http://www.crd.york.,Non-OADS,/arxiv_data1/oa_pdf/32/6c/bmjopen-2015-008440.PMC4636618.pdf
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 20.,Non-OADS,/arxiv_data1/oa_pdf/32/6c/bmjopen-2015-008440.PMC4636618.pdf
Coronary heart disease statistics 2010. https://www.bhf.org.uk/~/media/files/research/heart-statistics/hs2010_coronary_heart _disease_statistics.pdf (accessed 6 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/d3/11/bmjopen-2015-008861.PMC4636621.pdf
http://pathways.nice.org.uk/pathways/stable-angina#path=view%3A/pathways/stable-angina/managing-stable-angina.xml&content=view-node%3Anodes-anti-anginal-drug-treatment (accessed 19 Aug 2015).,OADS,/arxiv_data1/oa_pdf/d3/11/bmjopen-2015-008861.PMC4636621.pdf
http://www.nicedsu.org.uk/TSD%2010%20mapping %20FINAL.pdf (accessed 6 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/d3/11/bmjopen-2015-008861.PMC4636621.pdf
http://www.bls.gov/cpi/ (accessed 2 Jun 2013).,Non-OADS,/arxiv_data1/oa_pdf/d3/11/bmjopen-2015-008861.PMC4636621.pdf
http://www.ema.europa.eu/docs /en_GB /document_library/EPAR_-_Product_Information/human/000805/WC500045937.pdf (accessed 2 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/d3/11/bmjopen-2015-008861.PMC4636621.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-008326).,Non-OADS,/arxiv_data1/oa_pdf/01/05/bmjopen-2015-008326.PMC4636622.pdf
"Sydney: ACSQHC, 2014. http://www.safetyandquality.gov.au/wp-content/ Broom A, et al.BMJ Open 2015; 5:e008326.",Non-OADS,/arxiv_data1/oa_pdf/01/05/bmjopen-2015-008326.PMC4636622.pdf
"Geneva: WHO Press, 2014. http://apps.who.int/iris/ bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1(accessed Nov 2014).",Non-OADS,/arxiv_data1/oa_pdf/01/05/bmjopen-2015-008326.PMC4636622.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-008784).,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
Article 14. http://www.unhcr.ch 2.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
2014. http://www.unhcr.org/statistics 3.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
2013. http://www.unhcr.org/statistics 4.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
2010. http://www.consilium.europa.eu 5.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
2003. http://www.ue.eu.int 6.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
https://http://www.destatis.de/DE/ Publikationen/Thematisch/EinkommenKonsumLebensbedingungen/LebeninEuropa/EinkommenLebensbedingungen.html 21.,Non-OADS,/arxiv_data1/oa_pdf/eb/88/bmjopen-2015-008784.PMC4636623.pdf
2015. http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 19Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/8a/11/bmjopen-2015-008764.PMC4636625.pdf
2012. http://www.ssb.no/en/helse/statistikker/dodsarsak/aar/2013 –11–01?fane=om#content (accessed 13 Apr 2015).,OADS,/arxiv_data1/oa_pdf/8a/11/bmjopen-2015-008764.PMC4636625.pdf
"Oslo: NAV, 2014. https://www.nav.no/no/NAV+og+samfunn/Statistikk/AAP+nedsatt+arbeidsevne+og+uforetrygd+-+statistikk/Tabeller/Mottakere+av+uf%C3%B8repensjon+som+andel+av+befolkningen+*),+etter+fylke.+Aldersstandardiserte+tall.+Pr..409157.cms (accessed 14Sep 2015).",OADS,/arxiv_data1/oa_pdf/67/36/bmjopen-2015-009114.PMC4636626.pdf
"2015. https://www.ssb.no/ statistikkbanken/selecttable/hovedtabellHjem.asp?KortNavnWeb= Torske MO, et al.BMJ Open 2015; 5:e009114.",Non-OADS,/arxiv_data1/oa_pdf/67/36/bmjopen-2015-009114.PMC4636626.pdf
"NAV, 2011. https://www.nav.no/en/Home/Benefits +and+services/Pensions+and+pension+application+from+outside+Norway/Disability+benefit (accessed 7 Apr 2015).",Non-OADS,/arxiv_data1/oa_pdf/67/36/bmjopen-2015-009114.PMC4636626.pdf
https://www.ssb.no/statistikkbanken/selecttable/hovedtabellHjem.asp?KortNavnWeb=dodsarsak&CMSSubjectArea=helse&PLanguage=1&checked=true 35.,OADS,/arxiv_data1/oa_pdf/67/36/bmjopen-2015-009114.PMC4636626.pdf
"Author affiliations 1Division for Healthcare Technology Assessment Research, National Evidence- based Healthcare Collaborating Agency, Seoul, Republic of Korea, Seoul, Republic of Korea 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul NationalUniversity Hospital, Seoul, Republic of Korea 3Department of Information Statistics, College of Natural Science, Andong National University, Andong, Republic of Korea 4Real Estate R&D Institute, Korea Appraisal Board, Daegu, Republic of Korea 5Department of Obstetrics and Gynecology, Seoul National University College of College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea 6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center,Seoul, Republic of Korea 7Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea Acknowledgements The authors acknowledge Editage (https://www.editage.",Non-OADS,/arxiv_data1/oa_pdf/48/97/bmjopen-2015-008416.PMC4636627.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/48/97/bmjopen-2015-008416.PMC4636627.pdf
(http://www.ginasthma.org/) 25.,Non-OADS,/arxiv_data1/oa_pdf/48/97/bmjopen-2015-008416.PMC4636627.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 008094).,Non-OADS,/arxiv_data1/oa_pdf/b2/d0/bmjopen-2015-008094.PMC4636630.pdf
Secondary Cancer Facts & Figures 2013. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013 3.,Non-OADS,/arxiv_data1/oa_pdf/b2/d0/bmjopen-2015-008094.PMC4636630.pdf
28. http://www.ons.gov.uk/ons/rel/family-demography/family-size/2012/ family-size-rpt.html 29.,Non-OADS,/arxiv_data1/oa_pdf/ca/b3/bmjopen-2015-007682.PMC4636631.pdf
"Table 1 Abbreviations COS Core outcome set COMET Core outcome measures in effectiveness trialshttp://www.comet-initiative.org/ COSMIN Consensus-based standards for the selection of health measurement instrumentshttp://www.cosmin.nl/ FR Functional restorationIASP International association for the study of pain http://www.iasp-pain.org/ IMMPACT Initiative on methods, measurement, and pain assessment in clinical trialshttp://immpact.org/ MPT Multimodal pain therapy Synonymous: interdisciplinary, comprehensive OMERACT Outcome Measures in Rheumatology http://www.omeract.org/ RCT Randomised controlled trialTOPS Treatment outcomes in pain survey instruments 6 Kaiser U, et al.BMJ Open 2015; 5:e008146.",Non-OADS,/arxiv_data1/oa_pdf/0c/50/bmjopen-2015-008146.PMC4636634.pdf
2014. http://onlinelibrary.wiley.com/doi/10.,Non-OADS,/arxiv_data1/oa_pdf/0c/50/bmjopen-2015-008146.PMC4636634.pdf
11. http://www.omeract.org (12.2.2014).,Non-OADS,/arxiv_data1/oa_pdf/0c/50/bmjopen-2015-008146.PMC4636634.pdf
http://www.comet-initiative.org/studies/search (8.10.2014).,Non-OADS,/arxiv_data1/oa_pdf/0c/50/bmjopen-2015-008146.PMC4636634.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 009107).,Non-OADS,/arxiv_data1/oa_pdf/c5/64/bmjopen-2015-009107.PMC4636635.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c5/64/bmjopen-2015-009107.PMC4636635.pdf
Data sharing statement Additional data can be accessed via the Dryad data repository at http://datadryad.org/with the doi:10.5061/dryad.tq480.,OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
320000 1 May 2013 –30 April 2017. http://www.fp7-frame.eu/wp-content/materiale/reports/01-Deliverable-3.1.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
"London, UK: Department for International Development (DFID),2013. http://r4d.dfid.gov.uk/Output/192962/ 8.",Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://carnegieendowment.org/files/Violence_lit_review.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://ssrn.com/abstract=316861 14.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://ssrn.com/abstract=347077 15.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://www.nber.org/papers/w10750 16.,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://data.worldbank.org/indicator (accessed Jan 2013).,OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://hdr.undp.org/en/content/gender-development-index-gdi (accessed Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
http://info.worldbank.org/governance/wgi/index.aspx#home (accessed Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/e2/50/bmjopen-2014-007004.PMC4636637.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-008841).,Non-OADS,/arxiv_data1/oa_pdf/24/ec/bmjopen-2015-008841.PMC4636638.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/24/ec/bmjopen-2015-008841.PMC4636638.pdf
"The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org 13.",Non-OADS,/arxiv_data1/oa_pdf/24/ec/bmjopen-2015-008841.PMC4636638.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009477).,Non-OADS,/arxiv_data1/oa_pdf/d7/7c/bmjopen-2015-009477.PMC4636639.pdf
2008. http://www.mrc.ac.uk/complexinterventionsguidance 26.,Non-OADS,/arxiv_data1/oa_pdf/d7/7c/bmjopen-2015-009477.PMC4636639.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009426).,Non-OADS,/arxiv_data1/oa_pdf/d3/15/bmjopen-2015-009426.PMC4636640.pdf
Further details of the study can be found online (http://www.alswh.org.au) and in Lee et al.,OADS,/arxiv_data1/oa_pdf/7a/57/bmjopen-2015-008714.PMC4636641.pdf
Data sharing statement ALSWH and NO 2exposure data are available (see http://www.alswh.org.au and Knibbs et al19).,OADS,/arxiv_data1/oa_pdf/7a/57/bmjopen-2015-008714.PMC4636641.pdf
http://www.aihw.gov.au/publication-detail/?id=10737421466 24.,Non-OADS,/arxiv_data1/oa_pdf/7a/57/bmjopen-2015-008714.PMC4636641.pdf
"Philadelphia: Lippincott Williams & Wilkins, 2008. http://www.lww.com/Product/9781451190052 25.",Non-OADS,/arxiv_data1/oa_pdf/7a/57/bmjopen-2015-008714.PMC4636641.pdf
http://www.chlamydiascreening.nhs.uk/ps/resources.asp 2.,Non-OADS,/arxiv_data1/oa_pdf/93/99/bmjopen-2014-007455.PMC4636643.pdf
2013. http://www.chlamydia screening.nhs.uk/ps/data.asp 3.,Non-OADS,/arxiv_data1/oa_pdf/93/99/bmjopen-2014-007455.PMC4636643.pdf
http://www.health.gov.au/internet/main/publishing.nsf/Content/final-report-of-national-advisory-council-on-dental-health.htm 3.,Non-OADS,/arxiv_data1/oa_pdf/7f/e3/bmjopen-2015-009341.PMC4636644.pdf
http://www.aihw.gov.au/publication-detail/?id=6442467953 4.,Non-OADS,/arxiv_data1/oa_pdf/7f/e3/bmjopen-2015-009341.PMC4636644.pdf
http://www.aihw.gov.au/publication-detail/?id=10737420710 6.,Non-OADS,/arxiv_data1/oa_pdf/7f/e3/bmjopen-2015-009341.PMC4636644.pdf
http://www.aihw.gov.au/publication-detail/?id=60129546922 15.,Non-OADS,/arxiv_data1/oa_pdf/7f/e3/bmjopen-2015-009341.PMC4636644.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-008224).,Non-OADS,/arxiv_data1/oa_pdf/fd/d2/bmjopen-2015-008224.PMC4636645.pdf
†http://statbel.fgov.be.,Non-OADS,/arxiv_data1/oa_pdf/f8/1f/bmjopen-2015-008505.PMC4636646.pdf
‡http://www.insee.fr.,Non-OADS,/arxiv_data1/oa_pdf/f8/1f/bmjopen-2015-008505.PMC4636646.pdf
§http://www.geox.hu.,Non-OADS,/arxiv_data1/oa_pdf/f8/1f/bmjopen-2015-008505.PMC4636646.pdf
**http://www.cbs.nl.††http://www.neighbourhood.statistics.gov.uk.,Non-OADS,/arxiv_data1/oa_pdf/f8/1f/bmjopen-2015-008505.PMC4636646.pdf
Urban Atlas: accessible through http://www.eea.europa.eu/ data-and-maps/data/urban-atlas 19.,Non-OADS,/arxiv_data1/oa_pdf/f8/1f/bmjopen-2015-008505.PMC4636646.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 009251).,Non-OADS,/arxiv_data1/oa_pdf/a0/3d/bmjopen-2015-009251.PMC4636647.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/a0/3d/bmjopen-2015-009251.PMC4636647.pdf
http://www.ispor.org/DigestOfIntDB/CountryList.aspx (last accessed on 8 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/a0/3d/bmjopen-2015-009251.PMC4636647.pdf
"Rockville, MD: Agency for Healthcare Research and Quality, 2012. http://www.hcup-us.ahrq.gov/nisoverview.jsp (last accessed on 10 Apr 2015).Table 3 Test characteristics for the IMPACT rule for predicting in-hospital mortality Test characteristic Estimate (95% CI) Sensitivity, % 92.4 (90.7 to 93.8) Specificity, % 33.2 (32.7 to 33.7)PPV, % 4.6 (4.4 to 4.9)NPV, % 99.2 (99.0 to 99.4)AUC 0.74 (0.73 to 0.76) AUC, area under the receiver operator characteristic curve; IMPACT, In-hospital Mortality for PulmonAry embolism usingClaims daTa; NPV, negative predictive value; PPV, positivepredictive value.",Non-OADS,/arxiv_data1/oa_pdf/a0/3d/bmjopen-2015-009251.PMC4636647.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-008956).,Non-OADS,/arxiv_data1/oa_pdf/1e/f9/bmjopen-2015-008956.PMC4636648.pdf
2008. http://www.health.gov/paguidelines/pdf/paguide.pdf 30.,Non-OADS,/arxiv_data1/oa_pdf/1e/f9/bmjopen-2015-008956.PMC4636648.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-008643).,Non-OADS,/arxiv_data1/oa_pdf/4b/32/bmjopen-2015-008643.PMC4636649.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-008963).,Non-OADS,/arxiv_data1/oa_pdf/95/0c/bmjopen-2015-008963.PMC4636652.pdf
"45To ensure that non-replicated studies are not being repli-cated in an active, unpublished study, additional searches will be conducted in two international clinical trial registries (http://www.clinicaltrials.gov and http://www.controlled-trials.com).",Non-OADS,/arxiv_data1/oa_pdf/47/c7/bmjopen-2015-008244.PMC4636653.pdf
"Canadian Association for Drugs and Technologies in Health, 2009. https://www.cadth.ca/reassessment-health-technologies-obsolescence-and-waste(accessed 22 Oct 2013).",Non-OADS,/arxiv_data1/oa_pdf/47/c7/bmjopen-2015-008244.PMC4636653.pdf
National Institute for Health and Care Excellence 2015. http://www.nice.org.uk/guidance (accessed 20 Feb2015).,Non-OADS,/arxiv_data1/oa_pdf/47/c7/bmjopen-2015-008244.PMC4636653.pdf
2014. http://www.choosingwiselycanada.org (accessed 1 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/47/c7/bmjopen-2015-008244.PMC4636653.pdf
2014. http://www.nlm.,Non-OADS,/arxiv_data1/oa_pdf/47/c7/bmjopen-2015-008244.PMC4636653.pdf
http://www.odprn.ca/wp-content/uploads/2014/01/ODPRN-SR-protocol-final-2.pdf (accessed Jan 2015).,OADS,/arxiv_data1/oa_pdf/47/64/bmjopen-2015-009183.PMC4636655.pdf
Final report: inhaled corticosteroids and long acting beta agonists (ICS/LABA) forthe treatment of chronic obstructive pulmonary disease (COPD).http://www.odprn.ca/wp-content/uploads/2015/01/ICS-LABA-COPD-Qualitative-Report-Final-16_01_15.pdf (accessed Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/47/64/bmjopen-2015-009183.PMC4636655.pdf
http://www.R-project.org (accessed Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/47/64/bmjopen-2015-009183.PMC4636655.pdf
http://CRAN.R-project.org/package=meta (accessed Jan 2015).,OADS,/arxiv_data1/oa_pdf/47/64/bmjopen-2015-009183.PMC4636655.pdf
http://www.openbugs.,Non-OADS,/arxiv_data1/oa_pdf/47/64/bmjopen-2015-009183.PMC4636655.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 008211).,Non-OADS,/arxiv_data1/oa_pdf/7f/da/bmjopen-2015-008211.PMC4636658.pdf
Each participant will be given an individual treatment pack con-taining either esomeprazole or placebo which will beproduced by a contracted manufacturer IDT pharmaceuti- cals (http://en.idtaus.com.au).,Non-OADS,/arxiv_data1/oa_pdf/7f/da/bmjopen-2015-008211.PMC4636658.pdf
http://www.un.org/ millenniumgoals/ (accessed Feb 2015).9.,Non-OADS,/arxiv_data1/oa_pdf/7f/da/bmjopen-2015-008211.PMC4636658.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009165).,Non-OADS,/arxiv_data1/oa_pdf/68/90/bmjopen-2015-009165.PMC4636659.pdf
2001. http://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf 26.,Non-OADS,/arxiv_data1/oa_pdf/68/90/bmjopen-2015-009165.PMC4636659.pdf
http://www.health-literacy.eu (accessed May 2015).,Non-OADS,/arxiv_data1/oa_pdf/68/90/bmjopen-2015-009165.PMC4636659.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-008675).,Non-OADS,/arxiv_data1/oa_pdf/63/c7/bmjopen-2015-008675.PMC4636664.pdf
2015. http://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704 16.,Non-OADS,/arxiv_data1/oa_pdf/54/b6/bmjopen-2015-007905.PMC4636666.pdf
2015. https://www.nhg.org/dutch-college-general-practitioners 20.,Non-OADS,/arxiv_data1/oa_pdf/54/b6/bmjopen-2015-007905.PMC4636666.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/fc/2a/atr-04-03-27898.PMC4636667.pdf
2015. http://www.goldcopd.org/ 13.,Non-OADS,/arxiv_data1/oa_pdf/64/c1/bmjopen-2014-007284.PMC4636669.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2014-007538).,Non-OADS,/arxiv_data1/oa_pdf/36/d1/bmjopen-2014-007538.PMC4636670.pdf
http://vizhub.healthdata.org/gbd-compare/ (accessed 19 Jun 2014).,Non-OADS,/arxiv_data1/oa_pdf/36/d1/bmjopen-2014-007538.PMC4636670.pdf
http://www.mra.gov.bd/index.php?,Non-OADS,/arxiv_data1/oa_pdf/36/d1/bmjopen-2014-007538.PMC4636670.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009276).,Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
"Example trainingincludes: The Royal Society for Public Health (RSPH) Level 2 Award in Understanding Health Improvement and workshops on targeting, promoting and retaininginactive people to sport (http://makesportfun.com/;engaging women and girls in sport http://www.",Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
"▸Section A uses the International Physical Activity Questionnaire self-administered short form 35(IPAQ – SF http://www.ipaq.ki.se/ipaq.htm) to record fre- quency, intensity and duration of physical activity.This will allow reporting of: –Change in days (that last at least 30 min) of self- reported physical activity of (1) any intensity, (2)vigorous intensity and (3) moderate intensity; –Change in days (that last at least 30 min) of self- reported (1) walking, (2) sport and (3) any physicalactivity.",Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
UNESCO European Charter for Sport 1992. http://portal.unesco.org/ education/en/ev.php-URL_ID=2221&URL_DO=DO_TOPIC&URL_SECTION=201.html 25.,Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/inttime.pdf (accessed 20 Jun 2014).,OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
2011. http://www.ons.gov.uk/ons/rel/wellbeing/measuring-subjective-wellbeing-in-the-uk/analysis-of-experimental-subjective-well-being-data-from-the-annual-population-survey –april—september-2011/report-april-to-september- 2011.html (accessed 20 Jun 2014).,Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
An EQ-5D-5L value set for England OHE Seminar Oct 3rd 2014. http://www.slideshare.net/OHENews/ ohe-seminar-5-l-value-set-oct2014 49.,Non-OADS,/arxiv_data1/oa_pdf/26/08/bmjopen-2015-009276.PMC4636674.pdf
To view please visit the journal (http://dx.doi:10.,Non-OADS,/arxiv_data1/oa_pdf/52/22/openhrt-2015-000255.PMC4636679.pdf
"To combine these continuous data measured by different instru- ments, effect sizes, that is, standardised mean differences(SMDs), were calculated in Review Manager V .5.2 by means of Inverse Variance, random effects analysis (http://ims.cochrane.org/revman).",OADS,/arxiv_data1/oa_pdf/52/22/openhrt-2015-000255.PMC4636679.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/9f/64/atr-04-03-28381.PMC4636727.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/1f/fb/ircmj-17-10-17767.PMC4636747.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/03/65/ircmj-17-10-30246.PMC4636748.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/71/c3/atr-04-03-29184.PMC4636749.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/52/7e/ircmj-17-10-19256.PMC4636750.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/c7/c8/ircmj-17-10-17865.PMC4636751.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/a3/da/ircmj-17-10-18915.PMC4636752.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/52/33/ircmj-17-10-18172.PMC4636753.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/cc/f3/ircmj-17-10-28021.PMC4636754.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/60/e2/ircmj-17-10-19546.PMC4636755.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/4f/9b/ircmj-17-10-18895.PMC4636756.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/e8/e0/ircmj-17-10-19373.PMC4636757.pdf
